Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
08/2009 | Recent  |  14: Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions August inventions list 08/09

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
08/27/2009 > patent applications in patent subcategories. inventions list

20090215665 - Compositions and methods for promoting wound healing and tissue regeneration: Provided herein are compositions and methods for use in promoting wound healing and tissue regeneration following tissue injury in a subject.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090215668 - Methods of making and uses of compositions that modulate intronic region-encoded protein function: This invention relates to compositions and methods for modulating cellular activity of non-human organisms, and in particular fungi, and methods of identifying and using antifungal agents with improved specificity. More particularly, the technology described herein relates to the identification and use of compounds that target intron-encoded proteins, such as maturases.... Agent: Biotech Beach Law Group , Pc

20090215667 - Utility of phylloplanins as antibiotics, selective fungicides and for enhancing microbial resistance in plants: The present invention relates to plant proteins produced by a plant's epidermal layer that contribute to the innate pest/disease resistance of the plant (“phylloplanins”), compositions comprising the phylloplanins and methods of using them. In particular the methods relate to inhibiting or preventing microbial, e.g., fungal or bacterial, growth on a... Agent: Crowell & Moring LLP Intellectual Property Group

20090215666 - Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent: The present invention provides polypeptides useful for treating and preventing cancer. The present invention also provides therapeutic agents or methods for treating cancer using the polypeptides. The polypeptides of the present invention are composed of an amino acid sequence which comprises VIVIT and is preferably a polypeptide in which the... Agent: Townsend And Townsend And Crew, LLP

20090215669 - Compositions and methods for treatment of diabetes: The present invention relates to a composition comprising a peptide of the formula: (Xaa)n1-Xaa1-His-Thr-Asp-(Xaa)n2 wherein Xaa is any amino acid; Xaa1 is a hydrophobic amino acid; n1 is 0-10; and n2 is 0-10; and derivatives thereof; and insulin. Complexes of insulin and the peptides, methods of dispersing multimeric insulin complexes... Agent: Seed Intellectual Property Law Group Pllc

20090215670 - Site specific pegylated hemoglobin, method of preparing same, and uses thereof: The present invention provides pegylated hemoglobins comprising a maleimide polyethylene glycol (PEG) conjugated to a thiol moiety of a cysteine residue of hemoglobin, methods of preparing the pegylated hemoglobins, compositions and blood substitutes comprising the pegylated hemoglobins, and methods of treating a subject which comprise administering to the subject blood... Agent: Amster, Rothstein & Ebenstein LLP

20090215671 - Compositions and methods for treatment of neural disorders using transforming growth factor-beta superfamily proteins and their antagonists: Contemplated compositions and methods employ a TGF-beta superfamily protein or antagonist thereof to treat a neural disorder characterized by an imbalance in differentiated functional sensory and neural cells derived from a sensory/neural progenitor cell. Preferably, GDF-11 and/or antagonists thereof are employed in the treatment of diseases in which visual and/or... Agent: Fish & Associates, Pc Robert D. Fish

20090215672 - Cys-rich, cell surface glycoproteins: This invention relates to novel proteins, termed INSP206 and INSP208 herein identified as Cys-rich, cell surface glycoproteins, and to the use of these proteins and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090215673 - Process for purifying glycopeptide phosphonate derivatives: Disclosed are methods of purifying glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups that are useful as antibacterial agents. The methods include contacting a solution of the glycopeptide derivatives with a polystyrene-containing resin, eluting the resin with an aqueous solution, and isolating... Agent: Theravance, Inc.

20090215674 - Use of a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent: This invention is directed to methods of administering a polyene macrolide antifungal agent in combination with a glycopeptide antibacterial agent having a substituent comprising at least about 8 carbon atoms. The invention is also directed to methods of using a polyene macrolide antifungal agent in combination with a specified glycopeptide... Agent: Theravance, Inc.

20090215675 - Means for the inhibition of anti-beta1-adrenergic receptor antibodies: The present invention is related to a peptide selected from the group comprising a) a cyclic peptide of formula (I): Cyclo(AIa-x-x-x-x-x-x-x-x-x-Cys-x-x-x-Pro-x-Cys-Cys-xk-GIn), (I) whereby k is any integer from 0 to 6, preferably any integer from 1 to 6, more preferably k=6; b) a cyclic peptide of formula (II): Cyclo(Ala-x-x-Trp-x-x-Gly-x-Phe-x-Cys-xh-Gln), (II)... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090215676 - Method of treatment: Disclosed is a method for attenuating the effects of growth hormone (GH) in a subject. The method comprises the administration of both a GH antagonist and a somatostatin agonist to said subject, simultaneously or separately, continuously or periodically. In one preferred embodiment of the method an extended release somatostatin agonist... Agent: Alan F. Feeny, Esq.

20090215677 - Polymyxin derivatives and uses thereof: The present invention relates to a polymyxin derivative wherein R1, R2 and R3 are optional and R1, R2, R3, R5, R8 and R9 are cationic or neutral amino acid residues selected so that the total number of positive charges at physiological pH is at least two but no more than... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090215678 - Preventing vertical endoparasite infections: The present invention relates to the use of endoparasiticidal depsipeptides for producing pharmaceuticals for preventing vertical infection with endoparasites.... Agent: Bayer Healthcare Llc

20090215690 - Compositions and methods for inhibiting cell migration: The finding that Dickkopf1 (Dkk1) is a dual function protein demonstrates a mechanism for the coordination of cell migration and antagonism of Wnt/β-catenin signaling during developmental and pathological processes. The profile of Dkk proteins expressed by human breast cancers correlates with indicators of outcome: Dkk1 associates with markers of poor... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper LLP (us)

20090215692 - Compositions and methods to prevent cancer with cupredoxins: The present invention relates to compositions and methods comprising chemopreventive agents that may be cupredoxin(s) or variants, derivatives and structural equivalents of cupredoxins, and at least one other chemopreventive agent. Specifically, these compositions may comprise azurin from Pseudomonas aeruginosa, and/or the 50-77 residue region of azurin (p28). The at least... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20090215687 - Compounds for enhancing hypoxia inducible factor activity and methods of use: The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 3,6-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride, 2,8-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate, tilorone analogue R-9536-DA, indoprofen, ciclopiroxolamine, tryptophan, ansindione, nabumetone, oxybendazole, albendazole, tropicamide, pramoxine hydrochloride, atenolol, mebendazole, carbetapentane citrate, monensin sodium,... Agent: Irving N Feit Hoffmann & Baron

20090215679 - Disease-associated proteins: Disclosed are methods and compositions for early diagnosis, monitoring and treatment of an ocular disorder. In particular, the invention relates to a novel protein, that is differentially transcribed and expressed in subjects suffering from retinal dystrophies and the like, such as retinal dystrophy and age-related macular degeneration compared with healthy... Agent: Novartis Corporate Intellectual Property

20090215689 - Fgf2-binding peptides and uses thereof: FGF2-binding peptides are here described, which have been designed starting from the N-terminal region of PTX3, in particular spanning the PTX3(82-110) region. Synthetic peptides related to this sequence are able to bind FGF2 and to inhibit its pro-angiogenic activity in vitro and in vivo with no anticipated impact on innate... Agent: Steinfl & Bruno

20090215688 - Glp-i agonist and cardiovascular complications: Methods and uses for the treatment and prevention of cardiac and cardiovascular diseases comprising administration of a GLP-1 agonist.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090215680 - Inhibitor peptides: The invention concerns peptides useful as MAP kinase/ERK pathway-specific inhibitors relative to a given substrate in a given subcellular compartment.... Agent: Miller, Matthias & Hull

20090215694 - Lyophilized formulations of exendins and exendin agonist analogs: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090215693 - Methods for increasing hyaluronic acid levels and improving moisture retention in tissue: Disclosed is a method for increasing hyaluronic acid levels in tissue and increasing moisture retention in skin.... Agent: Donna J. Russell

20090215685 - Methods for inhibiting hair depigmentation and hair loss: The present invention aims to provide a method for inhibiting hair depigmentation and a method for inhibiting hair loss, in which hair depigmentation and hair loss are inhibited by collagen XVII.... Agent: Pearne & Gordon LLP

20090215681 - Methods of diagnosis and treatment of metabolic disorders: The invention features diagnostic methods for metabolic disorders (e.g., diabetes and obesity), methods for screening for compounds useful in the treatment of metabolic disorders, and methods for treatment of metabolic disorders that involve sirtuin2 or sirtuin3 nucleic acids or proteins or their agonists or antagonists.... Agent: Clark & Elbing LLP

20090215682 - Modified pyy (3-36) peptides and their effects on feeding behaviour: The present invention relates to compounds of formula (1); variants or derivatives thereof, or salts or solvates thereof. The present invention also relates to the use of such compounds to control appetite, feeding, food intake, energy expenditure and calorie intake, particularly in the treatment of obesity.... Agent: Fish & Richardson P.c.

20090215686 - Nk1-based polypeptides and related methods: The present invention includes various NK1-based polypeptides and polynucleotides, related compositions, methods of modulating Met activity in a cell, and related methods of treatment. Also, the present invention includes a method for designing an antagonist of a receptor tyrosine kinase from a receptor tyrosine kinase agonist.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20090215691 - Nogo receptor antagonists: Disclosed are immunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof and nucleic acids encoding the same. Also disclosed are compositions comprising, and methods for making and using, such Nogo receptor antibodies, antigen-binding fragments thereof, soluble Nogo receptors and fusion proteins thereof... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090215695 - Regulation of cytokine synthesis and release: Methods of treatment and prevention of diseases associated with release of neutrophil elastase and IL-8 by administration of TFPI and analogs of TFPI are disclosed. Methods of determining efficacy of treatment with TFPI, patient's responsiveness to treatment with TFPI, and the ultimate determination of patient prognosis are also disclosed.... Agent: Novartis Corporate Intellectual Property

20090215683 - Screening and therapeutic method for nsclc targeting cdca1-kntc2 complex: The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.... Agent: Townsend And Townsend And Crew, LLP

20090215696 - Toxoplasma gondii oocyst protein: Recombinant proteins have been developed for the detection of Toxoplasma gondii oocyst proteins for example in biological fluids. Isolated DNA sequences which encode these proteins have also been developed. The DNA sequences may be inserted into recombinant DNA molecules such as cloning vectors or expression vectors for the transformation of... Agent: Usda, Ars, Ott

20090215684 - Use of bpi protein for treatment of diseases: Use of a bactericidal/permeability-increasing (BPI) protein product for the manufacture of a medicament for therapeutic or preventive treatment of a disease involving a clinical disorder associated with insulin resistance in a human.... Agent: Berenbaum, Weinshienk & Eason, P.c

20090215697 - Composition for the treatment of atherosclerosis: The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least... Agent: Stites & Harbison Pllc

20090215698 - Lawsonia protein useful as a component in subunit vaccine and methods of making and using thereof: The present invention provides nucleic acid and amino acid sequences useful as the immunogenic portion of vaccines or immunogenic compositions effective for lessening the severity of the clinical symptoms associated with Lawsonia intracellularis infection or conferring protective immunity to an animal susceptible to such infection. Preferred amino acid sequences include... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090215700 - Metastin derivatives and use thereof: By substituting the constituent amino acids of metastin with specific amino acids, the metastin derivatives of the present invention achieve more improved blood stability, solubility, etc., reduced gelation tendency, improved pharmacokinetics, as well as exhibit an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity. The metastin derivatives... Agent: Edwards Angell Palmer & Dodge LLP

20090215699 - Pharmaceutically active antiviral peptides: The inventive peptides were found to have strong antiviral activity against HIV in general and particularly strong drug-resistant HIV activity without exerting any toxic or antiproliferative effects on cells. Consequently, using of the inventive peptides improves the conventional HIV therapy with its toxic side effects.... Agent: J C Patents, Inc.

20090215701 - Enhancement of iron chelation therapy: The present invention provides methods of enhancing the rate of iron release from ferritin. By increasing the amount of iron available for chelation, the invention also provides methods of treating conditions associated with iron overload. The invention also provides in one embodiment agents which are useful for treating iron overload.... Agent: Fenwick & West LLP

20090215702 - Uv-induced dermatitis inhibitor and atopic dermatitis inhibitor: At least one substance selected from the group consisting of a water-soluble peptide comprising at least one unit selected from the group consisting of an isoleucylglycylseryl unit, a prolylisoleucylglycylseryl unit, a glycylprolylisoleucylseryl unit, a glycylprolylisoleucylglycylthreonyl unit, a prolylisoleucylglycyl unit and a glycylprolylisoleucylglycyl unit and a water-soluble salt thereof can be... Agent: Wenderoth, Lind & Ponack, L.l.p.

20090215703 - Par-2 agonist: The present invention relates to a pharmaceutical composition for preventing/treating conditions associated with PAR-2. The present invention also relates to a method for preventing/treating the condition using the pharmaceutical composition and use for manufacturing the pharmaceutical composition. The pharmaceutical composition comprises a compound represented by the following general formula (1),... Agent: Westerman, Hattori, Daniels & Adrian, LLP

20090215705 - Alpha 7 nicotinic receptor selective ligands: The invention relates to the design and synthesis of 3-arylidene-anabaseine compounds that exhibit enhanced selectivity toward alpha7 nicotinic receptors. The compounds are expected to be useful in treating a wide variety of conditions, including neurodegenerative conditions such as Alzheimer's Disease, neurodevelopmental diseases such as schizophrenia, and certain peripherally located inflammations... Agent: Edwards Angell Palmer & Dodge LLP

20090215706 - C-linked glucuronide of n-(4-hydroxybenzyl) retinone, analogs thereof, and method of using the same to inhibit neoplastic cell growth: e

20090215704 - Health-related liquid compositions: There are disclosed liquid compositions comprising water, a fiber such as inulin, and a glycosaminoglycan that is selected from chondroitin sulfate, glucosamine, or a mixture thereof. The liquid compositions may further comprise at least one or more sweeteners, a source of calcium, at least one or more flavor additives, trehalose,... Agent: Cargill, Incorporated

20090215707 - Compound having cyclic structure and use thereof: e

20090215708 - Treatment of sexual dysfunction with proton pump agonists: Methods of treating a subject for sexual dysfunction are provided. Aspects of the methods include administering to the subject an effective amount of a proton pump agonist. Aspects of the invention further include proton pump agonist compositions employed in methods of the invention.... Agent: Bozicevic, Field & Francis LLP

20090215709 - Methylation markers for diagnosis and treatment of cancers: Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the... Agent: Banner & Witcoff, Ltd.

20090215710 - Carbohydrate based toll-like receptor (tlr) antagonists: The invention provides carbohydrate based compounds, methods of preparation, and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a carbohydrate based compound of the invention having a core structure comprising of one or more sugar moieties. The carbohydrate based compounds are useful... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090215711 - Novel compositions and methods in cancer: The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer that present novel therapeutic targets against cancer. The present invention... Agent: Novartis Vaccines And Diagnostics, Inc. Corporate Intellectual Property-r338

20090215861 - Antisense oligonucleotides for treating allergy and neoplastic cell proliferation: Antisense oligonucleotides for treating and/or preventing at least one of asthma, allergy, hypereosinophilia, general inflammation and cancer are provided. The oligonucleotides are directed against nucleic acid sequences coding for a receptor selected from the group consisting of a CCR3 receptor and a common sub-unit of IL-3, IL-5 and GM-CSF receptors.... Agent: David S. Resnick

20090215859 - Compositions and methods for modulating dhr96: Disclosed are compositions and methods for modulating DHR96 activity and identifying molecules that modulate DHR96 activity.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090215860 - Compositions and methods for regulating gene transcription: The invention is directed to compositions and methods for RNA-mediated gene regulation, e.g., transcription regulation, e.g., by transcriptional silencing of genes. In one aspect, the invention provides methods using siRNAs directed at a transcription regulator, e.g., a promoter or enhance sequence, of a gene target molecule. In one aspect, this... Agent: Morrison & Foerster LLP

20090215863 - Gene silencing of protease activated receptor 1(par1): The present invention relates to nucleic acid molecules, vectors, compositions, and methods useful for modulating protease-activated receptor 1 gene expression via RNA interference. In particular, the instant invention features small interfering RNA (siRNA) and short hairpin RNA (shRNA) molecules and methods for modulating the expression of protease-activated receptor 1 gene.... Agent: The Nath Law Group

20090215862 - Micro rna: Micro RNA capable of interacting with the 3′ untranslated region of kit protein mRNA is useful in treating kit-dependent tumours, and inhibitors therefor are useful in treating suppressed haematopoiesis in cancer patients or abnormal erythropoiesis in β-thalassemia, for example.... Agent: Foley & Lardner LLP

20090215865 - Nucleic acid molecules and collections thereof, their application and identification: The invention provides a method for characterising a sample comprising nucleic acid derived from a cell. The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA (miRNA) according to the invention or a mammalian ortholog thereof and characterizing the sample on... Agent: Traskbritt, P.c.

20090215864 - Oligoribonucleotide inhibitors of nrf2 and methods of use thereof for treatment of cancer: The invention provides novel double stranded oligoribonucleotides that inhibit the Nrf2 gene. The invention also provides a pharmaceutical composition comprising one or more such oligoribonucleotides, and a vector capable of expressing the oligoribonucleotide. The present invention also relates to methods and compositions for treating or preventing the incidence or severity... Agent: Cooper & Dunham, LLP

20090215866 - Akt ligands and polynucleotides encoding akt ligands: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate AKT activity. The ligands, homopolyligands, and heteropolyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal,... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090215874 - Aptamers as agonists: The present invention relates, in general, to aptamers and, in particular, to aptamers capable of stimulating target molecules and to methods of using same.... Agent: Nixon & Vanderhye, Pc

20090215867 - Cancer-cell-specific cell proliferation inhibitors: The present inventors discovered that although suppressing expression of the RecQ1 gene, a RecQ helicase family gene, shows suppressive effects on cell proliferation in cancer cells, such effects are not observed in human TIG3 cells (a normal diploid fibroblast cell line), which are normal cells. Hence, the present inventors discovered... Agent: Seed Intellectual Property Law Group Pllc

20090215880 - Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna: Introduction of double stranded RNA into cells, cell culture, organs and tissues, and whole organisms, particularly vertebrates, specifically attenuates gene expression.... Agent: Mueting, Raasch & Gebhardt, P.a.

20090215870 - Compositions and methods for targeting of viral vectors: Viral capsid proteins with increased targeting to neurons and increased retrograde transport are described. Chimeric virus particles comprising capsid proteins that (i) increase targeting to neurons and (ii) increase retrograde transport of the virus particle are described. Methods for introducing a nucleic acid into a neuron are also described.... Agent: Clark & Elbing LLP

20090215869 - Hepatitis c virus non-structural ns3/4a fusion gene: Aspects of the present invention relate to the creation of mutant hepatitis C virus (HCV) NS3/4A genes encoding proteins with altered protease activity. Embodiments include said NS3/4A genes, HCV peptides encoded by said nucleic acids, nucleic acids encoding said HCV peptides, antibodies directed to said peptides, compositions containing said nucleic... Agent: Knobbe Martens Olson & Bear LLP

20090215879 - Methods and compositions for adeno-associated virus (aav) with hi loop mutations: The invention provides modified AAV capsid proteins comprising substitutions in the HI loop. Suitable substitutions include affinity tags, sequences that facilitate detection and/or targeting peptides. The invention also provides virus capsids and virus vectors comprising the modified AAV capsid proteins and methods of using the same. Further provided are methods... Agent: Myers Bigel Sibley & Sajovec

20090215877 - Methods and compositions for the diagnosis and treatment of schizophrenia: Compositions and methods relating to the diagnosis and treatment of neuropsychiatric disorders, such as schizophrenia, schizoaffective disorders, and bipolar disorders are disclosed. Also provided are methods for screening therapeutic agents having efficacy for the treatment of such disorders.... Agent: Dann, Dorfman, Herrell & Skillman

20090215875 - Methods and kits for expanding hematopoietic stem cells: A method of increasing the expansion and/or differentiation of a hematopoietic stem cell (HSC) comprising: (a) increasing the level and/or activity of a polypeptide encoded by at least one gene selected from trim27, xbp1, sox4, smarcc1, sfpi1, fos, hmgb1, hnrpdl, vps72, tcfec, klf10, zfp472, ap2a2, gpsm2, gpx3, erdr1, tmod1, cnbp1,... Agent: Goudreau Gage Dubuc

20090215872 - Methods for controlling stem cell differentiation: Disclosed herein are methods for controlling stem cell differentiation through the introduction of transgenes having Xic, Tsix, or Xite sequences to block differentiation and the removal of the transgenes to allow differentiation. Also disclosed are small RNA molecules and methods for using the small RNA molecules to control stem cell... Agent: Clark & Elbing LLP

20090215876 - Mitotic progression genes and methods of modulating mitosis: The invention features methods of identifying candidate therapeutic compounds for the treatment of proliferative disorder. The invention also features methods for treating a proliferative disorder.... Agent: Clark & Elbing LLP

20090215871 - Simian adenovirus vectors and methods of use: A recombinant vector comprises a simian adenovirus capsid and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided.... Agent: Howson & Howson LLP

20090215868 - Therapeutic medicament for chronic obstructive pulmonary disease (copd), cystic fibrosis, and pulmonary hypertension: The present invention provides a prophylactic, therapeutic or ameliorative medicament for chronic obstructive pulmonary disease (COPD), cystic fibrosis or pulmonary hypertension. More specifically, the present invention provides: (1) a prophylactic, therapeutic or ameliorative medicament for chronic obstructive pulmonary disorder (COPD), cystic fibrosis or pulmonary hypertension, having an NF-κB decoy as... Agent: Banner & Witcoff, Ltd.

20090215873 - Therapeutic molecules and their uses: The present invention relates with the identification and use of oligonucleotides acting by a sequence independent mode of action for the prevention and treatment of thrombotic disorders, cholesterol related disorders, dyslipidemia, osteoporosis and snake venom effects.... Agent: Ogilvy Renault LLP

20090215878 - Treatment of chronic pain with zinc finger proteins: A variety of zinc finger proteins (ZFPs) and methods utilizing such proteins are provided for use in treating chronic pain. ZFPs that bind to a target site in genes that are aberrantly expressed in subjects having chronic pain are described. In addition, ZFPs that bind to a target site in... Agent: Townsend And Townsend And Crew, LLP

20090215712 - Pyrazole derivatives: The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest... Agent: Pfizer Inc Steve T. Zelson

20090215715 - Phosphoramidate derivatives of nucleoside compounds for use in the treatment of cancer: Phosphoramidate derivatives of nucleoside compounds such as cladribine, isocladribine, fludaribine and clofarabine have enhanced therapeutic potency in homo sapiens, in particular, enhanced potency with respect to a cancer such as leukaemia. Suitably the phosphoramidate is substituted at the P atom by Ar—O, where Ar is aryl or heteroaryl, either of... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.a.

20090215714 - Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder: The invention is based on the discovery that specific dosages of pyrimidine compositions, such as cytidine compositions, can be used to treat patients diagnosed with bipolar disorder.... Agent: Clark & Elbing LLP

20090215713 - Use of atp for the manufacture of a medicament for the prevention and treatment of oxidative stress and related conditions: The present invention provides the use of ATP for the manufacture of a medicine comprising ATP as an active ingredient for exerting a preventive or therapeutic pharmacological effect when administered to a mammal, preferably a human, selected from the group consisting of: a. modulating oxidative stress and the effects thereof... Agent: Kalow & Springut LLP

20090215716 - Nitroguanosine-3' 5'-cyclic monophosphate compound and protein kinase g activating agent: An object of the present invention is to provide a novel compound that is an agonist of guanosine-3′,5′-cyclic monophosphate and has an effect of activating protein kinase G. The present invention provides 8-guanosine-3′,5′-cyclic monophosphate compound which is represented by the following formula, and a pharmaceutical composition, especially a protein kinase... Agent: Greenblum & Bernstein, P.L.C

20090215718 - Carbohydrate composition for flat glucose response:

20090215717 - Sulfated oligosaccharides: The invention relates to sulfated oligosaccharides, more particularly to new pharmaceutical uses of sulfated oligosaccharides. The invention provides a method of preventing, treating or alleviating the symptoms of acute and chronic’, inflammatory disorders of the airways of mammals—including asthma and asthma-related pathologies. The invention further provides use of a sulfated... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090215721 - Dietary compositions and related methods of use: The present invention provides dietary compositions for mammalian consumption. In particular, the present invention provides compositions comprising pectin, a component comprising electrolytes, thickening agents, a sweetening agent, and water, and methods for making such compositions. In some embodiments, the dietary compositions are used for preventing and/or treating malabsorption dysfunction and... Agent: Casimir Jones, S.c.

20090215719 - Low molecular weight hyaluronic acid and/or salt thereof, method for producing same, and cosmetic preparation and food composition containing same: A low-molecular-weight hyaluronic acid and/or its salt is obtained by dispersing hyaluronic acid and/or its salt in an acidic water-containing medium.... Agent: Roetzel And Andress

20090215720 - Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation: A use of an anti-inflammatory polysaccharides composition comprising fucans and galactans to inhibit the release of one or more of IL-8, PGE2 and VEGF by a cell activated during an inflammatory process and an anti-inflammatory composition comprising a ratio of brown algae fucans/red algae galactans of between about 2.5/1 (w/w)... Agent: Wells St. John P.s.

20090215722 - Inhibition of antigen presentation with poorly catabolized polymers: Methods to prevent the rejection of immunogenic tissues in an animal by administering a non-immunogenic, poorly catabolized molecule in an amount sufficient to inhibit an immune response are described herein. Also described are compositions that are useful for inhibiting immune responses in animals that are recipients of cellular transplants. For... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper LLP (us)

20090215723 - Organic silicic acids complex for therapeutic and cosmetic applications: This invention describes materials containing organic silica, used in cosmetic for external uses (gel, cream or lotion) or for internal uses (microbeads/beads, tablets or solutions). These materials are vegetable extracts such as bamboo or algae which constitute richest sources in organic silica (more soluble and assimilable). After extraction in a... Agent: David S. Resnick

20090215724 - Pyrrolopyrazine kinase inhibitors: i

20090215725 - Substituted 4-aminocyclohexane derivatives:

20090215726 - Phosphono-pent-2-en-1-yl nucleosides and analogs: Compounds and compositions are provided for treatment, prevention, or amelioration of a variety of medical disorders associated with viral infections and/or cell proliferation. The compounds provided herein are 5-phosphono-pent-2-en-1-yl nucleosides and esters thereof.... Agent: Jones Day

20090215727 - Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphate and vitamin b6 related compounds: P5P can be used as effective treatments for the modulation of P2X7, IL-1β, and inflammation response, and for diseases in which prevention of P2X7-dependent pathways or prevention of release of IL-1β is desirable, such as epithelial cancer, leukemia, brain tumors, spinal cord injury, tuberculosis, Alzheimer's Disease, neurodegenerative diseases, autosomal recessive... Agent: Merchant & Gould Pc

20090215728 - Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use: P

20090215729 - Microparticle compositions to modify cancer promoting cells: This invention provides pharmaceutical compositions and methods related to the prevention and treatment of primary tumors and metastatic, malignant or spreading cancers by selectively targeting cancer associated myeloid derived cells by the targeted delivery of a bisphosphonate formulated with a non-liposomal particle carrier. In some aspects, the bisphosphonate particles have... Agent: Fenwick & West LLP

20090215730 - Antineoplastic compounds and pharmaceutical compositions thereof: Chemical compounds derived by in silico molecular modelling, having a well defined structure suitable for the blocking of the phosphorylation event, through the specific interaction of the chemical with the Casein Kinase 2 enzyme substrate phosphorylation domain or it's neighbourhood. This invention comprises also the pharmaceutical compositions containing such compounds,... Agent: Hoffmann & Baron, LLP

20090215731 - Reduction of side effects from aromatase inhibitors used for treating breast cancer: The present invention is directed generally to pharmaceutical compositions, methods, and kits for improving side effects associated with aromatase inhibitor treatment in a subject diagnosed with breast cancer. More specifically, the present invention provides compositions, methods, and kits comprising an aromatase inhibitor and an androgenic agent.... Agent: Jones Day

20090215732 - Combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma: The present invention provides pharmaceutical compositions comprising a glucocorticosteroid and a compound of formula: wherein m, R1, R2, R3, and R4 are as defined in the specification, and their use in therapy.... Agent: Fish & Richardson P.c.

20090215734 - Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations: Inhalation solutions for administration of muscarinic antagonists for the treatment of breathing disorders, such as COPD, are provided.... Agent: Wilson Sonsini Goodrich & Rosati

20090215733 - Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake: Methods of treating or reducing the risk of one or more effects or signs of induced hypogonadism after androgen or GnRH intake are disclosed herein. In an embodiment, a method of treating one or more effects after androgen or gonadotropin releasing hormone (GnRH) analogue intake comprises administering to a male... Agent: Eric P. Mirabel

20090215735 - Topical solution formulations containing a corticosteroid and a cyclodextrin: Solution formulations containing a corticosteroid, cyclodextrin, and xanthan gum are disclosed. The formulations are intended for topical application to the eye, ear, or nose.... Agent: Alcon

20090215736 - Caspase inhibitors and uses thereof: wherein Z is oxygen or sulfur; R1 is hydrogen, —CHN2, R, CH2OR, CH2SR, or —CH2Y; between R3 and R4 represents a single or double bond; Y is an electronegative leaving group; R2 is CO2H, CH2CO2H, or esters, amides or isosteres thereof; R3 is a group capable of fitting into... Agent: Vertex Pharmaceuticals Inc.

20090215737 - Pharmaceutical compositions - 2: The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of... Agent: Hollis-eden Pharmaceuticals, Inc.

20090215738 - Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake: Disclosed is a is a treatment for the adverse psychological effects (including depression, low self esteem, guilt, increased stress, anhedonia, decreased cognition, sleep disturbances, general fatigue, agitation/motor dyskinesia and decreased appetite) resulting from androgens or GnRH analogue intake, by administering a compound which antagonizes estradiol or its receptors, or blocks... Agent: Eric P. Mirabel

20090215739 - Chemical method of making a suspension, emulsion or dispersion of pyrithione particles: A method for producing a suspension, emulsion or dispersion of de-agglomerated particles (advantageously submicron-sized particles) of pyrithione salts comprising contacting agglomerated pyrithione salt particles with a de-agglomerating agent to produce the desired de-agglomerated pyrithione salt particles. Also disclosed is a method for making de-agglomerated submicron-sized particles of pyrithione salts comprising... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090215740 - Therapeutic substituted beta-lactams: m

20090215741 - 1h-pyrimido[4,5-b]indole derivatives, their preparation and therapeutic use:

20090215742 - Amide resorcinol compounds:

20090215743 - Tricyclic benzazepine derivatives and their use: The present application relates to novel tricyclic benzazepine derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, preferably for the treatment and/or prevention of cardiovascular disorders, especially of dyslipidaemias, arteriosclerosis, restenosis and... Agent: Barbara A. Shimei Director, Patents & Licensing

20090215744 - Solid formulations: The present invention is directed to solid formulations of the pharmaceutical compound 11-piperazin-1-yldibenzo[b,f][1,4]thiazepine as well as preparations, and pharmaceutical uses thereof.... Agent: Pepper Hamilton LLP

20090215745 - Association of a sinus node if current inhibitor and a calcium inhibitor, and pharmaceutical compositions containing it: e

20090215746 - Substituted pyrazolo[1,5-a]pyrimidines as calcium receptor modulating agents:

20090215747 - Heterocyclic compounds as inhibitors of beta-lactamases: This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in... Agent: Harness, Dickey & Pierce, P.L.C

20090215748 - Fxr agonists for treating vitamin d associated diseases: Provided are certain methods of treating at least one condition that can be treated by elevating the vitamin D receptor (VDR) activity level in a patient with at least one farnesoid X receptor (FXR) agonist. Also provided are certain methods of modulating levels of Cytochrome P450, family 27, subfamily B,... Agent: Wyeth/finnegan Henderson, LLP

20090215750 - Pyrrolopyrazine kinase inhibitors: o

20090215749 - Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor: The present invention is related to thiazolidine carboxamide derivatives of formula (II) for the treatment and/or prophylaxis of preterm labor, premature birth, dysmenorrhea and for stopping labor prior to cesarean delivery.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.c.

20090215751 - Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse: The invention relates to methods of and treatments for using pharmaceutical compositions from a class of compounds that directly or indirectly selectively modulates GABAA chloride channel activity to treat alcohol and/or stimulant substance abuse. The present invention also relates to methods of, and protocols for, relieving symptoms associated with alcohol... Agent: John S. Pratt, Esq Kilpatrick Stockton, LLP

20090215752 - Compounds, preparation and therapeutic use thereof: The invention relates to benzodiazepine derivatives having PDE2 inhibitory activities, as well as therapeutic methods of administering said compounds, in particular for treating various diseases of the central or peripheral nervous system. The invention further includes methods of preparing the subject compounds and pharmaceutical compositions containing them.... Agent: Gibbons P.c.

20090215753 - Topical compositions for paediatric use: The present invention provides pharmaceutical compositions for treating a paediatric mammal, the compositions comprising a therapeutic agent and a pharmaceutically acceptable carrier, the composition being suitable for topical application resulting in transdermal administration of the therapeutic agent and a systemic therapeutic effect. The invention also provides relates uses of the... Agent: Davidson, Davidson & Kappel, Llc

20090215754 - Methods and compositions for the treatment of neuropsychiatric and addictive disorders: The present invention relates to methods and compositions for treating neuropathic pain and neuropsychiatric disorders by administering agents that are effective in reducing the effective amount, inactivating, and/or inhibiting the activity of a Na+—K+-2Cl− (NKCC) cotransporter. In certain embodiments, the Na+—K+-2Cl− co-transporter is NKCC1.... Agent: Hunton & Williams LLP Intellectual Property Department

20090215755 - Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity: Use of a pyrazole-derived compound that is an antagonist for cannabinoid CB1 receptors, alone or combined with another active principal, for preparing medicinal products that are useful in the prevention and treatment of dyslipidemias and of diseases related to dyslipidemias and/or to obesity, such as metabolic syndrome, cardiovascular risks and... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090215756 - Formulations containing losartan and/or its salts: The invention relates, in general, to new formulations and dosage units containing losartan and/or its salts (e.g., losartan potassium) that are useful for the therapeutic treatment (including prophylactic treatment) of mammals, including humans, and a process for making the same. The process generally includes (i) mixing and blending losartan potassium... Agent: Hogan & Hartson LLP Ip Group, Columbia Square

20090215757 - Process for preparation of high-purity meloxicam and meloxicam potassium salt: The invention provides a process for the preparation of high purity meloxicam of the Formula (II). The meloxicam raw product is reacted with the solution of potassium hydroxide or potassium carbonate, whereby high purity meloxicam potassium salt monohydrate is produced. Said salt is subsequently treated with mineral or organic acid... Agent: K.f. Ross P.c.

20090215759 - Modulators for amyloid beta: wherein the substituents are as described in claim 1. Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090215758 - Use of 2,5-disubstituted thiazol-4-one derivatives in drugs: The invention relates to 2,5-disubstituted thiazol-4-one derivatives and to their use in the production of drugs, to methods for producing them and to drugs containing said compounds.... Agent: Crowell & Moring LLP Intellectual Property Group

20090215760 - Synergistic insecticide mixtures: The invention relates to insecticidal mixtures, comprising ethiprole and at least one other known active substance, belonging to the neonicotinoid family as well as to the use of said mixtures for controlling animal pests.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090215761 - Quinobenzoxazine analogs and methods of using thereof: e

20090215762 - Siloxane polymer containing tethered levofloxacin: A polymer that is a polysiloxane polymer has Levofloxacin groups, or pharmaceutically acceptable salts thereof, attached via linkers. The linkers may be hydrolytically labile thereby providing a manner of releasing the Levofloxacin from the polymer.... Agent: Foley & Lardner LLP

20090215763 - Substituted benzoxazinones: The present invention provides substituted oxazinone compounds, such as substituted benzoxazinones, which exhibit potent renin inhibition activities.... Agent: Townsend And Townsend And Crew, LLP

20090215764 - Antimicrobial agents: Provided herein are substituted aromatic compounds, which are tRNA synthetase inhibitors, and hence can be used as antimicrobial agents. Compounds described herein can be used for the treatment or prevention of a condition caused by or contributed to by gram positive, gram negative, anaerobic bacteria or fungal organisms, more particularly... Agent: Ranbaxy Inc. Intellectual Property Dept.

20090215765 - Neuroprotective compounds for treating optic neuropathies: Neuroprotective compounds for treating optic neuropathies and screening methods for identifying neuroprotective compounds.... Agent: Banner & Witcoff, Ltd.

20090215766 - Tetracyclic inhibitors of janus kinases: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.... Agent: Fish & Richardson Pc

20090215767 - Isoflavone derivatives and pharmaceutical compositions comprising the same: wherein R1 and R2, independently, include C1-C12 alkyl optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy, and R3 includes hydrogen, hydroxy or C1-C12 alkoxy optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy. The invention also provides a pharmaceutical composition for treatment of osteoporosis including... Agent: Muncy, Geissler, Olds & Lowe, Pllc

20090215768 - Isoxazole derivatives and pharmaceutical compositions comprising the same: wherein R1, R2, R3, R4 and R5, independently, include hydrogen, hydroxy or C1-C12 alkoxy optionally substituted with oxirane, thiirane, aziridine, amino, cycloamino, aminohydroxy or cycloaminohydroxy. The invention also provides a pharmaceutical composition for treatment of osteoporosis and cancer including an isoxazole derivative or a pharmaceutically acceptable salt thereof and a... Agent: Muncy, Geissler, Olds & Lowe, Pllc

20090215769 - Use of soluble guanylate cyclase activators for the treatment of raynaud's phenomenon: The present invention relates to a method for prevention or treatment of primary and secondary Raynaud's phenomenon comprising administration of an effective amount of a compound selected from compounds of formulae I-IV, and to pharmaceutical compositions containing these compounds.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090215771 - Jnk inhibitors: The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.... Agent: Wilmerhale/boston

20090215770 - Substituted quinazoline derivatives as inhibitors of aurora kinases: e

20090215773 - Dihydropyridine derivatives: The present invention relates to dihydropyridine derivatives having general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, phenyl, (1-5C)heteroaryl R2, R3 are independently (1-4C)alkyl, (2-4C)alkenyl, (2-4C)alkynyl, (1-4C)alkoxy, (24C)alkenyloxy, (2-4C)alkynyloxy, halogen X is SO2, CH2, C(O) or X is absent R4 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl,... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20090215772 - Hydroxybenzamide derivatives and their use as inhibitors of hsp90: e

20090215774 - Uses of indane compounds:

20090215776 - Organic compounds: in free or salt or solvate form, where T1, T2, X, Ra, Rb, R8 and R9 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds... Agent: Novartis Institutes For Biomedical Research, Inc.

20090215775 - Sulphonamido-substituted cyclohexyl sulphones for treatment of cancer: Compounds of formula (I) are disclosed for treatment of cancer.... Agent: Merck And Co., Inc

20090215778 - Alpha-substituted arylmethyl piperazine pyrazolo [1,5-alpha]pyrimidine amide derivatives: m

20090215777 - Pyrimidine derivatives as hsp90 inhibitors: The invention provides a compound for use as an inhibitor of Hsp90, the compound having the formula (I): or salts, tautomers, solvates or N-oxides thereof; wherein: A is N or a group CR3; R1 is a monocyclic or bicyclic carbocyclic or heterocyclic ring of 5 to 10 ring members of... Agent: Heslin Rothenberg Farley & Mesiti Pc

20090215779 - Oxadiazole derivatives as dgat inhibitors: e

20090215780 - Preparation and use of aryl alkyl acid derivatives for the treatment of obesity: This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090215781 - Alpha-helix mimetics and methods relating to the treatment of fibrosis: The invention provides α-helix mimetic structures of formula (I) with the definitions of A, B, D, E, G, W, R1 and R2 as set out in the description and a chemical library relating thereto. The compounds, pharmaceutical compositions comprising the compounds, and methods of the invention using the compounds, relate... Agent: Davis Wright Tremaine, LLP/seattle

20090215783 - Composition for induction or inhibition of stem cell differentiation: The present invention relates to composition and methods for inducing or inhibiting differentiation of stem cells. The invention also relates to applications in the treatment of medical conditions, e.g., osteoporosis, bone fracture, bone injuries, myocardiac infarction, cardiomyopathy, degenerative muscle diseases, myopathy, and urinary incontinence.... Agent: Seed Intellectual Property Law Group Pllc

20090215782 - Use of pde-5 inhibitors for endothelial repair of tissues impaired by trauma or disease: The invention relates generally to neovascularization and endothelial repair of tissues impaired by trauma or disease. Particularly, the invention relates to the function of endothelial progenitor cells in neovascularization and endothelial repair. More particularly, the invention relates to methods and pharmaceutical compositions for the treatment of tissues impaired by trauma... Agent: Dickstein Shapiro LLP

20090215784 - Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine: A novel maleate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.... Agent: Heslin Rothenberg Farley & Mesiti P.c.

20090215785 - Pyrrolopyrazine kinase inhibitors: n

20090215786 - Novel cysteine protease inhibitors and their therapeutic applications: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use.... Agent: Stites & Harbison Pllc

20090215787 - Preparations of new polymorphic forms of varenicline tartrate: The present invention is directed to an amorphous form, three novel polymorph form of crystalline varenicline tartrate, namely Form D, Form E and Form F. The present invention also provides processes of their preparations and pharmaceutical composition comprising such material and their use in therapy. Form D is new anhydrous... Agent: Mai De Ltd.

20090215788 - Pyrrolopyrazine kinase inhibitors: e

20090215789 - Cyclic hexadepsipeptides, processes for their production and their use as pharmaceuticals: The present invention provides cyclic hexadepsipeptides and their pharmaceutically acceptable salts, solvates and prodrugs, and methods for obtaining the compounds, by fermentation, optionally followed by post-biosynthesis chemical modification. The present invention further provides uses of cyclic hexadepsipeptides, and their pharmaceutically acceptable salts, solvates and prodrugs as pharmaceuticals, in particular to... Agent: Merchant & Gould Pc

20090215790 - Substituted oxindole derivatives, medicaments containing the latter and use thereof: The invention relates to novel oxindole derivatives of general formula (I), in which the substituents R1, R2, R3, Y1, Y2, m, n, W, X, B and Z are defined as cited in claim 1, to medicaments containing said derivatives and to the use of the latter for the prophylaxis and/or... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090215791 - New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine: 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine or a salt thereof is useful for the treatment of pain.... Agent: Hamilton, Brook, Smith & Reynolds, P.c.

20090215792 - Method of treating chronic myelogenous leukemia cells: Here, the inventors disclose the treatment of imatinib mesylate resistant chronic myelogenous leukemia cells with a cotreatment of vorinostat (SAHA, suberoylanilide hydroxamic acid) and dasatinib, a dual Abl/Src kinase (TK) inhibitor. Combined treatment of cultured human CML and BaF3 cells with vorinostat and dasatinib induced more apoptosis than either agent... Agent: Smith Hopen, Pa

20090215793 - Methods for treating drug resistant cancer: A method for treating drug-resistant cancer, includes: administering to a patient in need thereof, a compound of formula I, a tautomer of the compound, a salt of the compound, a salt of the tautomer, a mixture thereof, or a pharmaceutical composition comprising the compound, the tautomer, the salt of the... Agent: Foley & Lardner LLP

20090215794 - Serotonergic agents: m

20090215795 - Cyclic amidine derivatives:

20090215796 - Compositions, kits and methods for a titration schedule for pardoprunox compounds: The present invention is directed to compositions, kits, and methods for a titration schedule to facilitate the treatment of a central nervous system condition or disorder by administering a plurality of dosage units of a composition comprising a compound 7-(4-methyl)-1-piperazinyl-2(3H)-benzoxazolone (INN pardoprunox).... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090215797 - Stable emulsifiable concentrate formulation: The use of an N,N-dimethyl alkylamide or an N-alkanoyl morpholine provides a stable emulsifiable concentrate composition that hinders de-esterification and transesterification of mixtures of a carboxylic acid herbicide and an ester of a different carboxylic acid herbicide. The N,N-dimethyl alkylamide or N-alkanoyl morpholine additionally stabilizes emulsifiable concentrates containing a triazolopyrimidine... Agent: Dow Agrosciences Llc

20090215798 - Inhibitor compounds: The present invention relates to compounds and uses of compounds which interact with chitinase enzymes, in particular inhibition of those enzymes.... Agent: Myers Bigel Sibley & Sajovec

20090215800 - Enzyme and receptor modulation: Covalent conjugation of an alpha amino acid ester to a modulator of the activity of a target intracellular enzyme or receptor, wherein the ester group of the conjugate is hydrolysable by one or more intracellular carboxylesterase enzymes to the corresponding acid, leads to accumulation of the carboxylic acid hydrolysis product... Agent: Banner & Witcoff, Ltd.

20090215799 - Heterocyclic substituted bisarylurea derivatives: The present invention relates to heterocyclic substituted bisarylurea derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said... Agent: Arent Fox LLP

20090215802 - Deuterium-enriched lapatinib: The present application describes deuterium-enriched lapatinib, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, Pc

20090215801 - Novel 2-aminopyrimidinone derivatives and their use: This invention relates to novel compounds having the structural formula I below: (I) and to their pharmaceutically acceptable salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.... Agent: Pepper Hamilton LLP

20090215803 - Pyrimidinones as casein kinase ii (ck2) modulators: A compound having Formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1 and R2 are defined in the specification; pharmaceutical compositions thereof; and methods of use thereof.... Agent: Patent Dept Exelixis, Inc.

20090215805 - 4-heteroaryl pyrimidine derivatives and use thereof as protein kinase inhibitors: The present invention relates to compounds of formula (I) or formula (II), or pharmaceutically acceptable salts thereof. Further aspects relate to pharmaceutical compositions comprising compounds according to the invention, and the use of said compounds in the preparation of a medicament for treating a variety of disorders, including proliferative disorders,... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090215804 - Fumarate of 4- [[4- [[4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino] -2-pyrimidinyl]amino]benzonitrile: The present invention relates to the fumarate salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.... Agent: Philip S. Johnson Johnson & Johnson

20090215806 - Rosuvastatin calcium with a low salt content: Provided is rosuvastatin calcium with a low salt by product content and processes for preparing such rosuvastatin calcium.... Agent: Kenyon & Kenyon LLP

20090215807 - Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases: The invention provides compounds of general formula. [Chemical formula should be inserted here. Please see paper copy] (II) wherein R and R1 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Morgan Lewis & Bockius LLP

20090215809 - Crystalline form of a (3s)-aminomethyl-5-methyl-hexanoic acid prodrug and methods of use: A crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug and methods of preparing a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug, and methods of using a crystalline form of a (3S)-aminomethyl-5-hexanoic acid prodrug are provided.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090215808 - Oral pharmaceutical dosage forms: Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.... Agent: Durect Corporation Thomas P. Mccracken

20090215810 - Method to treat premature ejaculation in humans: The present invention belongs to the fields of pharmacology, medicine and medicinal chemistry, and provides methods and compositions for treating sexual dysfunction; more particularly, the invention relates to treatment of premature ejaculation in humans.... Agent: Fulbright & Jaworski L.l.p.

20090215811 - Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion: The present invention relates to a pharmaceutical composition including loratidine, its use in the treatment of upper respiratory mucosal congestion and a method of administration of the composition. Particularly, though not exclusively, the invention relates to a pharmaceutical composition including loratidine in an amount suitable for administration a maximum of... Agent: Edwards Angell Palmer & Dodge LLP

20090215812 - Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor: The present invention provides compositions and methods for evaluating the likelihood that a tumor is sensitive to an mTOR inhibitor, e.g., rapamycin or a rapamycin analog. The invention provides FKBP proteins as biomarkers for predicting the likelihood that a tumor is sensitive to an mTOR inhibitor. The methods include assessing... Agent: Choate, Hall & Stewart LLP

20090215813 - Histone deacetylase inhibitors as immunosuppressants: A method of preventing or suppressing an immune response or immune mediated response comprising administering an effective amount of an histone deacetylase inhibitor compound alone or in combination with a second pharmacologically active agent.... Agent: Novartis Corporate Intellectual Property

20090215814 - Method of inhibiting neurotrophin-receptor binding: The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75NTR common neurotrophin receptor and methods of use thereof. In one embodiment, the compound which inhibits binding of nerve growth factor to p75NTR comprises, particularly when bound to nerve growth factor, at least two... Agent: Gowling Lafleur Henderson LLP

20090215815 - Neurotrophin antagonist compositions: e

20090215816 - Imidazo(1,2-a)pyridine derivatives useful as peptide deformylase (pdf) inhibitors: The present invention relates to compounds of formula (I). These compounds are a novel type of peptide deformylase (PDF) inhibitors, and are therefore of great interest especially as new antibiotics.... Agent: Novartis Corporate Intellectual Property

20090215817 - Novel triazolopyridine compounds for the treatment of inflammation: wherein R1, R2, R3, R4, and R5 are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with... Agent: Pharmacia Corporation Global Patent Department

20090215818 - Thiozolidinedione derivatives as pi3 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using thiozolidinedione derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090215819 - Anti-infective and immunomodulatory compounds: The present invention provides pharmaceutical compositions and methods that include the use of anti-infective compounds that potentiate the host-immune response or limit or prevent the expression or activity of individual virulence factors. In addition, the compositions have immunomodulatory activity, and therefore can be used to prime host defenses to prevent... Agent: Clark & Elbing LLP

20090215820 - Novel alkyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: e

20090215823 - Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor: The present invention relates to methods for decreasing cellular DNA repair in a patient diagnosed with or suspected to have chronic lymphocytic leukemia (CLL); decreasing cellular NAD+ biosynthesis in a patient diagnosed with or suspected to have CLL; or sensitizing a patient diagnosed with or suspected to have CLL to... Agent: Wilmerhale/boston

20090215821 - N-substituted azacycles: wherein m, q, r, t and u are independently selected from 0 or 1; and p is 0, 1, 2, or 3; and A, B, D, X, Y, R, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are fully described herein. The compounds being particularly useful... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090215822 - Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors: The present invention relates to new compounds which are Oxadiazole derivatives of formula (I) wherein B, P, Q, W, R1 and R2 are defined in the description. Invention compounds are useful in the prevention or treatment of central or peripheral nervous system disorders as well as other disorders modulated by... Agent: Edwards Angell Palmer & Dodge LLP

20090215824 - Indazole derivatives as inhibitors of hormone sensitive lipase: The present invention relates to indazole derivatives of the general formulae I or II having the meanings indicated in the description, to the pharmaceutically useful salts thereof and the use thereof as drugs.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090215825 - Substituted pyrazoles, compositions containing such compounds and methods of use: The present invention relates to substituted pyrazoles, compositions containing such compounds and methods of treatment The compounds are glucagon receptor antagonists and thus are useful for treating, preventing or delaying the onset of type 2 diabetes mellitus.... Agent: Merck And Co., Inc

20090215826 - Solid forms of a pyrrolidine-3,4-dicarboxamide derivative: The invention is concerned with crystalline forms or amorphous forms of a pyrrolidine-3,4-dicarboxamide derivative, which is useful as an active ingredient of medicaments for the diseases which can be treated by the coagulation factor Xa inhibitors.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090215827 - Inhibitors of cxcr2: in which R1, R2, X, A, B and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable... Agent: Andrea Q. Ryan Sanofi-aventis U.s. Llc

20090215828 - Substituted indole derivatives: Substituted indole derivatives, processes for the preparation thereof, medicinal products and pharmaceutical compositions containing these compounds and the use of substituted indole derivatives to treat pain and other conditions and for other medical purposes.... Agent: Norris, Mclaughlin & Marcus, Pa

20090215829 - Thiophene carboxamides as inhibitors of the enzyme ikk-2: b

20090215831 - Inhibitors of the gastric h+, k+-atpase with enhanced therapeutic properties: Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.... Agent: Global Patent Group - Apx

20090215830 - Multiple ppi dosage form: Herein provided are dosage forms (variously referred to as “formulations”) comprising a PPI that is released from the dosage form as a first and a second dose. Each dose of PPI is present in an amount sufficient to raise the plasma levels of the PPI to at least 100 ng/ml.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090215832 - Method of combating turf pests with a combination of imidacloprid and bifenthrin: This invention relates to a method of controlling surface insect pests of turf using bifenthrin and imidacloprid.... Agent: Bayer Cropscience Lp

20090215833 - Thermodynamically stable form of a tosylate salt: The present invention relates to a novel form, thermodynamically stable at room temperature, of the tosylate salt of 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide, to processes for its preparation, to medicaments comprising it and to its use in the control of disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090215834 - Heterocyclic inhibitors of mek and methods of use thereof: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, and W are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of... Agent: Hogan & Hartson LLP

20090215835 - Treatment of cancer with sorafenib: The present invention provides compositions and methods for treating specific cancers with effective amounts of sorafenib.... Agent: Millen, White, Zelano & Branigan, P.c.

20090215836 - Roflumilast for the treatment of pulmonary hypertension: The invention relates to the use of Roflumilast, Roflumilast N-Oxide or a pharmaceutically acceptable salt of either for the treatment of pulmonary hypertension. The invention additionally relates to the use of Roflumilast, Roflumilast N-oxide or a pharmaceutically acceptable salt of either in combination with a PDE5 inhibitor or a pharmaceutically... Agent: Nath & Associates Pllc

20090215837 - Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss: in which R1 and R2 represent, independently of one another, OH, OR′, —NH2, —NHR′ or —NR′R″, and R′ and R″ represent, independently of one another, a saturated or unsaturated and linear or branched C1-C18 alkyl radical or an aryl radical, this alkyl or aryl radical optionally being substituted by at... Agent: Buchanan, Ingersoll & Rooney Pc

20090215838 - Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use: The invention describes compositions and kits comprising at least one organic nitric oxide enhancing salt of an angiotensin π antagonist, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating cardiovascular diseases; (b) treating renovascular diseases; (c)... Agent: Wilmerhale/dc

20090215839 - Sydnonimines-specific dopamine reuptake inhibitors and their use in treating dopamine related disorders: Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.... Agent: Dann, Dorfman, Herrell & Skillman

20090215840 - Methods for treating schizophrenia: Treatment of schizophrenia or humans suffering from conditions associated with high dopamine levels in ventral striatum or caudate nucleus administers the compound (2S)-2-{3-[3-({[(2R,4R)-4-tert-Butoxycarbonyl-2-(2-fluorophenyl)]-3-thiazolidinyl}carbonylmethyl) ureido]phenyl} propionic acid and its physiological acceptable salts.... Agent: The Marbury Law Group, Pllc

20090215841 - D2 receptor ligand-078: e

20090215842 - Method of treating schizophrenia prodrome: The present invention relates to a method of treating schizophrenia prodrome in human subjects using a NMDA glycine site agonist, a glycine transporter-1 inhibitor or mixtures thereof, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.... Agent: Coleman Sudol Sapone, P.c.

20090215844 - Compositions comprising nebivolol: Nebivolol has been shown to be beneficial in the treatment of cardiovascular diseases such hypertension, congestive heart failure, arterial stiffness and endothelial dysfunction. The present invention features a pharmaceutical composition comprising nebivolol and at least one other active agent, wherein the at least one other active agent is a cardiovascular... Agent: Frost Brown Todd, Llc

20090215843 - Tetrazole derivatives and their use for the treatment of cardiovascular diseases: The present application relates to novel tetrazole derivatives, processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090215845 - Fungicidal mixtures: Synergistically effective mixtures comprising prochloraz and tebuconazole and fungicidal compositions based thereon are highly suitable for protecting industrial materials, in particular wood and timber products, against attack, damage and/or destruction by biological pests.... Agent: Nicanor A Kohncke Lanxess Corporation

20090215846 - (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors: The invention provides compounds of the formula (I) wherein the variables are as defined in the specification. The compounds of the invention are inhibitors of metalloproteinase MMP-12 and are among other things useful for the treatment of obstructive airway diseases, such as chronic obstructive pulmonary disease (COPD).... Agent: Birch Stewart Kolasch & Birch

20090215848 - Novel imidazolidin-2-one derivatives as selective androgen receptor modulators (sarms): e

20090215847 - Tricyclic angiotensin ii agonists: wherein the dotted line, X1, X2, X3, A, Y1, Y2, Y3, Y4, Z1, Z2, R2 and R3 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful as selective agonists of the AT2 receptor, and thus, in particular, in the treatment of inter alia gastrointestinal conditions,... Agent: Nixon & Vanderhye, Pc

20090215849 - High stability aqueous gels comprising metronidazole and methods for the preparation thereof: e

20090215850 - Method for treating cb2 receptor mediated pain:

20090215851 - Method of preparing a porphyrin derivative, a porphyrin derivative, use of said porphyrin derivative and a pharmaceutical composition containing said porphyrin derivative: The present invention relates to a method of preparing a porphyrin derivative from a meso-acrylonitrile-substituted porphyrin compound. According to the invention a Vilsmeier reagent carrying an aromatic ring is used, wherein said Vilsmeier reagent is a soft electrophile. The use of this Vilsmeier reagent results in a porphyrin derivative having... Agent: Howrey LLP-eu

20090215852 - Compositions and methods for ameliorating cachexia: The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and... Agent: Morrison & Foerster LLP

20090215853 - Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer: A method and composition for preventing prostate cancer and/or reducing PSA levels and/or alleviating the symptoms of BPH (Benign Prostatic Hyperplasia) or PIN (prostatic intraepithelial neoplasia) by administration of an effective amount of a mixture of flavopereirine and alstonine. A method and composition for treating low-grade prostate cancer and preventing... Agent: Dale Evans

20090215854 - Antimicrobial compositions, products and methods employing same: Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respiratory syricytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large... Agent: Brinks Hofer Gilson & Lione

20090215856 - Methods for monitoring il-18: This invention relates to methods for monitoring IL-18.... Agent: Ropes & Gray LLP

20090215855 - New crystalline atorvastatin hemicalcium salt polymorph form: The present invention relates to a new crystalline polymorph B-52 form of atorvastatin hemicalcium salt [A[(3R,5R)-7-[3-phenyl-4-[(phenyl carbamoyl]-2-(4-fluorophenyl)-5-(1-methylethyl)-1H-pyrrole-1-yl]-3,5-dihydroxy-heptanoic acid calcium salt (2:1)], medicinal preparations containing the new polymorph form, process for the preparation thereof and the use of the new polymorph form for the preparation of medicinal products.... Agent: K.f. Ross P.c.

20090215857 - Therapeutic pyrrolidines: and pharmaceutically acceptable salts thereof, wherein A, J, Z, and R20 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of disorders and conditions including attention deficit hyperactivity disorder, neuropathic pain, urinary incontinence, generalized anxiety disorder,... Agent: Pfizer Inc. Patent Department

20090215858 - Substituted benzo-condensed cycloheptanone derivatives and their use for producing drugs: The invention relates to substituted benzo-condensed cycloheptanone derivatives, to methods for producing them, to drugs containing said compounds and to the use of said compounds for producing drugs.... Agent: Crowell & Moring LLP Intellectual Property Group

20090215881 - Polyphenolic bioprecursors: Cosmetic and therapeutic, in particular dermatological bioprecursors have the formula [A]n—PP—[B]m wherein PP is a polyphenol radical in which each hydroxyl function is protected by a group A or a group B, A is a saturated or unsaturated, substituted or unsubstituted alkyl radical having 1 to 20 carbon atoms which... Agent: Buchanan, Ingersoll & Rooney Pc

20090215882 - Lyophilized solid taxane composition, a process for preparing said solid composition, a pharmaceutical formulation and a kit for said formulation: A lyophilized solid composition of taxane (preferably docetaxel and paclitaxel), is suitable to prepare a pharmaceutical formulation to be administered to mammals, particularly humans, comprising a taxane, a tensoactive, a lyophilizing excipient, and acid; also essentially free from organic solvents. The solid composition is free from polysorbate 80 and polyoxyethylated... Agent: Ratnerprestia

20090215883 - Pharmaceutical formulation comprising taxane, a solid composition of taxane, a process for preparing said solid composition of taxane, a solubilizing composition of said solid composition of taxane, and a kit for the injectable formulation of taxane: A pharmaceutical formulation of taxane intended to be administered to mammals, preferably humans, comprises two compositions combined prior to being administered, forming a transparent solution free from precipitates, in which the compositions comprise a solid composition of lyophilized taxane, free from tensoactives, oils, polymers, solubility enhancers, preservatives and excipients; and... Agent: Ratnerprestia

20090215884 - Method for wound healing: The present invention relates generally to methods and compositions for promoting wound healing in a subject. In particular, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in wound healing and compositions therefor which contain such compounds.... Agent: Scully Scott Murphy & Presser, Pc

20090215885 - Antioxidant food composition and methods and uses thereof: Various food compositions are provided that provide nutritional components useful, only or in combination with a training regime, to prevent or delay the onset of cognitive decline.... Agent: Perkins Coie LLP

20090215886 - Anti-inflammatory formulation: Compositions comprising apocynin and paeonol. The compositions may be used for the treatment of inflammatory disease.... Agent: Flynn Thiel Boutell & Tanis, P.c.

20090215887 - 5-hydroxy-2-methyl-4h-pyran-4-one esters as novel tyrosinase inhibitors: Skin brightening compositions based on esters of 5-hydroxy-2-methyl-4H-pyran-4-one. Also disclosed are methods of making the compositions as well as methods of using the compositions.... Agent: Brett L. Nelson Eastman Chemical Company

20090215888 - Topical nail formulation: The present invention relates to a topical nail formulation comprising at least one active agent (e.g., tolnaftate) and at least one nail penetration enhancer selected from the group consisting of a fatty acid, an azone derivative, and mixtures thereof. The invention also relates to the use of said topical nail... Agent: Katten Muchin Rosenman LLP (c/o Patent Administrator)

20090215889 - Novel use of zinc gluconate for treating hydradenitis suppurativa: e

20090215890 - Gamma-hydroxybutyrate compositions containing carbohydrate, lipid or amino acid carriers: The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, or can target specific organs.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.a.

20090215891 - S-[2-[(1-lminoethy)amino]ethyl]-2-methyl-l-cysteine maleate hydrochloride crystalline salt: A novel mixed salt of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine is disclosed. The novel mixed salt, S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate hydrochloride, may be produced to form crystals that may be arranged as generally orderly packed agglomerates, which are particularly useful in making pharmaceutical compositions. Such pharmaceutical compositions are also described, as well as methods to make... Agent: Pharmacia Corporation Global Patent Department

20090215892 - Octanol formulations and methods of treatment using the same: The invention features pharmaceutical formulations containing octanol and esters thereof. The pharmaceutical formulations are useful for the treatment of involuntary tremors.... Agent: Clark & Elbing LLP

20090215893 - Parakeratosis inhibitor, pore-shrinking agent,or rough skin preventing/ameliorating agent, and external composition for skin: The invention provides a parakeratosis inhibitor, pore-shrinking agent, or rough skin preventing/amaliorating agent that has a function such as parakeratosis inhibition, pore shrinkage, or rough skin-inhibition/abatement, poses no safety problems such as sensory irritation, and is very safe, and to further provide an external composition for skin to which a... Agent: Snider & Associates

20090215894 - Inhibition of phosphatase activity of soluble epoxide hydrolase amino terminus and uses thereof: Inhibitors of the phosphatase activity of soluble epoxide hydrolase (sEH) are provided and are useful for in the treatment of diseases. These Inhibitors are based on derivatives of various epoxide hydrolase substrates that mimic the enzyme substrate so that there Is stable Interaction with the enzyme catalytic site. These inhibitors... Agent: Townsend And Townsend And Crew, LLP

20090215897 - Method for treatment and prevention of respiratory insufficiency: The invention relates to the use of a composition comprising eicosapentaenoic acid 5 (EPA, n-3), docosahexaenoic acid (DHA, n-3) and stearidonic acid (STA) and having a weight ratio STA/DHA of at least 0.1 for the manufacture of a pharmaceutical or nutritional composition for the treatment and/or prevention of dust mite... Agent: Bacon & Thomas, Pllc

20090215896 - Reelin deficiency or dysfunction and methods related thereto: A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the central nervous system (CNS) is described. Also described is a method to prevent, delay the onset of, or treat Reelin deficiency... Agent: Sheridan Ross P.c.

20090215895 - Therapeutic and carrier molecules: The present invention relates generally to compounds comprising a hydrocarbon chain portion and more particular to compounds comprising chemical derivatizations of the hydrocarbon chain which are useful therapeutic and prophylactic molecules. The present invention further provides compounds where the hydrocarbon chain portion is a carrier molecule for functional groups, moieties... Agent: Scully, Scott, Murphy & Presser, P.c.

20090215898 - Tranexamic acid formulations: Disclosed are immediate release oral tranexamic acid formulations and methods of treatment therewith.... Agent: Davidson, Davidson & Kappel, Llc

20090215900 - Composition and method for providing glutamine: A process for preparing a glutamine-supplemented food product by contacting water and a nutritive base that pre-dominantly comprises meat and carbohydrate with a peptide source of glutamine to form a wet mixture and heating the wet mixture at a temperature of from about 50° C. to about 105° C. for... Agent: Colgate-palmolive Company

20090215899 - N-phenyloxamide derivatives: wherein R1 represents a C6-10 aryl group; or a C6-10 aryl group substituted with a group or groups selected from the group consisting of a halogen atom, cyano group, nitro group, a C1-6 alkyl group, a halogenated C1-6 alkyl group, a C1-6 alkoxy group, a halogenated C1-6 alkoxy group and... Agent: Greenblum & Bernstein, P.L.C

20090215901 - Methods for treatment of nocturia: A method for the treatment of nocturia which consists of administering to a mammal in need of such treatment a therapeutically effective amount of a nonsteroidal anti-inflammatory drug consisting of loxoprofen or a pharmacologically acceptable salt thereof, wherein the mammal is a human who has a neurogenic bladder.... Agent: Frishauf, Holtz, Goodman & Chick, Pc

20090215902 - Methods for the treatment of dermatological disorders: m

20090215904 - Colchicine compositions and methods: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.... Agent: Cantor Colburn, LLP

20090215903 - Injectable liquid paracetamol formulation: The invention relates to an aqueous paracetamol solution for administration by means of infusion with a pH of between 4.5 and 6, containing at least one substance that can react with fenolates to produce the O-derivatives thereofor other co-ordination compounds. The injectable paracetamol solution has high stability, does not become... Agent: Ladas & Parry LLP

20090215905 - Novel substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors: e

20090215907 - Dosing regimes for trans-clomiphene: The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass, limitation of body performance capacity, reduction of bone density, reduction of libido, reduction... Agent: Howrey LLP - East

20090215906 - Methods and materials with trans-clomiphene for the treatment of male infertility: Compositions comprising trans-clomiphene for treating male infertility may be used to treat male infertility.... Agent: Howrey LLP - East

20090215908 - Toll like receptor (tlr) signaling antagonist: The present invention relates to novel synthetic toll like receptor antagonist. The present invention in particular provides compounds, methods and compositions for specifically inhibiting immune stimulation involving TLR ligands, especially TLR-4. The compounds are potentially useful in treatment of inflammation, autoimmunity, allergy, asthma, graft rejection, graft versus host disease, infection,... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090215909 - Cleaning composition that provides residual benefits: A composition for use on a hard surface. The composition has: (i) at least 7.5 wt. % of at least one surfactant selected; (ii) a transport rate factor of less than about 55 seconds; and (iii) an adhesion time of greater than about 8 hours.... Agent: S.c. Johnson & Son, Inc.

20090215910 - Method for the preparation of 1-benzotriazolyl carbonate esters of poly(ethylene glycol): The invention provides a method for preparing a 1-benzotriazolylcarbonate ester of a water-soluble and non-peptidic polymer by reacting a terminal hydroxyl group of a water-soluble and non-peptidic polymer with di(1-benzotriazolyl)carbonate in the presence of an amine base and an organic solvent. The polymer backbone can be poly(ethylene glycol). The 1-benzotriazolylcarbonate... Agent: Nektar Therapeutics

  
08/20/2009 > patent applications in patent subcategories. inventions list

20090209451 - Heteroarylaminopyrazole derivatives useful for the treatment of diabetes: The present invention relates to heteroarylaminopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20090209450 - Microrna fingerprints during human megakaryocytopoiesis: The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of cancer and myeloproliferative disorders. The invention also provides methods of identifying anti-cancer agents.... Agent: Macmillan Sobanski & Todd, LLC

20090209453 - Glycoprotein hormone analogs: This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090209454 - Method for purifying fsh or a fsh mutant: The invention relates to a method for purifying a glycoprotein, preferably FSH or a FSH mutant comprising the steps of subjecting a liquid containing said FSH or a FSH mutant to: (1) a dye affinity chromatography; (2) a weak anion exchange chromatography; (3) a hydrophobic interaction chromatography; and (4) a... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090209452 - Substantially pure glycopeptide antibiotics ac-98-1; ac-98-2; ac-98-3; ac-98-4 and ac-98-5: The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism Streptomyces hygroscopicus.... Agent: Wyeth Patent Law Group

20090209455 - Vitreous administration of erythropoietin: A therapeutic composition for treating and/or preventing retinal disorder includes intravitreally or transsclerally administered erythropoietin.... Agent: Osha Liang L.L.P.

20090209456 - Compositions and methods for improving facial and body aesthetics: Compositions and methods of treating facial and body tissue aesthetics and reconstruction are disclosed using immunosuppressive agents either by themselves or in conjunction with other soft tissue fillers.... Agent: K&l Gates LLP

20090209457 - Treatment of anti-erythropoietin antibody-mediated disorders with synthetic peptide-based epo receptor agonists: The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat or to prevent anti-erythropoietin (EPO) antibody-mediated disorders such as pure red cell aplasia (PRCA) that are characterized by anti-EPO antibodies. Pharmaceutical compositions,... Agent: Darby & Darby P.C.

20090209468 - Alpha-neurotoxin proteins with anti-inflammatory properties and uses thereof: The invention provides methods and compositions for treating arthritic conditions such as osteoporosis and rheumatoid arthritis. The treatment methods include administering an effective amount of a pharmaceutical composition comprising an isolated alpha-neurotoxin protein, or an effective variant or fragment thereof. The compositions are effective for decreasing the levels of pro-inflammatory... Agent: Margaret J. Mclaren, P.A. Mclaren Legal Services

20090209458 - Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling: Disclosed are compositions and methods related to cell-penetrating suppressor of cytokine signaling (SOCS) proteins that inhibit cytokine-induced signaling.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090209460 - Compositions and methods for treating obesity and related metabolic disorders: The present invention relates to the use of neuromedins in methods to treat and prevent conditions such as obesity and other food-related disorders. In addition, novel peptides, FNX Peptides, are provided, which find use in treating these disorders.... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090209464 - Flavivirus fusion inhibitors: The present invention relates to peptides and methods of inhibiting fusion between the virion envelope of Flaviviruses and membranes of the target cell, the process that delivers the viral genome into the cell cytoplasm. The invention provides for methods which employ peptides or peptide derivatives to inhibit Flavivirus:cell fusion. The... Agent: Olson & Cepuritis, Ltd.

20090209463 - Hgf precursor protein variant and active protein thereof: An HGF precursor protein variant, in which a peptide structure comprises a sequence including a peptide chain X inserted between an α chain of HGF or a polypeptide where 1 to 20 amino-acid residues from the C-terminus of the α chain are deleted, and a β chain of HGF or... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090209465 - Mct1 transporters expressed in blood brain barrier cells: MCT1 is consistently expressed at high levels in brain microvessel endothelial cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is actively transported by, the MCT1 transporter, and therefore a candidate substrate for crossing the blood brain barrier. The assays are useful in... Agent: Townsend And Townsend And Crew, LLP

20090209459 - Method of treating myasthenia gravis: The invention relates to the use of agents that bind the complement protein C5 in the treatment of diseases associated with inappropriate complement activation and in particular in the treatment of myasthenia gravis.... Agent: Klauber & Jackson

20090209461 - Modification of feeding behavior: Methods are disclosed for decreasing calorie intake, food intake, and appetite in a subject. The methods include peripherally administering a therapeutically effective amount of PYY or an agonist thereof to the subject, thereby decreasing the calorie intake of the subject.... Agent: Lando & Anastasi, LLP S2059

20090209466 - Peptides with anti-proliferative activity: The present invention relates to peptides with anti-proliferative activity, of sequence SEQ ID No. 1, SEQ ID No. 2 or SEQ ID No. 3.... Agent: Hunton & Williams LLP Intellectual Property Department

20090209462 - Regulation of function of angiopoietin: Pharmaceutical compositions that comprise a pharmaceutically acceptable carrier and either a therapeutically effective amount of an ECM-binding fragment of Ang-1 protein at comprises SEQ ID NO:1 and/or SEQ ID NO:2 or a homologous peptide thereof and pharmaceutical compositions that comprise a pharmaceutically acceptable carrier and a vector comprising a nucleic... Agent: Pepper Hamilton LLP

20090209470 - T24 antigen for immunodiagnosis of taenia solium cysticercosis: The present disclosure relates to T24 nucleic acid sequences, amino acid sequences, and antibodies. Methods for detecting and diagnosing Taenia solium infection in a subject using the T24 sequences and specific binding agents are also disclosed. The T24 sequences disclosed herein can be formulated into a pharmaceutical composition for administration... Agent: Klarquist Sparkman, LLP

20090209469 - Use of exendins and glp-1 receptor agonists for altering lipoprotein particle size and subclass composition: The present invention relates to altering the concentration of various lipid molecules, specifically for example by shifting from small LDL particles to large LDL and HDL particles. The present invention also relates to methods for increasing average lipid particle size and methods for improving the cardiovascular risk profile of a... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090209467 - Viral capsid proteins and any peptides or compositions thereof for the treatment of pathologic disorders: The present invention relates to viral capsid proteins, as a medicament for the treatment of a pathologic disorder. More particularly, the invention relates to the viral capsid proteins VP1, VP2 and VP3, preferably, the SV40 VP1 or any peptide, fragment, mutant, derivative and mixtures thereof or of virus-like particles (VLP's)... Agent: Paul D. Bianco Fleit Gibbons Gutman Bongini & Bianco Pl

20090209471 - Abuse-resistant amphetamine prodrugs: The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders,... Agent: Darby & Darby P.C.

20090209472 - Amide and peptide derivatives of dialkylenetriamines and their use as transfection agents: This invention relates to newly identified spermidine based surfactant compounds, to the use of such compounds and to their production. The invention also relates to the use of the spermidine based compounds to facilitate the transfer of polynucleotides into cells.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090209473 - Componds and methods for pormoting angiogenesis: Angiogenesis may be initiated or increased through the use of gamma-secretase inhibitors. The gamma-secretase inhibitor can be a dipeptide class, sulfonamide class, transition state mimic class, benzodiazepine class, or benzocaprolactam class gamma secretase inhibitor. Methods for initiating and increasing angiogenesis are used for disease prevention and treatment as well as... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090209474 - Novel uses for drugs targeting glutamine synthetase: The present invention relates to novel therapeutic uses of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof. Furthermore, the present invention relates to the use of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof, in obtaining methods of screening and of developing drugs. Finally, the present invention relates... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090209476 - Pesticidal compositions: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.... Agent: Dow Agrosciences LLC

20090209475 - Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same: e

20090209477 - Azacytidine analogues and uses thereof:

20090209478 - Compositions and methods for inhibiting expression of the hamp gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent: Alnylam/fenwick

20090209479 - Thiocarbon-protecting groups for rna synthesis: Aspects of the invention include 2′ protected nucleoside monomers that are protected at the 2′ site with thiocarbon protecting groups. Thiocarbon protecting groups of interest include thiocarbonate, thionocarbonate, dithiocarbonate groups, as well as thionocarbamate protecting groups. Aspects of the invention further include nucleic acids that include the protecting groups of... Agent: Agilent Technologies Inc.

20090209623 - Anti-sense nucleic acid derived from organism: Disclosed are: a method for producing an anti-sense nucleic acid which has a wide variation in nucleotide sequences and excellent anti-sense properties at a low cost in a simple manner and in a large scale; and a cosmetic composition or pharmaceutical composition comprising the anti-sense nucleic acid. A method is... Agent: Birch Stewart Kolasch & Birch

20090209621 - Compositions and methods for decreasing microrna expression for the treatment of neoplasia: The invention generally features compositions and methods that are useful for treating or diagnosing a neoplasia. The invention is based in part on the observation that c-Myc activated expression of a cluster of six miRNAs on human chromosome 13. Accordingly, the invention provides therapeutic compositions and methods for altering the... Agent: Edwards Angell Palmer & Dodge LLP

20090209624 - Compositions and their uses for gene therapy of bone conditions: In certain preferred embodiments, the present invention provides compositions and methods for the treatment of bone conditions associated with low bone density. In preferred embodiments, the present invention provides compositions and methods for the treatment of osteoprotegerin-responsive conditions.... Agent: Mirick, O'connell, Demallie & Lougee, LLP

20090209619 - Depression of herg k+ channel function in mammallan cells and applications to the control of cancer cells division: The use of an HERG channel inhibitor for controlling the proliferation of cancer cells. Examples of such HERG channel inhibitors include dofetilide, cisapride, E-4031 and a siRNA molecule targeting a sequence involved in the expression of an HERG channel. Other ERG channels are also targets for these inhibitors.... Agent: Ralph A. Dowell Of Dowell & Dowell P.C.

20090209622 - Diagnosis of anxiety disorders: The invention relates to methods for diagnosing a genetic predisposition or susceptibility for anxiety disorders in a human. The methods include detecting particular markers at the human RGS2 locus in a sample obtained from the human. The invention also relates to the improved diagnosis that is based on the analysis... Agent: Wolf Greenfield & Sacks, P.C.

20090209620 - Direct reversal of the suppressive function of cd4+regulatory t cells via toll-like receptor 8 signaling: CD4+ regulatory T (Treg) cells profoundly suppress host immune responses and thus protect against autoimmune disease while restricting desired immune responses such as antitumor immunity. Synthetic phosphorothioate-protected, guanosine-containing oligonucleotides can directly reverse the suppressive activity of Treg cells without involving dendritic cells. This effect appears to be transduced by signaling... Agent: Fulbright & Jaworski, LLP

20090209626 - Duplex oligonucleotides with enhanced functionality in gene regulation: Disclosed are methods of enhancing functionality of duplex oligonucleotides and compositions made by the methods. The duplex oligonucleotides include siRNAs, miRNA mimics, and piRNA mimics which contain modified nucleotides and mismatches between the two strands of the molecule at specific nucleotide positions.... Agent: Merchant & Gould PC

20090209625 - Modulation of chrebp expression: Disclosed herein are compounds, compositions, and methods for modulating the expression of ChREBP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and conditions.... Agent: Mcdermott Will & Emery

20090209628 - Multiple rnai expression cassettes for simultaneous delivery of rnai agents related to heterozygotic expression patterns: The present invention provides compositions and methods suitable for expressing y-x multiple-RNAi agents against an allele or alleles of interest in cells, tissues or organs of interest in vitro and in vivo so as to treat diseases.... Agent: Patton Boggs LLP

20090209618 - Pyruvate dehydrogenase kinases as therapeutic targets for cancer and ischemic diseases: The invention provides therapeutic and prophylactic compounds and methods for altering the activity of pyruvate dehydrogenase kinase (e.g. PDK1, PDK2, PDK3, PDK4). Such therapies are useful for the treatment of neoplasia. The invention further provides therapeutic and prophylactic compounds and methods of altering pyruvate dehydrogenase activity to treat or prevent... Agent: Edwards Angell Palmer & Dodge LLP

20090209627 - Rnai-mediated inhibition of connexin 43 for treatment of iop-related conditions: RNA interference is provided for inhibition of connexin 43 (Cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.... Agent: Alcon

20090209630 - Gene delivery formulations and methods for treatment of ischemic conditions: The present inventors have developed a novel approach for efficient delivery of angiogenic factors to the cardiac and peripheral vasculature that avoids problems with toxicity inherent to existing delivery technologies. Vectors carrying coding sequences for angiogenic agents including Del-1 or VEGF, or both, can be formulated with poloxamers or other... Agent: Dla Piper LLP (us)

20090209631 - Method for enhanced uptake of viral vectors in the myocardium: The present invention relates to improved therapies for the treatment of heart disease, particularly the improved delivery of therapeutic agents to heart tissue by direct infusion into the coronary circulation. A preferred embodiment of the invention is a method of treating or preventing a cardiovascular disease by transfecting cardiac cells... Agent: Knobbe Martens Olson & Bear LLP

20090209629 - Nucleic acid functionalized nanoparticles for therapeutic applications: Materials and methods for regulating gene expression using nanoparticles functionalized with antisense oligonucleotides are provided.... Agent: Marshall, Gerstein & Borun LLP

20090209480 - Central administration of stable formulations of therapeutic agents for cns conditions: The present invention concerns compositions, methods and/or apparatus of central administration of various CNS-active agents. In particular embodiments, intrathecal administration is advantageous for decreasing the systemic concentrations of CNS agent, thereby decreasing side effect toxicity, while allowing more effective delivery of the agent to the site of action, simultaneously decreasing... Agent: Morrison & Foerster LLP

20090209481 - Nucleoside prodrugs and uses thereof: Compounds having the formula I or II wherein R1, R2, B, and V are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20090209482 - Azacytidine analogues and uses thereof: m

20090209483 - Treatments for flaviviridae virus infection: The present invention provides methods for treating infections, in a host, by viruses belonging to the Flaviviridae family, such as HCV, comprising administering an Ara-C homologue to the host.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090209484 - Preventive and/or therapeutic agent for calcipenia: In the invention, difructose anhydride (DTA) being a disaccharide made of two molecules of fructose coupled together is administered. In particular, for inhibiting the postpartum drop of the calcium concentration in blood, DFA III and/or DFA IV is administered before childbirth delivery (in a cow, before an expected date of... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090209486 - Compositions of carbohydrates as dietary supplements: In accordance with the present invention, there is to provide a dietary supplement that provides humans and animals with the essential carbohydrates needed to maintain proper health and functionality, to fend off illness, act as viral inhibitors, lessen the aging process of cells and to provide pets with another level... Agent: Roger W. Brown, Ph.d.

20090209485 - Modulating angiogenesis with nod factors such as glucosamine oligosaccharides: This invention relates to the use of Nod factors and derivatives thereof for the modulation of blood vessel growth and development as well as compositions for modulating angiogenesis.... Agent: Seed Intellectual Property Law Group PLLC

20090209489 - Compositions for the treatment of diabetis, system ph disorders, high blood pressure, and a cancer marker system: In accordance with the present invention, there is to provide a dietary supplement that provides a mammal with the essential carbohydrates needed to maintain proper health and functionality, to fend off illness, to restore proper system pH, to provide a new treatment for pH based illnesses, to provide a new... Agent: Roger W. Brown, Ph.d.

20090209488 - Compositions for the treatment of exercise induced asthma: In accordance with the present invention, there is to provide a dietary supplement that provides a mammal with the essential carbohydrates needed to maintain proper health and functionality, to fend off illness, to provide an alternative treatment for exercise induced asthma and asthma related illnesses, to lessen the aging process... Agent: Roger W. Brown, Ph.d.

20090209487 - Compositions of carbohydrates as dietary supplements: In accordance with the present invention, there is to provide a dietary supplement that provides a mammal with the essential carbohydrates needed to maintain proper health and functionality, to fend off illness, lessen the aging process of cells and to provide pets with another level of medications equal to that... Agent: Roger W. Brown, Ph.d.

20090209490 - Disinfectant composition:

20090209491 - Lactams as conformationally constrained peptidomimetic inhibitors: The present invention relates to inhibitors of post-proline cleaving enzyme, such as inhibitors of dipeptidyl peptidase IV, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. In particular, the inhibitors of the present invention incorporate a lactam ring in the backbone of the inhibitors. The compounds of... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090209492 - Lipase inhibitors: The present invention relates to inhibitors of lipases, such as inhibitors of endothelial lipase, as well as pharmaceutical compositions thereof, and methods for using such inhibitors. The prototype of these inhibitors has lipophilic portion and an electrophilic site.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090209493 - Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor: A pharmaceutical composition for treatment of malignancies, in particular multiple myeloma (MM), comprises in combination a bisphosphonate, e.g. zoledronic acid or a salt or ester, and an HMG-CoA reductase inhibitor for simultaneous, sequential or separate use. Also provided is a method of treating a patient suffering from a malignant disease... Agent: Novartis Corporate Intellectual Property

20090209494 - 21-deoxymacbecin analogues useful as antitumor agents: The present invention relates to 21-deoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases or as a prophylactic pretreatment for cancer. The present invention also provides methods for... Agent: Dann, Dorfman, Herrell & Skillman

20090209495 - Use of edg receptor binding agents in cancer: Provided is a method for treating solid tumors, e.g. tumor invasiveness, and particularly inhibiting or controlling deregulated angiogenesis, using a sphingosine-1-phosphate receptor agonist, optionally in combination with a chemotherapeutic agent. The invention also comprises a combination of a sphingosine-1-phosphate receptor agonist with a chemotherapeutic agent.... Agent: Novartis Corporate Intellectual Property

20090209496 - Methods and compositions for enhancing the efficacy of rtk inhibitors: This invention relates to methods for treating, preventing and/or managing cancer in a subject including enhancing the efficacy of a Receptor Tyrosine Kinase inhibitor (e.g., a small molecule RTK inhibitor, e.g., Sorafenib or Erlotinib) by administering to the subject a Vascular Disrupting Agent (e.g., a Combretastatin or derivative thereof) sequentially... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090209497 - Method of treating lymphangioleiomyomatosis (lam): The invention provides a method for the treatment of Lymphangioleiomyomatosis (LAM) in the human subject in need thereof. The method comprises administering to the subject an effective amount of doxycycline or a salt thereof. The invention further provides a method for monitoring the efficacy of treatment. Treatment efficacy is monitored... Agent: Wolf Greenfield & Sacks, P.C.

20090209498 - Methods of treatment using cca1 inhibitors: Provided herein are methods for the treatment or prevention of a fungal infection in a host comprising the administration to the host a therapeutically or prophylactically effective amount of a CCA1 inhibitor.... Agent: Wilson Sonsini Goodrich & Rosati

20090209499 - Apiary veterinary composition: The present invention concerns veterinary compositions for the treatment and/or prevention of nosema disease (Nosemosis apium) in honey bees comprising 2-hydroxy-benzoic acid (salicylic acid) or 2-(acetyloxy)benzoic acid (acetyl-salicylic acid) or their salt(s) as an active ingredient. In one embodiment, a composition contains sugar-industry molasses (concentrated watery extract of Beta vulgaris... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090209501 - Method of treating and preventing secondary hyperparathyroidism: The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased... Agent: Marshall, Gerstein & Borun LLP

20090209500 - Use of vitamin d receptor agonists and precursors to treat fibrosis: This application relates to methods of treating, preventing, and ameliorating fibrosis, such as fibrosis of the liver, kidney, or pancreas. In particular, the application relates to methods of using a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors)... Agent: Klarquist Sparkman, LLP

20090209503 - Colonic delivery therapeutic agents for inflammatory bowel disease: The present invention discloses a therapeutic agent for inflammatory bowel disease, which is in the from of delivering 1 to 5 g of glutamine to the large intestine per one administration; and the therapeutic agent for inflammatory bowel disease with which an anti-inflammatory agent(s) is combined. This therapeutic agent for... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090209502 - Compositions of glycopyrronium salt for inhalation: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.... Agent: Mccarter & English, LLP Wilmington Basil S. Krikelis

20090209504 - Use of digitalis-like compounds in the treatment of affective disorders: Use of digitalis-like compounds such as 19-norbufalin derivatives in the treatment of affective disorders such as anxiety, depression and bipolar disorders is disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090209505 - Prodrugs of heteroaryl compounds: The present invention provides hydrophobic prodrugs of bases, nucleosides, and nucleotides as well as methods of using the prodrugs as antiviral and anti-cancer chemotherapeutic agents.... Agent: Townsend And Townsend And Crew, LLP

20090209506 - Amino derivatives of beta-homoandrostanes and beta-heteroandrostanes: New aminoalkoxyimino derivatives at position 3 of substituted B-homoandrostanes and B-heteroandrostanes, processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, such as heart failure and hypertension. In particular compounds having the general formula (I) are described, where the radicals have the meanings described... Agent: Lucas & Mercanti, LLP

20090209507 - 15-o-desmethylmacbecin derivatives and their use in the treatment of cancer or b-cell malignancies: The present invention relates to 15-O-desmethylmacbecin analogues according to the formula (IA) or (IB) herein, or a pharmaceutically acceptable salt thereof: wherein: R1 and R2 either both represent H or together they represent a bond (i.e. C4 to C5 is a double bond); and R3 represents H or CONH2 that... Agent: Dann, Dorfman, Herrell & Skillman

20090209508 - Compounds for photochemotherapy: Enzyme-activatable photosensitizing polymer conjugates are disclosed for photochemotherapeutic treatment of human diseases and disorders, bacteriologic or virologic indications, cosmetic applications and other pathologic situations. These polymer conjugates may comprise a polymer carrier, a photosensitizer, a quencher, a targeting molecule and/or a biocompatibilizing unit. These macromolecular conjugates may be designed to... Agent: Fulbright & Jaworski L.L.P.

20090209509 - Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer: Disclosed herein are novel zinc ionophores, zinc chelators and/or zinc complexes with enhanced aqueous solubility. Methods of treating cancer using at least one zinc ionophore and/or zinc chelator are also disclosed. Also disclosed herein are compositions and methods for treating cancer with combination therapy using at least one texaphyrin metal... Agent: Wilson Sonsini Goodrich & Rosati

20090209510 - Novel method of treating hyperlipidemia: A pharmaceutical composition useful for a prevention and/or treatment of hyperlipidemia, which comprises combining an effective amount of squalene synthase inhibitor and HMG-CoA reductase inhibitor is provided.... Agent: Edwards Angell Palmer & Dodge LLP

20090209512 - Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof: wherein R1 and R2 independently represent at least one group selected from a hydrogen atom, a halogen atom, an alkyl group, an aryl group, an aralkyl group, an alkoxy group, an aryloxy group, an alkylthio group, an arylthio group, an alkenyl group, an alkenyloxy group, an amino group, an alkylsulfonyl... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090209511 - Benzofuran derivatives: wherein x is a group of the formula: —N═ or —CH═; Y is an optionally substituted amino group, an optionally substituted cycloalkyl group or an optionally substituted saturated heterocyclic group; A is a single bond, a carbon chain optionally having a double bond within or at the end(s) of the... Agent: Birch Stewart Kolasch & Birch

20090209513 - Insecticidal compositions having improved effect: The present invention concerns boosting the activity of crop protection materials comprising active ingredients from the class of the phenyl-substituted cyclic ketoenols through the addition of ammonium salts and/or phosphonium salts or through the addition of ammonium salts and/or phosphonium salts and penetrants, the corresponding materials, processes for preparing them,... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090209514 - Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists: This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydronaphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the... Agent: Baker Botts L.L.P.

20090209515 - Association of a sinus node if current inhibitor and a beta blocker: i

20090209516 - 9-amino-acridine derivatives and method of treating autoimmune diseases using the same: The invention relates to compounds according to general formula (1) and/or their enantiomers, diastereomers, and their pharmaceutically compatible salts, and their use to manufacture a medication as well as medications. The compounds are suited for treatment of diseases connected with misfolded proteins.... Agent: Rankin, Hill & Clark LLP

20090209517 - Use of 5h-dibenz/b,f/azepine-5-carboxamide derivatives in the treatment of neuropathic pain and neurological disorders: This invention relates to the use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives in the manufacture of various medicaments for treating neuropathic pain and for treating neurological disorders which involve both motor impairment and neuropathic pain.... Agent: Conley Rose, P.C.

20090209518 - Pyrimidine compound and pests controlling composition containing the same: wherein R1 represents a hydrogen atom, halogen atom or C1-C4 alkyl; R2 represents C3-C7 alkynyloxy; R3 represents a hydrogen atom, halogen atom or C1-C3 alkyl; X represents C6 polymethylene, in which a CH2—CH2 may be replaced with a CH═CH, optionally substituted with at least one substituent selected from the group... Agent: Sughrue Mion, PLLC

20090209519 - Pyrimidine compound and pests controlling composition containing the same: wherein R1 represents a hydrogen atom, halogen atom or C1-C4 alkyl; R2 represents C3-C7 alkynyloxy; R3 represents a hydrogen atom, halogen atom or C1-C3 alkyl; X represents C7 polymethylene, in which a CH2—CH2 may be replaced with a CH═CH, optionally substituted with at least one substituent selected from the group... Agent: Sughrue Mion, PLLC

20090209520 - 2 -oxybenzamide derivatives as parp inhibitors: A compound of the formula (I): and pharmaceutically acceptable salts thereof, wherein: R2, R3, R4 and R5 are independently selected from the group consisting of H, C1-7 alkoxy, amino, halo or hydroxy; Y is —CRRC2—(CH2)m—, where m is 0 or 1, RC1 is selected from H, CH3 and CF3, and... Agent: Michael Best & Friedrich LLP

20090209522 - Heterocyclic non-peptide gnrh antagonists: A compound of formula (I): wherein either B is absent and A and Z are the same or different and are each hydrogen, halogen, alkyl, hydroxy, alkoxy, —CN, —C(Rc)2OH, —N(Rd)C(═X)Rc, —C(═X)N(Rc)(Rd), —S(O)m—Rc, —N(Rc)(Rd)S(O)2, —S(O)2N(Rc)(Rd), —N(Rc)2, aryl optionally substituted with Ra or —O-aryl optionally substituted with Ra; or B is present... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090209524 - Novel compounds: c

20090209523 - Pyrrolo[1,2-a] pyrazin-1(2h)-one and pyrrolo[1,2-d][1,2,4]triazin-1(2h)-one derivatives as inhibitors of poly(adp-ribose)polymerase (parp): The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative... Agent: Merck And Co., Inc

20090209521 - Inhibition of vegf translation: In accordance with the present invention, methods for inhibiting the translation of VEGF and methods for decreasing VEGF level by inhibiting VEGF translation are provided. In another aspect of the invention, compounds that inhibit the 5′-UTR-dependent translation of VEGF and methods for identifying such compounds are provided.... Agent: Jones Day

20090209525 - Enabling methods to identify allosteric modulators of receptor activity: A method developed to identify receptor modulators, involving providing a mutant receptor, wherein said mutant receptor has a mutation that alters the activity of said mutant receptor compared to a wild type receptor; contacting said mutant receptor with a candidate compound; and determining whether said candidate compound modulates the activity... Agent: Knobbe Martens Olson & Bear LLP

20090209526 - Inhibitors of protein aggregation: The invention relates generally to the use of diaminophenothiazine compounds to inhibit or reverse the aggregation of synuclein, and for their use in the manufacture of medicaments for this purpose (e.g. for the treatment of Parkinson's Disease). Also provided are related methods of detecting or labelling of aggregated synuclein.... Agent: Foley And Lardner LLP Suite 500

20090209527 - Methods for using rapamycin analogues in the treatment of neurological disorders: The present invention provides methods for treatment of neurological disorders or complications due to stroke or head injury; benign or malignant neoplastic disease, carcinomas and adenocarcinomas; proliferative disorders; and inflammatory disorders, comprising administering a compound as described herein to a subject in need thereof, and a pharmaceutically acceptable carrier, within... Agent: Wyeth Patent Law Group

20090209529 - 4,5-dihydro-oxazol-2-yl amine derivatives: wherein R1, R1′, R2, R3, R4, X, Ar, and m are as defined in the specification and claims and pharmaceutically active acid addition salts thereof. Compounds of the invention have Asp2 (β-secretase, BACE 1 or Memapsin-2) inhibitory activity and are useful for the treatment of diseases characterized by elevated β-amyloid... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090209528 - Substituted tetrahydroisoquinoline compound, their preparation and use in medicaments: The present invention relates to substituted tetrahydroisoquinoline compounds of general formula (I), a process for their preparation, medicaments comprising said substituted tetrahydroisoquinoline compounds as well as the use of said substituted tetrahydroisoquinoline compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or... Agent: Albert Bordas, P.A.

20090209530 - Inhibitors of cyclin-dependent kinases, compositions and uses related thereto: The invention pertains to novel cyclin dependent kinase inhibitors (cdks) and specifically, but not exclusively, as inhibitors of cdk/cyclin complexes. As described herein, the inhibitors of this invention are capable of inhibiting the cell-cycle machinery and consequently may be useful in modulating cell-cycle progression, ultimately controlling cell growth and differentiation.... Agent: Leon R. Yankwich

20090209531 - Pyrimido-benzimidazole derivatives and the use thereof in the form of agonists and antagonists of melanocortin receptors: The invention relates to novel pyrimido-benzimidazole derivatives. Said products exhibit a good affinity for certain melanocortin receptor sub-types, in particular MC4 receptors. Said products represent a particular interest for treating pathological disorders and diseases associated with one or several melanocortin receptors. Pharmaceutical compositions containing said products and the use thereof... Agent: Hunton & Williams LLP Intellectual Property Department

20090209533 - Aldh-2 inhibitors in the treatment of addiction: e

20090209532 - Pharmaceutical compounds: Compounds of formula (I) exhibit COMT enzyme inhibiting activity and are thus useful as COMT inhibitors.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090209534 - Novel compounds and use of tetrahydropyridopyridothiophenes: The use of tetrahydropyridothiophenes of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, is novel for treating hyperproliferative diseases and/or disorders responsive to the induction of apoptosis.... Agent: Millen, White, Zelano & Branigan, P.C.

20090209535 - 6-ether/thioether-purines as topoisomerase ii catalytic inhibitors and their use in therapy: The present invention relates to certain purines of the following formulae, which act as topoisomerase II catalytic inhibitors: wherein: J is independently: —H or —NRN1RN2; X is independently: —O—, or —S—; Q is independently: a covalent bond, C1-7alkylene, C2-7alkenylene, C2-7alkynylene, C3-7cycloalkylene, C3-7cycloalkenylene, or C3-7cycloalkynylene; T is independently: a group A1... Agent: Michael Best & Friedrich LLP

20090209536 - Aminoquinazoline cannabinoid receptor modulators for treatment of disease: The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.... Agent: Global Patent Group - Kal Attn: Ms Lavern Hall

20090209537 - Aurora inhibitors: The present invention provides an Aurora inhibitor which comprises, as an active ingredient, an indazole derivative represented by Formula (I) (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof, an Aurora inhibitor which comprises, as an active ingredient, an... Agent: Fitzpatrick Cella Harper & Scinto

20090209538 - Therapeutic substituted lactams: e

20090209540 - Novel biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same: Disclosed are biaryl benzoimidazole derivatives. They have an inhibitory effect on calcium influx in HEK cells, thereby showing a powerful antagonistic effect on a vanilloid receptor, and further have an analgesic effect, thereby being useful for preventing or treating pain, acute pain, chronic pain, neuropathic pain, postoperative pain, migraine, arthralgia,... Agent: Sughrue Mion, PLLC

20090209539 - Pyrimidine derivatives as alk-5 inhibitors: Compounds of formula (I) in free or salt or solvate form, where T1, T2, Ra and Rb have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the... Agent: Novartis Corporate Intellectual Property

20090209541 - Aprepitant compositions: Pharmaceutical compositions comprising aprepitant, wherein aprepitant solubility in aqueous media is enhanced.... Agent: Dr. Reddy''s Laboratories, Inc.

20090209542 - Heterocyclic inhibitors of mek and methods of use thereof: and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8, R9, and W are as defined in the specification. Such compounds are MEK inhibitors and are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of... Agent: Hogan & Hartson LLP

20090209544 - Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes: The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention... Agent: Merck And Co., Inc

20090209545 - Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine: A novel besylate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20090209543 - Folates, compositions and uses thereof: The present invention relates to folates, compositions and uses thereof; In particular, this invention describes a crystalline or amorphous compound which is a substituted or unsubstituted folate or a reduced folate, or the natural or unnatural isomers thereof, of at least one organic base, as well as compositions and uses... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090209547 - C-8 halogenated macrolides: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20090209546 - L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine: A novel L-malate salt of (6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine) is provided.... Agent: Heslin Rothenberg Farley & Mesiti P.C.

20090209548 - Formulation for stimulating hair growth: The present invention is directed to a topical formulation comprising the Compound 6-[[(3S,4R)-3,4-dihydro-3-hydroxy-6-[(3-hydroxyphenyl)sulfonyl]-2,2,3-trimethyl-2H-1-benzopyran-4-yl]oxy]-2-methyl-3(2H)-pyridazinone in a formulation comprising at least one pharmaceutically acceptable carrier. Particularly, the formulation may be used to promote hair growth, including alleviating alopecia.... Agent: Pfizer Inc. Patent Department

20090209549 - Analogs of benzoquinone-containing ansamycins and methods of use thereof: The present invention provides analogs of benzoquinone-containing ansamycins and uses thereof for treating and modulating disorders associated with hyperproliferation, such as cancer. The present invention provides analogs of benzoquinone-containing ansamycins where the benzoquinone is reduced to a hydroquinone and trapped by reaction with a suitable acid, preferably ones that increase... Agent: Foley Hoag, LLP (w/ipx)

20090209550 - Substituted triazolopyridines: Disclosed herein are substituted triazolopyridine serotonin reuptake modulators and/or 5-HT receptor modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20090209551 - Essential tremor diagnostic and treatment: The invention relates to an in vitro method for diagnosing essential tremor wherein a mutation of dopamine D3 receptor gene or protein is sought. The invention further relates to the use of a ligand having anti-dopamine D3 receptor activity for treatment of essential tremor.... Agent: Stites & Harbison PLLC

20090209552 - Organic compounds: e

20090209553 - Arylpiperazine derivatives and uses thereof:

20090209555 - 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial:

20090209556 - Soluble guanylate cyclase activators:

20090209554 - Thiazoliums as transketolase inhibitors: The present invention provides N-3′-pyridyl-methyl or N-2′-pyrazinylmethyl thiazolium derivatives of formula (I) which are useful as transketolase inhibitors wherein R1, R2, R3, Y, R5-R9, Ra-Rd, n and X− are as defined herein. The present invention also provides pharmaceutical compositions comprising the compounds of formula (I). The invention provides methods for... Agent: Henry D. Coleman Coleman Sudol Sapone, P.C.

20090209557 - Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity: e

20090209558 - Polymer formulations for delivery of bioactive materials: Delivery of drugs in association with PLGA polymers which have crystallinity resulting from the presence of long chain alkyl groups in terminal units.... Agent: Bell & Associates

20090209559 - Pharmaceutical compounds: wherein A, n, R1, R2, and R3 have any of the values defined herein and the pharmaceutically acceptable salts thereof have activity as inhibitors of PI3K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behavior associated with PI3 kinase such as... Agent: Viksnins Harris & Padys Pllp

20090209560 - Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3: An anti-inflammation substrate for decreasing the proinflammation induced by the cytokines and inhibiting the lung function degeneration is provided. The anti-inflammation substrate includes one selected from the group consisting of a 7-[2-[4-(2-chlorobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine, a 7-[2-[4-(4-nitrobenzene)piperazinyl]ethyl]-1,3-dimethylxanthine, a respective pharmaceutical acceptable salt thereof, and a combination thereof.... Agent: Volpe And Koenig, P.C.

20090209561 - Xanthine derivatives with hm74a receptor activity: The present invention relates to therapeutically active xanthine compound derivatives, corresponding pharmaceutical formulations containing, processes for making or manufacture and the use of the aforementioned compounds in therapy, particularly in the treatment of diseases where under-activation of the HM74A receptor contributes to the disease or where activation of the receptor... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090209562 - Fused ring 4-oxopyrimidine derivative: e

20090209564 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20090209563 - Pyridinoylpiperidines as 5-ht1f agonists: The compounds of the present invention are useful for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine in a mammal. The present invention also relates to a process for the synthesis of intermediates in the synthesis of compounds of Formula I.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090209565 - Therapeutic agent for inflammatory bowel disease: According to the present invention, an effective and safe therapeutic agent for inflammatory bowel disease including ulcerative colitis and Crohn's disease can be provided. The balance between the therapeutic effect on a chronic inflammation such as inflammatory bowel disease and the adverse side effect of the compound is superior to... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090209567 - Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof: The present invention provides rosuvastatin and intermediates thereof having a low level of alkylether impurity and processes for the preparation thereof.... Agent: Kenyon & Kenyon LLP

20090209566 - Spirocyclic compounds: The present invention relates to a novel class of substituted spirocyclic compounds, represented by the following structural Formula: I Wherein A, B and D are independently selected from CR12, NR1a, C(O) and O; E is selected from a bond, CR12, NR1a, C(O) and O; wherein at least one of A,... Agent: Merck And Co., Inc

20090209568 - Spiro [benzopyran] or spiro [benzofuran] derivatives which inhibit the sigma receptor: The present invention relates to compounds having pharmacological activity towards the sigma (σ) receptor, and more particularly to spiro[benzopyran] or spiro[benzofuran] derivatives, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy and prophylaxis, in particular for the treatment of psychosis.... Agent: Cooper & Dunham LLP

20090209570 - 6-aminomorphinane derivatives, method for the production and use thereof: This invention relates to compounds of the formula (I).... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090209569 - Selective opioid compounds: which relates to morphinan compounds useful as μ, δ, and/or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic... Agent: Elmore Patent Law Group, PC

20090209571 - Phenanthrene derivatives as mpges-1 inhibitors: The invention encompasses novel compounds of Formula or pharmaceutically acceptable salts thereof. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful to treat pain and/or inflammation from a variety of diseases or conditions, such as osteoarthritis, rheumatoid arthritis and acute or chronic pain.... Agent: Merck And Co., Inc

20090209572 - 36-des(3-methoxy-4-hydroxycyclohexyl) 36-(3-hydroxycycloheptyl) derivatives of rapamycin for the treatment of cancer and other disorders: The present invention relates to novel 36-des(3-methoxy-4-hydroxycyclohexyl)-36-(3-hydroxycycloheptyl)rapamycin derivatives, methods for their production, and uses thereof. In a further aspect the present invention provides for the use of these 36-des(3-methoxy-4-hydroxycyclohexyl)-36-(3-hydroxycycloheptyl)rapamycin derivatives in the treatment of cancer and/or B-cell malignancies, the induction or maintenance of immunosuppression, the treatment of transplantation rejection, graft... Agent: Wyeth Patent Law Group

20090209573 - Compounds and compositions as hedgehog pathway modulators: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a... Agent: Genomics Institute Of The Novartis Research Foundation

20090209574 - Fluoroquinolone derivatives for ophthalmic applications: The present invention relates to fluoroquinolone derivatives having enhanced ocular penetration characteristics and/or antimicrobial activity, and to compositions comprising such derivatives. The derivatives and compositions are particularly well suited for treating ophthalmic bacterial infections. The present invention more particularly relates to the discovery that a 2-methyl substitution on a diazabicyclo... Agent: Alcon

20090209575 - Method for treating neuropathic pain and associated syndromes: The present invention is directed to the use of ibudilast for treating neuropathic pain.... Agent: Robins & Pasternak LLP

20090209576 - Pharmaceutical composition containing clopidogrel camphorsulfonate or polymorphic forms thereof: A pharmaceutical composition of the present invention which comprises clopidogrel camphorsulfonate of formula (I) or its polymorphic forms as an active ingredient is useful for treating or preventing a platelet aggregation-associated disease.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090209578 - Chemical compounds: The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, Het and m are as defined in the description. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors.... Agent: Pfizer Inc Steve T. Zelson

20090209577 - Novel triazolopyridine compounds: wherein R1, R2 and R3, are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase... Agent: Pfizer Inc. Patent Department

20090209579 - Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nAChR), activation of nAChRs, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands... Agent: Millen, White, Zelano & Branigan, P.C.

20090209580 - Antitumor agent for thyroid cancer: e

20090209581 - Nitroxides for use in treating or preventing immunological diseases: Pharmaceutical compositions are provided that are useful in treating immunological diseases. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of a gene related to an immunological disease. Methods are also provided for the use of the... Agent: Knobbe Martens Olson & Bear LLP

20090209582 - Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists: wherein R1 and X are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention also relates to pharmaceutical compositions comprising such compounds, methods of using such compounds to treat diseases associated with 5-HT4 receptor activity, and processes and intermediates useful for preparing... Agent: Theravance, Inc.

20090209583 - 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors: The present invention relates to 2-(substituted-amino)-benzothiazole sulfonamide compounds and derivatives, their use as protease inhibitors, in particular as broad-spectrum HIV protease inhibitors, processes for their preparation as well as pharmaceutical compositions and diagnostic kits comprising them. The present invention also concerns combinations of the present 2-(substituted-amino)-benzothiazole sulfonamide compounds and derivatives... Agent: Philip S. Johnson Johnson & Johnson

20090209584 - Antibacterial mutilins: A compound of formula (I) wherein R and R2 and the attached nitrogen atom form pyrrolidinyl or piperidinyl. R1 is a group of formula (II). R3 and R′3 are hydrogen, deuterium or halogen. R4, R5 and R10 are independently of each other hydrogen or alkyl. R6, R7 and R8 are... Agent: D. Peter Hochberg Co. L.p.a.

20090209585 - Cycloalkene derivatives, process for production of the derivatives, and use of the same: c

20090209586 - Piperidine derivatives as human papilloma virus inhibitors: HPV inhibitors with formula (I) where G1 represents a hydrocarbonated bond or chain possibly substituted by one or two alkyl groups, G2 represents a group (see formula Ia+Ib) or R represents a hydrogen, an alkyl, halogenoalkyl, or a prodrug radical such as carbamate, acetyl or dialkylaminomethyl, G represents a bond... Agent: Foley And Lardner LLP Suite 500

20090209587 - Repaglinide formulations: Processes for preparing solid pharmaceutical compositions comprising repaglinide or a derivative thereof, including a step of granulation. Embodiments include fluid bed granulation.... Agent: Dr. Reddy''s Laboratories, Inc.

20090209589 - N-[(pyridin-2-yl) methoxy] hetrocyclyl carboxamide derivatives and related compounds as fungicides: o

20090209588 - Novel compounds, their preparation and use: Novel compounds of the general formula (I), in which the variables are as defined in claim 1, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds are useful in the treatment and/or prevention of... Agent: High Point Pharmaceuticals, Inc.

20090209590 - Histone deacetylase and tubulin deacetylase inhibitors: In recognition of the need to develop novel therapeutic agents and efficient methods for the synthesis thereof, the present invention provides novel inhibitors of histone deacetylases, tubulin deacetylases, and/or aggresome inhibitors, and pharmaceutically acceptable salts and derivatives thereof. The inventive compounds fall into two classes—“isotubacin” class and “isoisotubacin” class—all of... Agent: Choate, Hall & Stewart/harvard University

20090209592 - Inhibitors of the gastric h+, k+-atpase with enhanced therapeutic properties: Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.... Agent: Global Patent Group - Apx

20090209593 - Novel antibacterial agents: This invention relates to novel macrolides, to the preparation of novel macrolides, to the use of such novel macrolides for preventing, treating, or ameliorating various conditions, and to the use of such novel macrolides as antibacterial agents.... Agent: Barnes & Thornburg LLP

20090209591 - Pharmaceutical product for injection: The present invention is related to a pharmaceutical product for injection comprising a container including a closure suitable for preparations for injection, the container containing an acid labile proton pump inhibitor, a salt thereof, a solvate of the acid labile proton pump inhibitor or a salt thereof, wherein the container... Agent: Nath & Associates PLLC

20090209594 - Method of treating of demyelinating diseases or conditions: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090209595 - Method of treating of demyelinating diseases or conditions: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation,... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090209596 - Oxazole hydroxamic acid derivatives and use thereof: Provided are an oxazole hydroxamic acid derivative and a pharmaceutically useful salt thereof as a histone deacetylase inhibitor The oxazole hydroxamic acid derivative and pharmaceutically useful salt thereof, prepared in accordance with the present invention, can treat and/or prevent various cancers and inflammatory diseases caused by histone deacetylase.... Agent: Gibbons P.C.

20090209597 - Imidazole derivatives and their use for modulating the gaba alpha receptor complex: o

20090209598 - Resorcine derivatives and their use as pesticides: This invention relates to resorcine derivatives of formula (I) wherein R1 is phenyl or a 5- to 6-membered heteroaromatic ring which may contain 1 to 3 heteroatoms selected from oxygen, nitrogen and sulfur, wherein phenyl or the heteroaromatic ring may be fused to a ring selected from phenyl and a... Agent: Brinks, Hofer, Gilson & Lione

20090209599 - Eye drop containing roflumilast: An object of the present invention is to enhance the efficacy of roflumilast in an eye drop containing roflumilast as an active ingredient. By formulating at least one type of viscosity-increasing agent in the eye drop containing roflumilast as an active ingredient, an eye drop in which the efficacy of... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090209600 - Moisturization improvement via a heated niacinamide containing flowable cosmetic transferred onto skin: A product and method for moisturizing skin is herein described. The product is a package with associated instructions for applying a niacinamide containing cosmetic composition to skin dispensed from a heating device. The heated cosmetic composition imparts a more rapid moisturization than expected from an identical composition applied at room... Agent: Unilever Patent Group

20090209601 - Use of rxr agonists for the treatment of osteoarthritis: Disclosed herein are methods of preventing and treating osteoarthritis through the use of RXR agonists.... Agent: Potter Anderson & Corroon LLP/wyeth Attn: Janet E. Reed, Ph.d.

20090209602 - Chemical compounds: wherein, for example, R1 is an optionally substituted aryl or optionally substituted heteroaryl group, Y is a direct bond, or a defined linking group and R2 is an optionally substituted aryl, an optionally substituted cycloalkyl or an optionally substituted heterocyclic group; together with processes for their preparation, pharmaceutical compositions containing... Agent: Morgan Lewis & Bockius LLP

20090209603 - Olmesartan medoxomil with reduced levels of impurities: The present invention provides the preparation of olmesartan medoxomil containing less than about 0.1% of one or more of the impurities OLM-Me, OLM-Cl, and OLM-eliminate.... Agent: Kenyon & Kenyon LLP

20090209604 - Topical combination therapy for treating acne: Described are aqueous topical compositions containing a combination of benzoyl peroxide, at least one dicarboxylic acid having 6 to 12 carbon atoms, and at least one vitamin B.sub.3 compound in aqueous vehicles containing at least one 1,2-alkanediol having from 5 to 7 carbon atoms. The compositions are suitable for treatment... Agent: Jerry Zhang

20090209605 - Nematicidal compositions: The present invention concerns nematicidal compounds, their formulation as nematicidal composition and their use for controlling nematodes, preferably plant parasitic nematodes.... Agent: Wolf Greenfield & Sacks, P.C.

20090209606 - Cancer treatments: Methods and compositions for treating cancers characterized by death-resistant cancer cells are described. In general, such methods involve administration of a therapeutically effective amount of a compound that induces mitotic catastrophe in the some, and preferably most or all, of the cancerous cells. Methods for assessing the efficacy of such... Agent: Woodcock Washburn LLP

20090209607 - Inhibitors of akt activity: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20090209608 - Deuterium-enriched asenapine: The present application describes deuterium-enriched asenapine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20090209609 - Thienopyrroles and pyrrolothiazoles as new therapeutic agents: e

20090209610 - Polymorphic form of 6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1h-pyrrolizin-5-ylacetic acid: The present invention relates to a new crystalline modification of 6-(4-chlorophenyl)-2,2-dmethyl-7-phenyl-2, S-dihydro-1H-pyrrolizin-S-ylacetic acid which is referred to as polymorph B. It has a peak in the solid state 13C-NMR spectrum (with adamantane as external reference standard; CH group d=29.45 ppm) in the range from 179.8 to 180.2 ppm and can... Agent: Edwards Angell Palmer & Dodge LLP

20090209611 - Fluvastatin sodium crystal forms, processes for preparing them, compositions containing them and methods of using them: Provided are crystalline forms of fluvastatin sodium and processes for their preparation.... Agent: Kenyon & Kenyon LLP

20090209614 - Glutamine-containing compositions and a method for increasing blood flow using same: The present invention provides a glutamine-containing composition which functions to increase blood flow. Glutamine is present in the composition in an amount of 25 mg/kg body weight to 150 mg/kg body weight. By administering the composition to a subject in need thereof, the blood flow in the capillary vessels can... Agent: Cermak & Kenealy LLP Acs LLC

20090209612 - Process for the preparation of atorvastatin: The invention relates to processes for the preparation of atorvastatin. Atorvastatin is known by the chemical name [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid. The hemi-calcium salt of atorvastatin is useful as an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA reductase). The invention also relates to pharmaceutical compositions that include the atorvastatin or a... Agent: Ranbaxy Inc. Intellectual Property Dept.

20090209613 - Use of allymercaptocaptopril for treating or preventing obesity and obesity related diseases: Use of allylmercaptocaptopril for treating or preventing obesity and/or an obesity related disease or disorder is disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090209615 - Inhibitors of matrix metalloproteinases to treat neurological disorders: The invention provides methods to treat neurological disorders, opthalmological disorders, or a combination thereof by administering a compound that inhibits MMPs. A compound that inhibits MMPs is represented by the compound of formula (I) shown herein.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090209616 - Preparation of romidepsin: The invention provides an improved process for preparing romidepsin. The process involves producing, purifying, or storing romidepsin under conditions that prevent the formation of undesired adducts. Purifying romidepsin at an apparent pH lower than approximately 6.0 (e.g., between an apparent pH of 4.0 and 6.0) has been discovered to prevent... Agent: Choate, Hall & Stewart LLP

20090209617 - Duloxetine salts: The subject of the present invention is the provision of new salts of duloxetine of the Formula (I) with organic acids, process for their preparation and medicinal products containing thereof. The new salts are essentially free from the impurity of the Formula (II) and possess high purity and high stability.... Agent: K.f. Ross P.C.

20090209632 - Percutaneously absorptive ophthalmic preparation comprising olopatadine: The present invention provides a percutaneously absorptive preparation for preventing or treating allergic eye disease, which comprises olopatadine or a salt thereof as an active ingredient. In addition, the present invention provides a method for preventing or treating allergic eye disease, which comprises applying a percutaneously absorptive preparation comprising olopatadine... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090209633 - Treatment of pain with resiniferatoxin and related analogs: A method of treating inflammatory pain conditions is provided that involves administering an effective amount of a TRPV1 agonist, such as resiniferatoxin, tinyatoxin and related potent agonists and their analogs, to a patient to selectively induce nerve terminal depolarization block and/or nerve terminal death in select TRPV1-containing neurons, to provide... Agent: Siu School Of Medicine Office Of Technology Transfer

20090209634 - Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis: The present invention is a method for treating, preventing, reversing, arresting or inhibiting the occurrence, development and maturation of seizures or seizure-related disorders. More specifically, the present invention is directed to methods for the use of benzo-fused heterocycle sulfamide derivatives of formula (I) and formula (II) as described herein to... Agent: Philip S. Johnson Johnson & Johnson

20090209636 - Novel use of (-)-epigallocatechin gallate: An apparatus for generating a data stream having a series of segments using data organized in subsequent data frames, a data frame having more important and less important data. It comprises a packetiser for packetising data from a data frame into the series of segments having a first segment and... Agent: Nixon & Vanderhye, PC

20090209635 - Topical cromolyn formulations: The present invention provides a topical composition comprising (a) at least one delivery agent compound and (b) a cromoglycic acid compound. Methods of treatment, and methods of preparing the topical composition are also provided.... Agent: Emisphere Technologies, Inc

20090209637 - Use of chromen-4-one derivatives: where R1 and R2 may be identical or different and are selected from H, —C(═O)—R7, —C(═O)—OR7, alkyl groups, alkenyl groups, hydroxyalkyl groups and/or cycloalkyl groups and/or cycloalkenyl groups, R3 is H or alkyl groups, R4 is H or OR8, R5 and R6 are selected from —H, —OH, alkyl groups, alkenyl... Agent: Millen, White, Zelano & Branigan, P.C.

20090209638 - Treatment for depressive disorders: A method of treating depression comprising administering a melatonin agonist.... Agent: Hoffman Warnick LLC

20090209639 - Process for modifying drug crystal formation: A process for modifying the crystal habit of acicular drug substances, crystals obtained by such a process, and particular crystal forms or modifications of mycophenolic acid or mycophenolate sodium are provided, as well as pharmaceutical compositions comprising the crystals, methods of treatment and uses thereof.... Agent: Novartis Corporate Intellectual Property

20090209640 - Prevention of and countermeasures against viral infection: The present invention relates to a method for treating viral infection, which includes administering arginine and a high dose of vitamin C. It also relates to an agent for treating viral infection, which includes arginine and coated vitamin C.... Agent: Oliff & Berridge, PLC

20090209641 - Pharmaceutical composition for administration by injection: A pharmaceutical composition for administration by injection, comprising a mixture of platinum complex of general formula (I), wherein A and A′ independently of one another are an NH3 group or an amino or diamino group containing 1 to 18 carbon atoms, B and B′ independently of one another are a... Agent: Notaro & Michalos P.C.

20090209642 - Hydroxy acid complexes for antiaging and skin renovation: This invention relates to certain divalent or polyvalent metals of first transition series of the Periodic Table of Elements and including zinc and Molybdenum, complexed concurrently with an amino acid and a hydroxy acid in a novel spirocyclic bidentate chemical complex form (FIG. 1). Upon topical application said metal complexes... Agent: Shyam K. Gupta Bioderm Research

20090209643 - Method for modulating stem cell growth: In one embodiment, provided is a composition comprising a prostaglandin compound for modulating stem cell proliferation and/or differentiation in a mammalian subject. In another embodiment, the instant application is a composition comprising a prostaglandin compound for, which comprises a prostaglandin compound for modulating proliferation and/or differentiation of stem cells of... Agent: Sughrue Mion, PLLC

20090209644 - Lipotoxicity relieving agent: In view of the situation that a clinically acceptable medical agent which has the action of preventing and relieving the lipotoxicity with no significant side effects is not yet provided, such medical agent is provided. An agent for relieving lipotoxicity which comprises an unsaturated fatty acid containing 18 to 22... Agent: Birch Stewart Kolasch & Birch

20090209645 - Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form: Methods for treating vasomotor symptoms associated with menopause are described.... Agent: King & Spalding LLP

20090209646 - Tranexamic acid formulations: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.... Agent: Davidson, Davidson & Kappel, LLC

20090209647 - Nutritional method: A method of improving nutrition and/or treating low grade inflammation in an elderly human subject comprises administering to said subject a cysteine source so as to provide metabolically available cysteine in the diet of said subject in a proportion relative to all available amino acids which is greater that the... Agent: Nestle Healthcare Nutrition

20090209648 - Phenylacetic acid derivatives: Compounds of formula (I) pharmaceutically acceptable salts thereof, and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.... Agent: Novartis Corporate Intellectual Property

20090209649 - Alpha-glucosidase inhibitor, inhibitor for blood glucose level elevation and functional food containing tricaffeoylaldaric acid and method for producing tricaffeoylaldaric acid: Components that demonstrate an α-glucosidase inhibitory activity and hyperglycemic inhibitory activity have clearly been provided from among the components included in Yacon. The present inventors found that as a result of screening for a strong anti-oxidant component in a Yacon aerial portion extract, an antioxidant activity was converged in a... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090209650 - Materials and methods for improving the health of shrimp: The subject invention provides methods for improving shellfish health. In specific embodiments, the invention provides methods for accelerating and/or augmenting shrimp growth; improving immunity; and enhancing fertility in shellfish. To do so, the present invention provides materials and methods for administering a cysteamine compound to shrimp.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090209651 - Use of 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl) propane-1-one for improved skin contouring or against cellulite: A cosmetic or dermatological preparation which is suitable for application to skin and comprises 3-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propane-1-one in a concentration which is effective for at least one of increasing skin moisture content, moisturizing skin, improving the surface structure of the skin, reducing cellulite, increasing the resilience and elasticity of skin, strengthening the... Agent: Greenblum & Bernstein, P.L.C

20090209653 - Agent for increasing testosterone level: Provided is a substance which is a safer and more commonly-consumed food ingredient that increase the testosterone level. The testosterone enhancer of the invention comprises vitamin K as an active ingredient. The vitamin is preferably menaquinone-4 and/or menaquinone-7. This enhancer is useful as pharmaceutical agents, supplements, health foods or functional... Agent: Kohn & Associates, PLLC

20090209652 - Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy: The invention provides methods and compositions for treating and preventing a skin rash secondary to anti-epidermal growth factor receptor (EGFR) therapy, where the method comprises applying a vitamin K analog or a phosphatase inhibitor to the skin.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090209655 - Isoflavone metabolites: There are disclosed compounds of formulae (I) or (II) in which A is selected from the group consisting of (1), (2), (3) and (4); OH, and one of R1 and R2 is selected from H, OH and OCH3, and the other of R1 and R2 is selected from OH and... Agent: Barnes & Thornburg LLP

20090209654 - Prenylflavonoid formulations: Methods and formulations for increasing the water solubility and/or bioavailability of prenylfiavonoids are disclosed. The formulations may be employed to treat a disease states, including cancer.... Agent: Kenneth E. Jenkins Townsend And Townsend And Crew LLP

20090209656 - Disinfection/sanitation method where the material is treated with a solution comprising benzyl alcohol and c2-3 alcohol: The present invention relates to a method for disinfection or sanitation of different material, especially sensitive material, such as chromatographic media with various sensitive ligands. The invention also relates to a composition for use in such a method. The method for disinfection/sanitation, comprises exposing the material to be treated to... Agent: Ge Healthcare Bio-sciences Corp. Patent Department

20090209657 - Soap kit for women's intimate hygiene and composition of soap for the menstrual period: The present invention refers to a soap kit, preferably liquid, for women's intimate hygiene devised to take into consideration the different phases of the menstrual cycle, keeping the vaginal flora and helping to prevent infection. Besides that, the present invention also refers to a soap composition, preferably liquid, for intimate... Agent: Alston & Bird LLP

20090209658 - Embolic compositions: Embolic compositions comprising macromers having a backbone comprising a polymeric backbone comprising units with a 1,2-diol or 1,3-diol structure, such as polyvinyl alcohol, and pendant chains bearing crosslinkable groups and, optionally, other modifiers. When crosslinked, the macromers form hydrogels having many properties advantageous for use as embolic agents to block... Agent: Law Office Of Collen A. Beard, LLC

20090209660 - Biomaterial containing degradation stabilized polymer: The present invention relates to a polymer based material comprising a water binding agent, whereas the water binding agent is present in an amount sufficient to chemically and/or physically absorb and/or adsorb water to prevent degradation of the polymer. It also relates to a polymer based material which comprises a... Agent: Leydig Voit & Mayer, Ltd

20090209659 - Liquid thickeners for aqueous systems: Liquid thickener for aqueous systems containing, as viscosity suppressing agent, from 5 to 40% wt of ethoxylated mono- and/or di-glycerides of carboxylic acids having from 6 to 18 carbon atoms, from 15 to 40% wt of a polyurethane associative thickener, obtained from the reaction of at least one organic polyisocyanate,... Agent: Paul S Madan Madan & Sriram, PC

20090209661 - Delivery particle: The present application relates to agglomerates/particles comprising encapsulated, benefit agents, compositions comprising such agglomerates/particles, and processes for making and using such agglomerates/particles and compositions comprising such agglomerates/particles. Such agglomerates/particles are processed to a form that minimizes or eliminate certain drawbacks associated with incorporating encapsulated benefit agents in consumer products.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090209662 - Isomaltulose with improved flowability: The invention concerns a crystalline isomaltulose product having improved flow properties as bulk product and no tendency toward long-time compaction, method for production of this product as well as a new use of isomaltulose.... Agent: BatemanIPLaw Group

20090209663 - Long term weight maintenance: This invention is in the field of weight maintenance, more in particular in the field of long term weight maintenance of humans. The invention relates to the use of a mixture of a triglyceride oil having a solid fat content at ambient to body temperature and an emulsifier for maintaining... Agent: Nixon & Vanderhye, PC

20090209664 - Demulsifiers and methods for use in pharmaceutical applications: Demulsifiers containing an anionic surfactant selected from alkylsulfosuccinates, alkylsulfonates, alkylphosphonic acids, and their salts; a nonionic surfactant selected from ethylene oxide/propylene oxide copolymers, ethoxylated fatty acids of polyethylene glycol, terpene alkoxylates, and modified alkanolamides; or a combination of an anionic and a nonionic surfactant, and methods of use thereof in... Agent: Rhodia, Inc.

  
08/13/2009 > patent applications in patent subcategories. inventions list

20090203572 - Method for in vitro molecular evolution of protein function: The invention provides a method for generating a polynucleotide sequence or population of sequences from parent polynucleotide sequences, the method comprising the steps of (a) providing a first population of polynucleotide molecules and a second population of polynucleotide molecules, the first and second populations together constituting plus and minus strands... Agent: Dann, Dorfman, Herrell & Skillman

20090203574 - Method for modulating hair growth: The present invention relates to the use of Lhx2 as a target for modulating the hair growth. Screening assays for identifying agents which increase or decrease the expression or activity of Lhx2 are provided.... Agent: Licata & Tyrrell P.C.

20090203575 - Targeted therapeutic proteins: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor.... Agent: Choate, Hall & Stewart LLP

20090203573 - Use of dietary fibres against muscle wasting: A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides,... Agent: Foley And Lardner LLP Suite 500

20090203576 - Methods and compositons for pulmonary delivery of insulin: Systemic delivery of insulin to a mammalian host is accomplished by inhalation of a dry powder of insulin. It has been found that dry insulin powders are rapidly absorbed through the alveolar regions of the lungs.... Agent: Novartis Corporate Intellectual Property

20090203577 - Azepinoindole derivatives as pharmaceutical agents: The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090203578 - Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use: e

20090203580 - Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity: Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating graft rejection, transplant rejection or diabetes in a subject. Other embodiments herein relate to compounds including naturally occurring and synthetic mutant compositions of alpha-1 antitrypsin, wherein the alpha-1... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090203579 - Glycopegylated granulocyte colony stimulating factor: The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action... Agent: Morgan, Lewis & Bockius LLP (sf)

20090203582 - Lysobactin amides: The invention relates to lysobactin amides and methods for their preparation, as well as their use for manufacturing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.... Agent: Morrison & Foerster LLP

20090203581 - Novel peptides for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090203583 - Use of type-b lantibiotic-based compounds having antimicrobial activity: The present invention provides methods for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject, the method comprising administering to the subject a type-B lantibiotic. In particular, the invention provides methods for the treatment or prophylaxis of a Clostridium difficile infection. The... Agent: Morgan Lewis & Bockius LLP

20090203584 - Peptide-based compounds: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.... Agent: Ge Healthcare, Inc.

20090203585 - Capreomycin derivatives and their use as antibacterials: The present invention relates to phenylurea derivatives of capreomycin I, IIB, IIA, or IB, and metabolites and pharmaceutically acceptable salts and solvates thereof. The compounds of the present invention are useful as antibacterial agents for treating bacterial infections and for treating disorders caused by bacterial infections. The present invention also... Agent: Array Biopharma, Inc.

20090203598 - Abc transporter ligand: Compositions and methods of using scorpion venom peptide that is a ligand for ABC transporters. One aspect provides a peptide having at least 80% sequence identity to SEQ ID NO: 1. The peptide Is believed to have a molecular mass of about 3.7 kDa and specifically interacts with cystic fibrosis... Agent: Pabst Patent Group LLP

20090203611 - Anti-microbial defensin-related peptides and methods of use: An antimicrobial peptide and its analogs that are insensitive to physiological salt and divalent cation concentrations is provided, as are methods for their use to treat and prevent bacterial infections. The peptides are especially useful to treat infections caused by bacteria that are resistant to traditional antibiotic therapy.... Agent: Fellers Snider Blankenship Bailey & Tippens

20090203594 - Anticancer peptide: A polypeptide and methods of using the polypeptide for treating malignancy by administering to a subject a composition of the polypeptide. Pharmaceutical compositions of the polypeptide.... Agent: Gordon & Rees LLP

20090203589 - Chemically modified human growth hormone receptor antagonist conjugates: The present invention provides a chemically modified human Growth Hormone (hGH) receptor antagonists prepared by attaching a single polyethylene glycol moiety to the N-terminus. The chemically-modified protein according to the present invention have decreased PEGylation heterogeneity and which may also have increased binding affinity.... Agent: Pfizer Inc. Patent Department

20090203602 - Compositions and methods for diagnosis and treatment of type 2 diabetes: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20090203603 - Compositions for the treatment and prevention of nephropathy: Compositions and methods for the prevention and treatment of nephropathy, including hypertensive and diabetic nephropathy, and nephropathy associated with insulin resistance and metabolic syndrome are described. Compositions of the invention include a compound that binds to a receptor for the glucagon like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090203587 - Diagnosis and therapy of cell proliferative disorders characterized by resistance to trail induced apoptosis: Described are methods and compounds for diagnosis and therapy of subsets of cell proliferative disorders which are characterized by resistance to TRAIL induced apoptosis. Examples of such diseases are B-cell chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and prostate cancer. Furthermore, methods for identifying drugs which are suitable for... Agent: Baker & Daniels LLP

20090203593 - Immunogenic constructs: The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a p12 polypeptide sequence and an mpa polypeptide sequence, wherein said ahpC polypeptide... Agent: Clark & Elbing LLP

20090203592 - Infant nutrition with hydrolised proteins: The invention concerns a method to treat and/or prevent childhood obesity comprising administering a nutritional composition containing fat, digestible carbohydrates and protein, wherein the protein comprises at least 25 wt. % peptides with a chain length of 25 to 30 amino acids based on dry weight of protein.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090203607 - Method and compositions for simultaneously regulating memory and mood: The present invention is concerned with methods and compositions for simultaneously treating or modulating memory and mood within the same individual.... Agent: St. Onge Steward Johnston & Reens, LLC

20090203586 - Method for ameliorating an inflammatory skin condition: The present invention relates to the use of thioredoxin in the manufacture of a medicament suitable for application to a skin surface for ameliorating an inflammatory skin condition. The present invention further relates to a method of ameliorating an inflammatory skin condition comprising applying to a skin surface an effective... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090203590 - Method for the inhibition of angiogenesis: The present invention is based on the discovery that Matrilin-1 has antiangiogenic and anticancer properties. The invention is directed to a method of treating a disease that responds to an inhibition of angiogenesis. Additionally, the invention can be applied to those at risk for developing a disease that responds to... Agent: David S. Resnick

20090203601 - Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant: The invention relates to a method for treating or preventing neutropenia in a patient receiving chemotherapy by administering a multi-PEGylated granulocyte colony stimulating factor (G-CSF) variant on the same day that chemotherapy is administered.... Agent: Maxygen, Inc. Intellectual Property Department

20090203591 - Methods and compositions for emergency contraception using endothelin receptor antagonists: Disclosed are methods and compositions containing endothelin receptor antagonists for emergency contraception.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090203605 - Methods for treating a condition characterized by dysfunction in protein homeostasis: Methods are provided for treating conditions characterized by dysfunction in protein homeostasis in a patient in need thereof. A method for treating a condition characterized by dysfunction in protein homeostasis in a patient in need thereof is provided which comprises administering to the patient a proteostasis regulator in an amount... Agent: Fenwick & West LLP

20090203610 - Methods of treating obesity or diabetes using nt-4/5: The invention concerns methods for treating obesity, non-insulin dependent diabetes mellitus, metabolic syndrome, and other related diseases by administering an NT-4/5 polypeptide. The invention also concerns compositions and kits comprising an NT-4/5 polypeptide.... Agent: Pfizer Inc

20090203597 - Methods to restore glycemic control: Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090203599 - N-terminal modified peg-trail, method for preparing and uses thereof: Disclosed herein are an N-terminal modified PEG-TRAIL conjugate and a preparation method and use thereof. The PEG-TAIL conjugate has pharmaceutical activity identical or similar to that of native TRAIL (TNF-related apoptosis-inducing ligand) with extended in vivo half-life and enhanced stability. Compared to native TRAIL, the PEG-TAIL conjugate exhibits high solubility... Agent: Cheryl H Agris Phd

20090203595 - Neuregulin variants and methods of screening and using thereof: The present invention provides polypeptide variants of neuregulin-1β (NRG-1β) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1β and methods of using polypeptide variants of NRG-1β for treating diseases.... Agent: Jones Day

20090203608 - Novel proteins and use thereof: The present invention provides a novel secretory/membrane protein associated with adipocyte differentiation and/or metabolism function, specifically, an adipocyte-derived secretory/membrane protein containing amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090203588 - Outcome prediction and risk classification in childhood leukemia: Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.... Agent: Coleman Sudol Sapone, P.C.

20090203600 - Pharmaceutical composition for the prophylaxis and treatment of hiv infection and its use: Pharmaceutical compositions for the prophylaxis and treatment of HIV infection and its use are provided. Particularly, the present invention provides a pharmaceutical composition comprising anti-virus peptides, use of said composition for manufacturing a medicament for the prophylaxis and treatment of HIV infection, and method for preventing and treating HIV infection... Agent: Hiscock & Barclay, LLP

20090203596 - Phosphatase inhibitor protein-1 as a regulator of cardiac function: The present invention relates to novel nucleic acids which encode novel mutant forms of Inhibitor Protein-1 (1-1). In particular, the 1-1 mutant forms comprise altered phosphorylation sites of PKC-α. In addition, the present invention relates to methods of regulating cardiac contractility and function, and for treatment of cardio myopathy and... Agent: Edwards Angell Palmer & Dodge LLP

20090203604 - Soothing agent and food for treating fatigue: e

20090203613 - Systems and methods for preparing autologous fibrin glue: The invention provides a system for preparing an autologous solid-fibrin web suitable for regenerating tissue in a living organism. The system includes a sealed primary container containing a separation medium and a low-density high-viscosity liquid. The separation medium is capable of separating red blood cells from plasma when the container... Agent: Michael Best & Friedrich LLP

20090203606 - Systems for and methods of use of therapeutic nutrition for the management of age-associated and age-specific health conditions of the elderly: Nutritional compositions which provide for improved taste profiles for the elderly while simultaneously providing nutrition specific to assist in the management of nutritional deficiencies that lead to age specific and age associated health conditions in the elderly. There are also provided products using these compositions and incorporating packaging design, volume... Agent: Lewis, Rice & Fingersh, Lc Attn: BoxIPDept.

20090203614 - Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration: The present invention provides compositions and methods for treating age-related macular degeneration (AMD). More specifically, the methods of the invention target amyloid proteins and drusen that tend to accumulate in the eyes of those patients suffering from AMD. AMD is treated in the methods of the invention by providing agents... Agent: Alcon

20090203609 - Use of il-1 inhibitors for treating il-1 mediated diseases: The invention relates to methods for treating or preventing arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and methotrexate. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the methotrexate is N-[4-[(2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid. The invention also relates to... Agent: Amgen Inc.

20090203612 - Xenorhabdus tc proteins and genes for pest control: The subject invention relates to novel Xenorhabdus toxin complex (TC) proteins and genes that encode these proteins. More specifically, the subject invention relates to TC genes and proteins obtainable from Xenorhabdus strain Xwi. The subject invention also provides an exochitinase obtainable from the Xwi strain. This exochitinase can be used... Agent: Baker & Daniels LLP- Dow Agrosciences

20090203617 - Chimeric peptides for the regulation of gtpases: Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer.... Agent: Knobbe Martens Olson & Bear LLP

20090203616 - Methods for treating pain and screening analgesic compounds: The present invention relates to the use of compounds that block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090203615 - Use of activity dependent neurotrophic factor for enhancing learning and memory: pre-and post-natal administration: The present invention provides methods for improving performance (e.g., learning and/or memory) using ADNF polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.... Agent: Townsend And Townsend And Crew, LLP

20090203618 - Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification: The present invention refers to analog compounds of peptides having the amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4, including analgesic peptides derived from snakes of species such as Crotalus durissus terrificus; their uses in the treatment, diagnosis... Agent: Fish & Richardson PC

20090203619 - Artificial platelets: Therapeutic agents suitable for use as artificial platelets are described. The agents comprise a fibrinogen binding precursor bound to an insoluble carrier, wherein the fibrinogen binding precursor can be converted by a wound site specific agent, such as thrombin, to a fibrinogen binding component bound to the carrier. The fibrinogen... Agent: Seed Intellectual Property Law Group PLLC

20090203620 - Methods for attenuating release of inflammatory mediators and peptides useful therein: The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090203624 - Alpha-fetoprotein peptides: The invention relates to compounds that include peptides that inhibit estrogen receptor dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090203622 - Method of treating metastatic stage prostate cancer: The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090203623 - Method of treating prostate cancer with gnrh antagonist: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090203625 - Phage display selection of anti fungal peptides: A method for the identification of peptides having an affinity for the surface of fungi is provided as is a method for the identification of peptides capable of affecting the development of a fungus. Also provided are compositions containing peptides identified using the method of the present invention. In addition,... Agent: Senniger Powers LLP

20090203621 - Tripeptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1: The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification... Agent: Foley And Lardner LLP Suite 500

20090203626 - Pediatric amino acid solution for parenteral nutrition: The present invention relates to an amino acid solution for the parenteral nutrition of pediatric patients. The amino acid solution provides for an increased concentration of glutamine, tyrosine, cysteine and taurine, while the concentrations of phenylalanine and methionine is small. Glutamine and tyrosine are provided in the form of oligopeptides.... Agent: The Nath Law Group

20090203627 - Specific binding sites in collagen for integrins and use thereof: The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods... Agent: Benjamin Aaron Adler Adler & Associates

20090203628 - Composition, method and kit for treating skin disorders and improving skin condition: The present invention provides a composition, method and kit for treating skin disorders and improving skin condition. The composition, method and kit is particularly suited for treating acne vulgaris, seborrhea, rosacea, hirsutism, psoriasis, oily skin, dry skin, discoloration, post inflammatory hyper pigmentation, sun spots, and wrinkles.... Agent: Wilson Sonsini Goodrich & Rosati

20090203629 - Inhibitors of cathepsin b: The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway... Agent: Townsend And Townsend And Crew, LLP

20090203631 - Peptide deformylase inhibitors as novel antibiotics: A macrocyclic peptide deformylase (PDF) inhibitor comprising a peptide or peptide mimetic having three residues, P1′, P2′, and P3′, wherein P2′ connects P1′ and P3′, wherein P1′ and P3′ each have a side chain, and wherein the side chains on P1′ and P3′ are crosslinked to form the macrocyclic PDF... Agent: Calfee Halter & Griswold, LLP

20090203630 - Process for preparing atazanavir bisulfate and novel forms: m

20090203632 - Compositions and methods for treating contracture: A method for treating contracture is provided that includes administering to a patient in need thereof a composition that includes a therapeutic agent effective in treating contracture. Compositions, devices, and kits for use in treating contracture are also described.... Agent: Seed Intellectual Property Law Group PLLC

20090203633 - Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents —RB, —CORC etc. in which RB... Agent: Sughrue Mion, PLLC

20090203634 - Compositions and uses of amooranin compounds: Amooranin (AMR) has been found to cause tumor cell death through G2/M cell cycle arrest, caspase activation, and apoptosis. Furthermore, it has been demonstrated that AMR is a substrate for P-glycoprotein. Based on these activities, AMR compounds, including AMR analogs, can be used in the treatment of a number of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090203635 - Hxaaa01 polynucleotides: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090203767 - Inhibition stat-1: The present invention relates to inhibitors of the transcription factor STAT-1, their use as therapeutic means as well as their use for the prevention or therapy of cardio-vascular complications like restenosis after percutaneous angioplasty or stenosis of venous bypasses, the graft versus host reaction, the ischemia/refusion-related damage in the context... Agent: Fulbright & Jaworski L.L.P.

20090203765 - Modulation of eif4e-bp2 expression: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.... Agent: Mcdermott Will & Emery

20090203766 - Vwf aptamer formulations and methods for use: The invention relates to the formulation, dosing, administration and use of an aptamer antagonist therapeutic that binds to von Willebrand Factor.... Agent: Mintz, Levin, Cohn, Ferris, Glovskyand Popeo, P.C.

20090203769 - Modulation of the integrin-linked kinase signaling pathway provides beneficial human cardiac hypertrophy and post myocardial infarction remodeling: Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process for mediating a broadly adaptive form of human cardiac hypertrophy and a protective process for post myocardial infarction (MI), both comprising illiciting an... Agent: Vedder Price, PC

20090203768 - Nucleic acid-containing complex: A nucleic acid-containing complex, containing a nucleic acid and a biodegradable polymer, especially a positively-charged water-insoluble biodegradable polymer, is disclosed. The complex has excellent properties of sustainedly releasing a desired nucleic acid, especially DNA, to a site in need of a treatment. Since the complex can be taken up to... Agent: Foley & Lardner LLP

20090203636 - Prevention and treatment of cancer and other diseases: Nucleoside chemical compounds, which interact with specific structures of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) are disclosed. The compounds interfere with the activities of telomerase and reverse transcriptase, and are useful as antivirals, antibacterials and anticancer agents. Methods of treating or preventing cancers in patients involving administration of a... Agent: Nanda P B A Kumar Reed Smith

20090203637 - Novel cytostatic 7-deazapurine nucleosides: c

20090203638 - Pharmaceutical compositions and methods for metabolic modulation: Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and... Agent: Fish & Associates, PC Robert D. Fish

20090203640 - Crystalline forms of gemcitabine amide prodrug, compositions and use thereof: The present invention relates to novel crystal forms of an amide prodrug of gemcitabine, compositions thereof and methods for using.... Agent: Eli Lilly & Company

20090203639 - Methylation markers for diagnoses and treatment of cancers: Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the... Agent: Banner & Witcoff, Ltd.

20090203641 - Antibiotic compositions and related screening methods: Moenomycin inhibits bacterial growth by clocking the transglycosylase activity of class A penicillin-binding proteins (PBPs), which are key enzymes in bacterial cell wall synthesis. The binding affinities of moenomycin A with various truncated PBPs were compared showing that the transmembrane domain is important for moenomycin binding. Full-length class-A PBPs from... Agent: Greenberg Traurig LLP (la)

20090203643 - Method and composition for avoiding or mitigating the formation of preservative residues on the surface of wood treated with micronized copper-containing compositions: Disclosed is a wood preservative composition comprising micronized copper and copper-amine complex, wherein the copper component of the copper amine complex is from about 5% to about 50% by weight, based upon the total weight of copper in the composition. The copper amine complex serves to avoid wood surface “chalking”... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090203642 - Spray-dried chitin nanofibrils, method for production and uses thereof: The invention relates to a novel method for production of nanofibrillar chitin, sustainable from an industrial manufacturing standpoint and suitable for producing chitin nanofibrils having improved properties and free from less crystalline components. The invention also relates to novel chitin nanofibrils obtained with said method and characterized by an increased... Agent: Nixon & Vanderhye, PC

20090203645 - Broad spectrum disinfecting and sterilizing composition: The present invention relates to antimicrobial compositions including an aromatic dialdehyde and a quaternary ammonium compound wherein the aromatic dialdehyde is orthophthalaldehyde, isophthalaldehyde, terephthalaldehyde, or combinations thereof, and the ratio of aromatic dialdehyde to quaternary ammonium compound is from about 10:1 to about 1:5. The invention also relates to methods... Agent: Hoffmann & Baron, LLP

20090203644 - Compositions for treating and/or preventing diseases characterized by the presence of metal ions: The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including silicon-amino compounds. In some cases, a silicon-amino compound of the invention may be bidentate, tridentate, or otherwise polydentate, and... Agent: Wolf Greenfield & Sacks, P.C.

20090203646 - Use of sodium narcistatin for reducing internal adhesions and fibrosis: The present invention concerns a method for reducing or preventing development of adhesions, fibrosis or scar tissue within serous body cavities by using sodium narcistatin.... Agent: Jennings, Strouss & Salmon, P.L.C

20090203647 - 5-fluoro pyrimidine derivatives: This present disclosure is related to the field of 5-fluoro pyrimidines and their derivatives and to the use of these compounds as fungicides.... Agent: Dow Agrosciences LLC

20090203648 - Modified phosphocalcic compound, injectable composition containing same: A phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to... Agent: Buchanan, Ingersoll & Rooney PC

20090203649 - Dermatological anti-wrinkle agent: p

20090203650 - Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention of osteoporosis: The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture... Agent: Darby & Darby P.C.

20090203651 - Use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome: e

20090203652 - Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases: where Ar is an aromatic ring and Ra, Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, such as psoriasis, rheumatoid arthritis, ulcerative cholitis and for the treatment of damages caused by ischemia... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090203653 - Compositions and methods using apocynin compounds and nitric oxide donors: The invention describes novel compositions comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The invention also provides novel kits comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and... Agent: Wilmerhale/nitromed

20090203654 - Cosmetic and pharmaceutical compositions: e

20090203655 - Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation: This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical... Agent: Hunton & Williams LLP Intellectual Property Department

20090203656 - Method for the reduction of dangerous blood sugar levels: The present invention relates to a method and procedure for reducing immediate serum glucose levels without resort to drugs. Specifically, the invention discloses a regular regimen comprising modest exercise, daily nutritional supplements and a series of specific, time sensitive steps, which, when followed will optimize the effects of the invention.... Agent: Edward P. Black

20090203657 - Dual pharmacophores - pde4-muscarinic antagonistics: e

20090203659 - Method of enhancing hair growth: wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is... Agent: Allergan, Inc.

20090203658 - Neuroactive steroid compositions and methods of use therefor: Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090203660 - Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in... Agent: Allergan, Inc.

20090203661 - Betulinic acid, derivatives and analogs thereof and uses therefor: Provided herein provided herein are novel analogs and derivatives of betulinic acid. Also provided is a method for inhibiting an activity of one or more specificity protein (Sp) transcription factors cells associated with a neoplastic disease using betulinic acid, betulinic acid analog(s) and/or derivative(s) effective to decrease expression of a... Agent: Benjamin Aaron Adler Adler & Associates

20090203662 - Novel derivatives of cholest-4-en-3-one oxime, pharmaceutical compositions containing them and preparation method: or one of its esters and/or of its addition salts with pharmaceutically acceptable acids, particularly as a cytoprotective drug, preferentially a cardioprotective and/or neuroprotective drug, the compounds of formula I wherein R is R2, R3, R4, R5 or R6 as novel compounds as well as their preparation method and use.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090203663 - Chemical compounds: The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases... Agent: Astrazeneca R&d Boston

20090203664 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicyclo[3.2.0]heptane: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.... Agent: Paul D. Yasger Abbott Laboratories

20090203665 - Heterocyclic-substituted phenyl methanones: e

20090203666 - Compounds and compositions as hedgehog pathway modulators: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a... Agent: Genomics Institute Of The Novartis Research Foundation

20090203667 - Pentadienamide derivatives: e

20090203668 - Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors:

20090203670 - Combination antidepressants wafer: A sheet-like pharmaceutical preparation (dosage form) that quickly disintegrates on contact with moisture, based on hydrophilic polymers for the release of at least one active agent. The dosage form contains an active agent combination for treating depression, and at least one active agent selected from the antidepressant group of drugs.... Agent: D. Peter Hochberg Co. L.p.a.

20090203669 - Compositions and methods for the treatment of addiction and other neuropsychiatric disorders: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced... Agent: Fish & Richardson PC

20090203671 - Method of treating cancer: Methods of treating cancer in patients comprising administering thereto aurora kinase inhibitors and TRAIL (tumor necrosis factor (TNF)-related apoptosis inducing ligand) inhibitors is disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090203672 - Substituted sulfonamide compounds: t

20090203673 - 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments: The present invention encompasses compounds of general Formula (I) wherein X and R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090203674 - Pyrimidine compound and pests controlling composition containing the same: wherein R1 represents a hydrogen atom, halogen atom or C1-C4 alkyl; R2 represents C3-C7 alkynyloxy; R3 represents a hydrogen atom, halogen atom or C1-C3 alkyl; X represents C4 polymethylene, in which a CH2—CH2 may be replaced with a CH═CH, optionally substituted with at least one substituent selected from the group... Agent: Sughrue Mion, PLLC

20090203675 - Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20090203677 - Dual pharmacophores - pde4-muscarinic antagonistics: m

20090203676 - G-protein coupled receptor agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20090203678 - Pharmaceutical compositions for the treatment of protozoan parasitic diseases: The present invention relates to the use of a Rho/ROCK/PI3K/Akt pathway modulator for the manufacture of a medicament intended for the prevention or the treatment of pathologies associated with an infection by a protozoan parasite.... Agent: Young & Thompson

20090203679 - Galenical formulations of organic compounds: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of HCTZ and a hydrophilic filler selected from the group a carbohydrate or combinations thereof, e.g. sugars, sugar alcohols and starches or combinations... Agent: Novartis Corporate Intellectual Property

20090203680 - In vivo studies of crystalline forms of meloxicam: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.... Agent: Rakoczy Molino Mazzochi Siwik LLP

20090203681 - Novel n-(2-amino-phenyl)-amide derivatives: and pharmaceutically acceptable salts thereof, processes for the manufacture of these novel compounds and medicaments containing such compounds. The compounds of the present invention show anti-proliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion. The invention also covers the use... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090203682 - Rapamycin analogues and the uses thereof in the treatment of neurological disorders: Method of treatment of neurological disorders or complications due to stroke or head injury through the administration of a pharmaceutical composition including a pharmaceutically acceptable excipient or carrier and a compound of formula I are provided:... Agent: Wyeth Patent Law Group

20090203683 - Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them: wherein Ra, Rb, Rc, A, B, C, D, and X are as defined herein, or a tautomer, stereoisomer, or salt thereof, particularly a physiologically acceptable salt thereof. In addition, pharmaceutical compositions comprising an effective amount of a compound of formula (I), methods for the treatment or prophylaxis of benign or... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090203684 - Tyrosine kinase inhibitors: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives of formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat... Agent: Merck And Co., Inc

20090203686 - Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)- 3-hydroxy-3,4-dihydro-2h-chroman-6-yl derivatives: e

20090203685 - Anti-proliferative compounds from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof: The present invention is directed to molecules deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and having potent anti-proliferative and/or cytotoxic activity, especially against tumoral cells. The present invention also concerns the uses of these molecules in therapeutic application, for the treatment of different cancers. The invention also discloses the use of... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090203689 - Abca-1 elevating compounds and methods: useful for treating various disease states, in particular, insulin resistance, diabetes, dyslipidemia, coronary artery disease, and inflammation. The compounds of the present invention elevate cellular expression of the ABCA-1 gene as well as increasing the level of ABCA-1 protein, which may result in an increase in HDL levels in the... Agent: Cv Therapeutics, Inc.

20090203687 - Fused ring heterocycle kinase modulators: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.... Agent: Wilson Sonsini Goodrich & Rosati

20090203688 - Heterocyclic compounds: e

20090203690 - 5-substituted indazoles as kinase inhibitors: wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4,... Agent: Paul D. Yasger Abbott Laboratories

20090203691 - Novel 1h-indazole compounds: Wherein R1 is a C6-C14 aromatic cyclic hydrocarbon group etc.; R2, R4 and R5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C1-C6 alkylene group etc.; X is a single bond, or a group represented by —CO—NH— or... Agent: Birch Stewart Kolasch & Birch

20090203692 - Novel chemical compounds: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with hYAK3 activity.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090203693 - Therapeutic agent for liver fibrosis: The present invention provides a therapeutic agent for hepatic fibrosis and a method for treatment of hepatic fibrosis. 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analogue thereof can prevent the fibrillation in the liver, and therefore can be used as a therapeutic agent for hepatic fibrosis or in the method for treatment of hepatic... Agent: Darby & Darby P.C.

20090203694 - Inhibitors of undecaprenyl pyrophosphate synthase: The present invention relates to compounds that are selective and/or potent inhibitors of UPPS. In addition to compounds which inhibit UPPS, the invention also provides pharmaceutical compositions comprising these compounds and methods of using these compounds for treating bacterial disease, such as bacterial infection.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090203696 - Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics: wherein A, Q, X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. The disclosure also relates to pharmaceutical compositions containing a compound of formula (I), to processes for preparing the compounds of formula (I), and to methods of using the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090203695 - Compounds iv: e

20090203697 - Heterocyclic type cinnamide derivative: (In the formula, Ar1 represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like; Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group or the like; X1 represents —CR3═CR4— (wherein R3 and R4... Agent: Birch Stewart Kolasch & Birch

20090203698 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of... Agent: Ropes & Gray LLP

20090203699 - Aminomethylpyridine derivatives, method for preparing same and therapeutic use thereof: The present invention pertains to aminomethylpyridine derivatives, to their preparation and to their therapeutic application.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090203700 - Azolylmethyloxiranes, their use for controlling phytopathogenic fungi, and compositions comprising them: e

20090203701 - Prophylactic and/or therapeutic agent for rheumatoid arthritis:

20090203702 - Inhibitors of p38: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions... Agent: Ropes & Gray LLP

20090203704 - Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative: An object is to provide a novel quinoxaline derivative. Another object is to provide a light-emitting element with low driving voltage. Still another object is to provide a light-emitting element with low power consumption. Yet another object is to provide a light-emitting device and an electronic device each having low... Agent: Cook Alex Ltd

20090203703 - Thienopyrimidine derivatives: or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090203705 - Spiro compounds as npy y5 receptor antagonists:

20090203706 - Lysine-based polymeric linkers: The present invention provides polymeric linkers containing branching moieties. Methods of making the polymeric linkers and methods of making conjugates using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090203707 - Methods for treating pain: This invention relates to methods for treating a patient suffering from neuropathic or nociceptive pain which may be mechanical, visceral, and/or inflammatory in nature, comprising administering a therapeutically effective amount of Ranolazine to a patient in need thereof.... Agent: Cv Therapeutics, Inc.

20090203708 - Novel substituted-1-h-quinazoline-2,4-dione derivatives, preparation method thereof and pharmaceutical composition containing the same: Disclosed herein are novel substituted-1H-quinazoline-2,4-dione derivatives, a preparation method thereof, and a pharmaceutical composition containing the same. The novel substituted-1H-quinazoline-2,4-dione derivatives are excellent in binding affinity and selectivity for 5-HT6 receptors over other receptors, inhibit serotonin(5-HT)-stimulated cAMP accumulation, and disrupt apomorphine(2 mg/kg, i.p.)-induced hyperactivity in rats. Thanks to these effects,... Agent: Lucas & Mercanti, LLP

20090203709 - Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor: A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.... Agent: Paul D. Yasger Abbott Laboratories

20090203710 - Novel piperidine derivative: Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep... Agent: Merck And Co., Inc

20090203711 - Inhibitors of p38 map kinase: wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7cycloalkyl, aryl or heteroaryl or —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen or optionally... Agent: Banner & Witcoff, Ltd.

20090203712 - Urea derivative: e

20090203713 - Hedgehog pathway antagonists to treat disease: Compounds, compositions, kits and methods for modulating hedgehog pathway activity, and treating conditions related to abnormal or aberrant hedgehog pathway activity, are disclosed.... Agent: Edwards Angell Palmer & Dodge LLP

20090203714 - Furo[3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors: The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as... Agent: Edwards Angell Palmer & Dodge LLP

20090203715 - Novel 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals: The present invention relates to 2-hetarylthiazole-4-carboxamide derivatives of the formula (I), the use thereof as medicament for the treatment of various disorders, and processes for the preparation thereof... Agent: Millen, White, Zelano & Branigan, P.C.

20090203716 - Pyrimidine low molecular weight ligands for modulating hormone receptors: e

20090203717 - Fused heterocyclic compound: wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090203718 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and an IGF-1R inhibitor to a mammal suffering from a cancer.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090203719 - Enhancing treatment of mdr cancer with adenosine a3 antagonists: The present invention discloses the use of high affinity adenosine A3 receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A3 receptors and cancers expressing P-glycoprotein or MRP. In preferred embodiments, adenosine A3 receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or... Agent: King Pharmaceuticals, Inc.

20090203720 - Methods for inhibiting cell growth: Cell growth is inhibited and/or cell death is induced in a cell by administering an RXR agonist and an inhibitor of casein kinase 1α. A cell or a tissue can be screened for enhanced susceptibility to cell death or interference with cell growth. Conditions characterized by uncontrolled cell growth or... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090203721 - Use of siramesine in the treatment of cancer: The present invention relates to the treatment of cancer. In particular, the invention provides pharmaceutical compositions comprising siramesine for the treatment of cancer. The invention further provides a method of treatment comprising administering siramesine to a patient suffering from cancer.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20090203723 - 6,7-unsaturated-7-carbamoyl substituted morphinan derivative: e

20090203722 - Novel compositions and methods for enhancing potency or reducing adverse side effects of opiold agonists: The invention generally relates to novel compositions and methods with an opioid agonist and an opioid antagonist to differentially dose a human subject so as to either enhance analgesic potency without attenuating an adverse side effect of the agonist, or alternatively maintain the analgesic potency of the agonist while attenuating... Agent: Bell, Boyd & Lloyd, LLP

20090203724 - Solid and crystalline dutasteride and processes for preparation thereof: The solid state chemistry of 17β-N-[2,5-bis(trifluoromethyl)phenyl]carbamoyl-4-aza-5-α-androst-1-en-3-one of which the international nonproprietary name is Dutasteride (the active ingredient in products marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) and its process for preparing. The synthetic process comprises formation of the mixed anhydride, its subsequent reaction with 2,5-bis(trifluoromethyl)phenylamine in the presence... Agent: Patent Central LLC Stephan A. Pendorf

20090203725 - Androgen receptor modulator compounds and methods: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors and/or modulate the amount of androgen receptors; and to methods for making and using such compounds. Also provided are compositions containing such compounds and methods for making and using such compositions.... Agent: K&l Gates LLP

20090203727 - Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion: The present invention relates to a pharmaceutical composition including loratadine or a pharmaceutically acceptable form thereof, and phenylephrine or a pharmaceutically acceptable form thereof, for treating upper respiratory/mucosal congestion, optionally by administering to a patient four times a day.... Agent: HallihanIPPartners, LLC

20090203726 - Substituted tetrahydroquinolines as antibacterial agents: e

20090203728 - Naphthalamide derivatives having antiproliferative activity: The invention relates to compounds for use in medicine. The compounds are of general formula (I) as disclosed herein and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, wherein X, X′ and X″ are independently O or S; Z is N or P; R3 is optional and... Agent: Wilmerhale/new York

20090203730 - Bicyclic ppat inhibitors as antibacterial agents: Disclosed are compounds of Formula I, pharmaceutical compositions comprising Formula I and methods of treating bacterial infections. The disclosed compounds are inhibitors of PPAT (phosphopantetheine adenyl transferase), and are useful in the treatment and prevention of diseases caused by bacteria, particularly bacteria dependent on PPAT, for example, species such Escherichia... Agent: Mccarter & English, LLP Boston

20090203729 - Process for producing high-purity prasugrel and acid addition salt thereof: The present invention is directed to providing prasugrel hydrochloride or the like with a reduced content of OXTP. A method for producing prasugrel hydrochloride with a reduced content of OXTP, comprising dissolving free prasugrel containing OXTP in an inert solvent and adding hydrochloric acid optionally dropwise to the solution for... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090203731 - Treatment of depression and other affective disorders: The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor, or any other compound which causes an elevation in... Agent: Darby & Darby P.C.

20090203732 - Thiazolones for use as p13 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090203733 - Pharmaceutical composition: This invention relates to a pharmaceutical composition for mammals and, more particularly, to a pharmaceutical composition which enhances the action of an anaesthetic used in both human and veterinary applications, which, at least partly, reduces the risk of respiratory depression and enhances pulmonary perfusion. The pharmaceutical composition is characterised in... Agent: Darby & Darby P.C.

20090203734 - F1f0-atpase inhibitors and related methods: The present invention relates to inhibitors of mitochondrial F1F0-ATPase, methods for their discovery, and their therapeutic use. In particular, the present invention provides the compound PK11195 and structurally and functionally related compounds as F1F0-ATPase inhibitors, and methods of using such inhibitors as therapeutic agents to treat a number of conditions.... Agent: Casimir Jones, S.c.

20090203735 - Treatments for neuropathy: Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds,... Agent: Richard Aron Osman

20090203736 - Piperidine sulphonamide derivatives: wherein Ar1, Ar2, R1, R2, m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula I are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090203737 - Pyrrole derivatives as positive allosteric modulators of metabotropic receptors: The present invention relates to new compounds which are Pyrrole derivatives of formula (I) wherein A, B, P, Q5W, R1 and R2 are defined in the description. Invention compounds are useful in the prevention or treatment of central or peripheral nervous system disorders as well as other disorders modulated by... Agent: Edwards Angell Palmer & Dodge LLP

20090203738 - Pharmaceutical composition for treating bulimia and depression arising from bulimia: Provided is a pharmaceutical composition for the treatment of bulimia in which a cholinesterase inhibitor is combined with at least one member selected from the group consisting of sibutramine, a pharmacologically acceptable salt thereof, an active metabolite thereof, a prodrug thereof and a solvate thereof. The pharmaceutical composition is useful... Agent: Venable LLP

20090203739 - Anti-inflammatory agents: The invention provides compounds, pharmaceutical compositions and uses of compounds of general formula (I) or a pharmaceutically acceptable salt thereof, for the preparation of a medicament intended to treat an inflammatory disorder; wherein z X is 1, 2 or 4; X is —CO—Yk—(R1)n or SO2—Yk—(R1)n; k is 0 or 1;... Agent: Schwegman, Lundberg & Woessner, P.A.

20090203740 - 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them: 4-(trifluoromethanesulfonyloxyphenyl)propionic acid derivatives and pharmaceutical composition containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these... Agent: Birch Stewart Kolasch & Birch

20090203742 - Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors: wherein R1 is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from C1-6alkyl, hydroxy, amino, halogen, aminoC1-4alkyl and mono- or di(C1-4alkyl)amino; R2 is hydrogen or C1-6alkyl; L is a direct bond, —O—, C1-6alkanediyl-O— or —O—C1-6alkanediyl; R3 is phenylC1-4alkyl; R4 is C1-6alkyl; R5... Agent: Philip S. Johnson Johnson & Johnson

20090203741 - Crystals of benzoxadiazole derivative: Means for Resolution A solving means includes β-form crystal of 4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole, which shows an endothermic peak at 145 to 150° C. according to a differential scanning calorimeter analysis (DSC analysis) and shows X-ray powder diffraction peaks at 9.8, 11.1, 12.8, 13.3, 17.1, 20.2, 21.2 and 22.3 in 2θ(°), and the... Agent: Sughrue-265550

20090203743 - Small molecule entry inhibitors: N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(═O)—, —O—C(═O)—,... Agent: Philip S. Johnson Johnson & Johnson

20090203744 - Novel pyridine derivatives: The present invention relates to novel pyridine derivatives of the formula (I), their stereoisomers, and their pharmaceutically acceptable salts, and compositions. The present invention more particularly provides novel pyridine derivatives of the general formula (I).... Agent: Greenblum & Bernstein, P.L.C

20090203745 - Heterocyclic compounds for the inhibition of integrins and use thereof: The present invention relates to compounds of formula (I) wherein: A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090203746 - Synergistic insecticidal composition containing chloronicotynyle and pyrethroids compounds: A synergistic insecticidal composition is formed containing a Chloronicotynyle compound and a Pyrethroids compound. The Chloronicotynyle compound is provided in an amount preferably ranging from 0.1 to 5.0% by weight of the synergistic insecticidal composition. The Pyrethroids compound is provided in an amount preferably ranging from 1 to 60% by... Agent: Jones, Tullar & Cooper, P.C.

20090203747 - Novel chemical compounds and the uses thereof as a medicine: s

20090203748 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological... Agent: Paul D. Yasger Abbott Laboratories

20090203750 - 5-ht2c receptor agonists as anorectic agents: This invention relates to compounds which modulate receptors of the 5-HT2 family of receptors, and particularly to compounds which modulate 5-HT2C receptors. Compounds of the invention include agonists and selective agonists for the 5-HT2C receptor Compounds of the invention include selective agonists for the 5-HT2C receptor which exhibit significantly less... Agent: Greenlee Winner And Sullivan P C

20090203749 - Agent for control of degranulation reaction and cytokine production: To provide an agent capable of controlling the degranulation reaction and/or cytokine production of mast cell and the like. The present invention provides an agent for controlling a degranulation reaction and an agent for controlling a cytokine production, comprising a substance capable of controlling an intracellular zinc ion concentration, particularly,... Agent: Leydig Voit & Mayer, Ltd

20090203751 - Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators: The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II... Agent: Philip S. Johnson Johnson & Johnson

20090203752 - Compounds for nonsense suppression, and methods for their use: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a... Agent: Hoffmann & Baron, LLP

20090203753 - 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3h)-one-derivatives as beta2 adrenoreceptor agonists: The present invention provides compounds of formula (I) wherein e, R1, R2, R3, R4, R5, R4′, R5′, R6, R7, A, D, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20090203754 - Anti-bacterial drug targeting of genome maintenance interfaces: Methods for the design and identification of novel antimicrobial compounds are provided, as well as antimicrobial compounds identified using these methods. Pharmaceutical compositions that include these antimicrobial compounds are provided as well. The antimicrobial compounds inhibit the binding of a prokaryotic single-stranded DNA binding protein to a polypeptide. In some... Agent: Warf/bhgl

20090203755 - Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia: t

20090203756 - Biocidal compositions:

20090203757 - Ethylene glycol esters as photoactive agents:

20090203758 - Alpha crystalline form of the arginine salt of perindopril, a process for its preparation and pharmceutical compositions containing it.:

20090203760 - Cyclic agonists and antagonists of c5a receptors and g protein-coupled receptors: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090203759 - Pharmaceutical formulation of nitrooxyderivatives of nsaids: e

20090203761 - Process for preparing (3-oxo-2,3-dihydro-1h-isoindol-1-yl) acetylguanidine derivatives:

20090203762 - Methods for the production of biliverdin: The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.... Agent: Berenato, White & Stavish, LLC

20090203763 - Substituted benzhydrylethers: Disclosed herein are substituted benzhydrylethers of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of their use thereof.... Agent: Global Patent Group - Apx

20090203764 - Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases: Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several... Agent: Morrison & Foerster LLP

20090203770 - Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins: The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding... Agent: Townsend And Townsend And Crew, LLP

20090203771 - Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate: The present invention provides a novel method for producing a compound represented by formula (III) shown below, which comprises treating a compound represented by formula (I) shown below with a trivalent chromium compound and at least one kind of metal selected from the group consisting of manganese and zinc in... Agent: Clark & Elbing LLP / Eisai

20090203772 - Vaginal health products: The invention provides compositions and methods for increasing cell growth, stimulating cell turnover and promoting the secretion of mucus within the reproductive tract of a female mammal.... Agent: Dority & Manning, P.A.

20090203773 - Compounds for the treatment of non-autoimmune type 2 diabetes mellitus and/or syndrome x: The present invention relates to compounds of the formula (I); wherein R1 is H, CH3 or OCH3; R3=H, OH, CH3, OCH3, O-glucose or benzoyloxy; R4=H; R5=H or OH; R6=H or OCH3; R7=H, CH3, OCH3, cinnamoyloxy or (3,4,5-trimethoxy)-benzoyloxy; R8=H, OH, CH3 or OCH3; or R7 and R8 form together a group... Agent: Nixon & Vanderhye, PC

20090203774 - Substituted benzyl ester derivative and use thereof: e

20090203775 - Novel compound and a novel microorganism for producing the novel compound: The present invention relates to a novel compound represented as by formula (I). The present invention also provides a novel strain named as Alternaria alternata var. monosporus, which can produce the compound of formula (I). The inventive strain is cultured in the medium to produce and mass the inventive compound... Agent: Birch Stewart Kolasch & Birch

20090203776 - Methods of using menthol propyleneglycol-carbonate and analogs thereof for producing anti-inflammatory and anti-angiogenic effects: Menthol propyleneglycal-carbonate, analogs thereof and compositions containing such compounds are administered to mammals, preferably humans, to produce anti-inflammatory or anti-angiogenic effects.... Agent: Brooks Kushman P.C.

20090203777 - Organic compounds: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).... Agent: Novartis Institutes For Biomedical Research, Inc.

20090203779 - Esters of long-chain alcohols and preparation thereof: Disclosed is a composition and methods of treating a skin condition. The ester includes an ester and a dermatologically acceptable carrier. The ester is represented by the general formula 1:... Agent: Brett L. Nelson Eastman Chemical Company

20090203778 - Fatty acid analogues, i.e. including dha derivatives for uses as a medicament: A compound of formula (I) wherein R1 and R2 are different and each is chosen from a methyl group and a hydrogen atom; wherein X is chosen from a carboxylic acid group, a carboxylate group, a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex, or pro-drug of said compound.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090203780 - Use of a polyunsaturated fatty acid compound: A polyunsaturated fatty acid having 20 carbon atoms and four double bonds, or a derivative thereof, in an orally administrable form, can be used to treat or prevent obesity and/or for weight management. The polyunsaturated fatty acid may, for example, be used in the form of a food supplement, a... Agent: Morgan Lewis & Bockius LLP

20090203781 - N-n-acyloxypropyl lysine methyl ester-and n,n-bis(n-acyloxypropyl) lysine methyl ester-type compounds and use thereof as surface-active agents with an antimicrobial activity: The invention relates to novel compounds having an amphiphilic character (cationic, anionic, amphoteric and non-ionic), derivatives of n acyloxypropyl-type lysine amino acid according to general formula (I), which are intended to be used in the food, pharmaceutical and cosmetic industries as surface-active agents having a self-aggregating capacity and antimicrobial properties.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090203782 - Alpha 2 delta ligands for fibromyalgia and other disorders: R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The... Agent: Pfizer Inc. Patent Department

20090203783 - Therapeutic agent for acute cerebral infarct: An agent for treating acute cerebral infarction, comprising (2R)-2-propyloctanoic acid or a salt thereof, which is used for administration after a lapse of time of from about 5 hours to about 72 hours from the onset of the disease is useful for treating acute cerebral infarction, since it safely improves... Agent: Sughrue-265550

20090203785 - Method and process for producing youthful-appearing, small-pored, and smooth skin: A method and process for producing youthful appearing, small-pored, and smooth skin by pre-treating the skin topically with retinoic acid, applying carbon particles on the skin, removing the carbon particles by exploding them with laser light, and post-treating the skin topically with retinoic acid. When treating the face, removing the... Agent: Bush Intellectual Property Law Group, LLC

20090203784 - Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors: The present invention relates to methods and compositions for treating diseases. More specifically, the present invention relates to the administration of multiple drugs as part of a treatment of disease. Specific embodiments of the invention relate to a treatment regimen for neuroblastomas and other N-MYC, c-MYC, and L-MYC amplified and... Agent: Davis Wright Tremaine LLP - San Francisco

20090203788 - Method of enhancing reproductive function of mammals by feeding of conjugated linoleic acids: This invention provides methods for improving reproductive performance of lactating dairy cows and other mammals. The method in the case of cows comprises feeding to the cows, a composition comprising conjugated linoleic acids (CLAs), cis-9, trans-11 and trans-10, cis-12. When these CLAs are fed daily to dairy cows starting at... Agent: Hodgson Russ LLP The Guaranty Building

20090203786 - Methods and composition for improving cognitive function: Compositions and methods for enhancing cognitive function in animals are disclosed. The compositions and methods utilize long chain polyunsaturated fatty acids.... Agent: Wendell Ray Guffey Nestle Purina Petcare Global Resources

20090203787 - Very long chain polyunsaturated fatty acids, methods of production, and uses: The present invention relates to processes for production of Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs). The present invention also relates to compositions (e.g., nutritional supplements and food products) containing such VLC-PUFAs. In one embodiment, the present invention is directed to methods for biosynthesis and production of the VLC-PUFAs described... Agent: Dunlap Codding, P.C.

20090203789 - Fast dissolution amino acid composition: The present invention relates to oral dosage formulations for the rapid release of amino acids. A rapid release is achieved through the process of milling whereby the milled amino acids are more readily bioavailable.... Agent: Torys LLP

20090203790 - Gamma-l-pga producing microorganism, method of producing gamma-l-pga using the microorganism, crosslinked substance produced using the microorganism, and external dermal agent produced using the microorganism: There are provided a microorganism characterized by producing poly-γ-L-glutamate with a molecular weight of 1,300,000 or greater and uniform optical purity under liquid culture conditions, a method of screening for the microorganism, a method of producing poly-γ-L-glutamate having large molecular weight by using the microorganism, and poly-γ-L-glutamate having an average... Agent: Leydig Voit & Mayer, Ltd

20090203792 - Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators: A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α2δ subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that... Agent: Alston & Bird LLP

20090203791 - Nateglinide-containing preparation: The present invention discloses, as a immediate-release preparation useful as an antidiabetic, a nateglinide-containing preparation comprising nateglinide as an active ingredient wherein the nateglinide is amorphous.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090203793 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed as Formula (I).... Agent: Wellstat Management Company. LLC

20090203794 - Aqueous anaesthetic composition comprising propofol: The invention discloses an aqueous anaesthetic Propofol composition that is stable, autoclave sterilized, suitable for parental administration, having reduced incidence of pain upon injection. The composition comprises propofol, 2-hydroxypropyl-β-cyclodextrin and a local anaesthetic, Lignocaine.... Agent: Thorpe North & Western, LLP.

20090203795 - Polyquaternium-1 synthesis methods and associated formulations: A multipurpose solution for contact lens care, comprising: an aqueous liquid medium; a quaternary ammonium polymer having an average molecular weight as determined by the proton NMR method of at least 22 k, and methods for making.... Agent: Abbott Medical Optics, Inc.

20090203796 - Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen: The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk... Agent: Foley And Lardner LLP Suite 500

20090203797 - Antimycotic patch: e

20090203798 - Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol: A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.... Agent: Novartis Corporate Intellectual Property

20090203799 - Novel compositions comprising carotenoids: A novel composition for delivering carotenoids (e.g. α- and β-carotene, lycopene) and/or other physiologically active ingredients to the colon of humans after ingestion and for producing liquid food compositions insusceptible to polyphenol-protein reactions can be obtained by encapsulating said active ingredients with pectin, in particular with low-methoxylated pectin.... Agent: Nixon & Vanderhye, PC

20090203800 - Cytostatic composition: A cytostatic composition comprising an effective amount of an aldehyde in a pharmacological salt solution is shown to be effective at inhibiting growth of a number of cancerous cell lines.... Agent: Donn K. Harms Patent & Trademark Law Center

20090203801 - Methods of inhibiting ethylene responses in plants using dicyclopropene compounds: Methods of applying dicyclopropene compounds and compositions thereof to block ethylene receptors in plants are disclosed. Methods include applying to the plant an effective ethylene response-inhibiting amount of a dicyclopropene compound or composition thereof. Dicyclopropene compounds, enantiomers, stereoisomers or salts thereof are also provided.... Agent: Myers Bigel Sibley & Sajovec

20090203802 - Powder composition, a dispersion of powder in oil, and a cosmetic comprising the same: and a powder and/or a coloring agent, a dispersion of powder in an oil in which the powder composition is dispersed, and cosmetics comprising the same, wherein each R1 is, independently, an organic group selected from the group consisting of C1-30 alkyl groups, aryl groups, aralkyl groups, fluorinated alkyl groups,... Agent: Birch Stewart Kolasch & Birch

20090203803 - N-acylated chitinous polymers and methods of use thereof: The invention pertains to N-acetylated, N, O-carboxyalkylchitosans and methods for using the chitosans to treat disorders, such as cancer, nervous system disorders, urinary tract disorders, and reproductive tract disorders.... Agent: Edwards Angell Palmer & Dodge LLP

  
08/13/2009 > patent applications in patent subcategories. inventions list

20090203572 - Method for in vitro molecular evolution of protein function: The invention provides a method for generating a polynucleotide sequence or population of sequences from parent polynucleotide sequences, the method comprising the steps of (a) providing a first population of polynucleotide molecules and a second population of polynucleotide molecules, the first and second populations together constituting plus and minus strands... Agent: Dann, Dorfman, Herrell & Skillman

20090203574 - Method for modulating hair growth: The present invention relates to the use of Lhx2 as a target for modulating the hair growth. Screening assays for identifying agents which increase or decrease the expression or activity of Lhx2 are provided.... Agent: Licata & Tyrrell P.C.

20090203575 - Targeted therapeutic proteins: Targeted therapeutics that localize to a specific subcellular compartment such as the lysosome are provided. The targeted therapeutics include a therapeutic agent and a targeting moiety that binds a receptor on an exterior surface of the cell, permitting proper subcellular localization of the targeted therapeutic upon internalization of the receptor.... Agent: Choate, Hall & Stewart LLP

20090203573 - Use of dietary fibres against muscle wasting: A composition nutritional containing dietary fibres is useful for the treatment of muscle wasting, if the dietary fibre comprise at least 30 wt. % of galacto-oligosaccharides or other oligosaccharides having mainly anhydropyranose units, and having a chain length of 3-10 units. The composition may further contain other oligo- or polysaccharides,... Agent: Foley And Lardner LLP Suite 500

20090203576 - Methods and compositons for pulmonary delivery of insulin: Systemic delivery of insulin to a mammalian host is accomplished by inhalation of a dry powder of insulin. It has been found that dry insulin powders are rapidly absorbed through the alveolar regions of the lungs.... Agent: Novartis Corporate Intellectual Property

20090203577 - Azepinoindole derivatives as pharmaceutical agents: The present invention relates to compounds of formula I, which exhibit affinity for the farnesoid X receptor.... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090203578 - Certain crystalline diphenylazetidinone hydrates, pharmaceutical compositions thereof and methods for their use: e

20090203580 - Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity: Embodiments herein illustrate methods and compositions for treating medical disorders. In certain embodiments, compositions and methods relate to reducing, inhibiting or treating graft rejection, transplant rejection or diabetes in a subject. Other embodiments herein relate to compounds including naturally occurring and synthetic mutant compositions of alpha-1 antitrypsin, wherein the alpha-1... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20090203579 - Glycopegylated granulocyte colony stimulating factor: The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action... Agent: Morgan, Lewis & Bockius LLP (sf)

20090203582 - Lysobactin amides: The invention relates to lysobactin amides and methods for their preparation, as well as their use for manufacturing medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.... Agent: Morrison & Foerster LLP

20090203581 - Novel peptides for use in the treatment of obesity: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090203583 - Use of type-b lantibiotic-based compounds having antimicrobial activity: The present invention provides methods for the treatment or prophylaxis of a microbial infection of the lower intestine or colon in a subject, the method comprising administering to the subject a type-B lantibiotic. In particular, the invention provides methods for the treatment or prophylaxis of a Clostridium difficile infection. The... Agent: Morgan Lewis & Bockius LLP

20090203584 - Peptide-based compounds: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.... Agent: Ge Healthcare, Inc.

20090203585 - Capreomycin derivatives and their use as antibacterials: The present invention relates to phenylurea derivatives of capreomycin I, IIB, IIA, or IB, and metabolites and pharmaceutically acceptable salts and solvates thereof. The compounds of the present invention are useful as antibacterial agents for treating bacterial infections and for treating disorders caused by bacterial infections. The present invention also... Agent: Array Biopharma, Inc.

20090203598 - Abc transporter ligand: Compositions and methods of using scorpion venom peptide that is a ligand for ABC transporters. One aspect provides a peptide having at least 80% sequence identity to SEQ ID NO: 1. The peptide Is believed to have a molecular mass of about 3.7 kDa and specifically interacts with cystic fibrosis... Agent: Pabst Patent Group LLP

20090203611 - Anti-microbial defensin-related peptides and methods of use: An antimicrobial peptide and its analogs that are insensitive to physiological salt and divalent cation concentrations is provided, as are methods for their use to treat and prevent bacterial infections. The peptides are especially useful to treat infections caused by bacteria that are resistant to traditional antibiotic therapy.... Agent: Fellers Snider Blankenship Bailey & Tippens

20090203594 - Anticancer peptide: A polypeptide and methods of using the polypeptide for treating malignancy by administering to a subject a composition of the polypeptide. Pharmaceutical compositions of the polypeptide.... Agent: Gordon & Rees LLP

20090203589 - Chemically modified human growth hormone receptor antagonist conjugates: The present invention provides a chemically modified human Growth Hormone (hGH) receptor antagonists prepared by attaching a single polyethylene glycol moiety to the N-terminus. The chemically-modified protein according to the present invention have decreased PEGylation heterogeneity and which may also have increased binding affinity.... Agent: Pfizer Inc. Patent Department

20090203602 - Compositions and methods for diagnosis and treatment of type 2 diabetes: The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics... Agent: Mintz Levin Cohn Ferris Glovsky & Popeo

20090203603 - Compositions for the treatment and prevention of nephropathy: Compositions and methods for the prevention and treatment of nephropathy, including hypertensive and diabetic nephropathy, and nephropathy associated with insulin resistance and metabolic syndrome are described. Compositions of the invention include a compound that binds to a receptor for the glucagon like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090203587 - Diagnosis and therapy of cell proliferative disorders characterized by resistance to trail induced apoptosis: Described are methods and compounds for diagnosis and therapy of subsets of cell proliferative disorders which are characterized by resistance to TRAIL induced apoptosis. Examples of such diseases are B-cell chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and prostate cancer. Furthermore, methods for identifying drugs which are suitable for... Agent: Baker & Daniels LLP

20090203593 - Immunogenic constructs: The present invention relates to molecules, which can be used to induce a therapeutic or prophylactic immune response against MAP. In particular, the present invention relates to polypeptides comprising an alipC polypeptide sequence, a gsd polypeptide sequence, a p12 polypeptide sequence and an mpa polypeptide sequence, wherein said ahpC polypeptide... Agent: Clark & Elbing LLP

20090203592 - Infant nutrition with hydrolised proteins: The invention concerns a method to treat and/or prevent childhood obesity comprising administering a nutritional composition containing fat, digestible carbohydrates and protein, wherein the protein comprises at least 25 wt. % peptides with a chain length of 25 to 30 amino acids based on dry weight of protein.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090203607 - Method and compositions for simultaneously regulating memory and mood: The present invention is concerned with methods and compositions for simultaneously treating or modulating memory and mood within the same individual.... Agent: St. Onge Steward Johnston & Reens, LLC

20090203586 - Method for ameliorating an inflammatory skin condition: The present invention relates to the use of thioredoxin in the manufacture of a medicament suitable for application to a skin surface for ameliorating an inflammatory skin condition. The present invention further relates to a method of ameliorating an inflammatory skin condition comprising applying to a skin surface an effective... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090203590 - Method for the inhibition of angiogenesis: The present invention is based on the discovery that Matrilin-1 has antiangiogenic and anticancer properties. The invention is directed to a method of treating a disease that responds to an inhibition of angiogenesis. Additionally, the invention can be applied to those at risk for developing a disease that responds to... Agent: David S. Resnick

20090203601 - Method for the treatment of neutropenia by administration of a multi-pegylated granulocyte colony stimulating factor (g-csf) variant: The invention relates to a method for treating or preventing neutropenia in a patient receiving chemotherapy by administering a multi-PEGylated granulocyte colony stimulating factor (G-CSF) variant on the same day that chemotherapy is administered.... Agent: Maxygen, Inc. Intellectual Property Department

20090203591 - Methods and compositions for emergency contraception using endothelin receptor antagonists: Disclosed are methods and compositions containing endothelin receptor antagonists for emergency contraception.... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090203605 - Methods for treating a condition characterized by dysfunction in protein homeostasis: Methods are provided for treating conditions characterized by dysfunction in protein homeostasis in a patient in need thereof. A method for treating a condition characterized by dysfunction in protein homeostasis in a patient in need thereof is provided which comprises administering to the patient a proteostasis regulator in an amount... Agent: Fenwick & West LLP

20090203610 - Methods of treating obesity or diabetes using nt-4/5: The invention concerns methods for treating obesity, non-insulin dependent diabetes mellitus, metabolic syndrome, and other related diseases by administering an NT-4/5 polypeptide. The invention also concerns compositions and kits comprising an NT-4/5 polypeptide.... Agent: Pfizer Inc

20090203597 - Methods to restore glycemic control: Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20090203599 - N-terminal modified peg-trail, method for preparing and uses thereof: Disclosed herein are an N-terminal modified PEG-TRAIL conjugate and a preparation method and use thereof. The PEG-TAIL conjugate has pharmaceutical activity identical or similar to that of native TRAIL (TNF-related apoptosis-inducing ligand) with extended in vivo half-life and enhanced stability. Compared to native TRAIL, the PEG-TAIL conjugate exhibits high solubility... Agent: Cheryl H Agris Phd

20090203595 - Neuregulin variants and methods of screening and using thereof: The present invention provides polypeptide variants of neuregulin-1β (NRG-1β) that have enhanced or decreased binding affinity to ErbB3 and/or ErbB4. The invention also provides methods of screening and producing polypeptide variants of NRG-1β and methods of using polypeptide variants of NRG-1β for treating diseases.... Agent: Jones Day

20090203608 - Novel proteins and use thereof: The present invention provides a novel secretory/membrane protein associated with adipocyte differentiation and/or metabolism function, specifically, an adipocyte-derived secretory/membrane protein containing amino acid sequence which is the same or substantially the same as an amino acid sequence represented by SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090203588 - Outcome prediction and risk classification in childhood leukemia: Genes and gene expression profiles useful for predicting outcome, risk classification, cytogenetics and/or etiology in pediatric acute lymphoblastic leukemia (ALL). OPAL1 is a novel gene associated with outcome and, along with other newly identified genes, represent a novel therapeutic targets.... Agent: Coleman Sudol Sapone, P.C.

20090203600 - Pharmaceutical composition for the prophylaxis and treatment of hiv infection and its use: Pharmaceutical compositions for the prophylaxis and treatment of HIV infection and its use are provided. Particularly, the present invention provides a pharmaceutical composition comprising anti-virus peptides, use of said composition for manufacturing a medicament for the prophylaxis and treatment of HIV infection, and method for preventing and treating HIV infection... Agent: Hiscock & Barclay, LLP

20090203596 - Phosphatase inhibitor protein-1 as a regulator of cardiac function: The present invention relates to novel nucleic acids which encode novel mutant forms of Inhibitor Protein-1 (1-1). In particular, the 1-1 mutant forms comprise altered phosphorylation sites of PKC-α. In addition, the present invention relates to methods of regulating cardiac contractility and function, and for treatment of cardio myopathy and... Agent: Edwards Angell Palmer & Dodge LLP

20090203604 - Soothing agent and food for treating fatigue: e

20090203613 - Systems and methods for preparing autologous fibrin glue: The invention provides a system for preparing an autologous solid-fibrin web suitable for regenerating tissue in a living organism. The system includes a sealed primary container containing a separation medium and a low-density high-viscosity liquid. The separation medium is capable of separating red blood cells from plasma when the container... Agent: Michael Best & Friedrich LLP

20090203606 - Systems for and methods of use of therapeutic nutrition for the management of age-associated and age-specific health conditions of the elderly: Nutritional compositions which provide for improved taste profiles for the elderly while simultaneously providing nutrition specific to assist in the management of nutritional deficiencies that lead to age specific and age associated health conditions in the elderly. There are also provided products using these compositions and incorporating packaging design, volume... Agent: Lewis, Rice & Fingersh, Lc Attn: BoxIPDept.

20090203614 - Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration: The present invention provides compositions and methods for treating age-related macular degeneration (AMD). More specifically, the methods of the invention target amyloid proteins and drusen that tend to accumulate in the eyes of those patients suffering from AMD. AMD is treated in the methods of the invention by providing agents... Agent: Alcon

20090203609 - Use of il-1 inhibitors for treating il-1 mediated diseases: The invention relates to methods for treating or preventing arthritis. The method comprises administering to patients in need thereof therapeutically effective amounts of an IL-1 inhibitor and methotrexate. In a preferred embodiment, the IL-1 inhibitor is human recombinant IL-1ra and the methotrexate is N-[4-[(2,4-diamino-6-pteridinyl)methylamino]benzoyl]-L-glutamic acid. The invention also relates to... Agent: Amgen Inc.

20090203612 - Xenorhabdus tc proteins and genes for pest control: The subject invention relates to novel Xenorhabdus toxin complex (TC) proteins and genes that encode these proteins. More specifically, the subject invention relates to TC genes and proteins obtainable from Xenorhabdus strain Xwi. The subject invention also provides an exochitinase obtainable from the Xwi strain. This exochitinase can be used... Agent: Baker & Daniels LLP- Dow Agrosciences

20090203617 - Chimeric peptides for the regulation of gtpases: Chimeric peptides or fusion proteins are disclosed that include a RhoGAP activity domain and at least one specificity domain that targets a specific Rho protein. The fusion proteins can be used to inhibit any GTPase activity within a cell. The fusion proteins are particularly advantageous for the treatment of cancer.... Agent: Knobbe Martens Olson & Bear LLP

20090203616 - Methods for treating pain and screening analgesic compounds: The present invention relates to the use of compounds that block the α9α10 subtype of the nicotinic acetylcholine receptor (nAChR) for treating pain, such as neuropathic pain and inflammatory pain, and inflammatory disorders, such as arthritis. The present invention also relates to screening compounds to identify analgesic agents that block... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090203615 - Use of activity dependent neurotrophic factor for enhancing learning and memory: pre-and post-natal administration: The present invention provides methods for improving performance (e.g., learning and/or memory) using ADNF polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.... Agent: Townsend And Townsend And Crew, LLP

20090203618 - Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification: The present invention refers to analog compounds of peptides having the amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4, including analgesic peptides derived from snakes of species such as Crotalus durissus terrificus; their uses in the treatment, diagnosis... Agent: Fish & Richardson PC

20090203619 - Artificial platelets: Therapeutic agents suitable for use as artificial platelets are described. The agents comprise a fibrinogen binding precursor bound to an insoluble carrier, wherein the fibrinogen binding precursor can be converted by a wound site specific agent, such as thrombin, to a fibrinogen binding component bound to the carrier. The fibrinogen... Agent: Seed Intellectual Property Law Group PLLC

20090203620 - Methods for attenuating release of inflammatory mediators and peptides useful therein: The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090203624 - Alpha-fetoprotein peptides: The invention relates to compounds that include peptides that inhibit estrogen receptor dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090203622 - Method of treating metastatic stage prostate cancer: The invention provides methods and dosing regimens for treating metastatic stage prostate cancer in a subject using degarelix, as well as related methods of using degarelix in a subject identified as having metastatic stage prostate cancer, and methods of using degarelix to prevent or delay the progression of locally advanced... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090203623 - Method of treating prostate cancer with gnrh antagonist: The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090203625 - Phage display selection of anti fungal peptides: A method for the identification of peptides having an affinity for the surface of fungi is provided as is a method for the identification of peptides capable of affecting the development of a fungus. Also provided are compositions containing peptides identified using the method of the present invention. In addition,... Agent: Senniger Powers LLP

20090203621 - Tripeptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1: The present invention relates to the use of a regulatory protein RS1 fragment or a nucleic acid molecule encoding said regulatory protein RS1 fragment for the preparation of a pharmaceutical composition for the amelioration, prevention and/or treatment of a metabolic disease or a secondary disorder caused by a (pathological) modification... Agent: Foley And Lardner LLP Suite 500

20090203626 - Pediatric amino acid solution for parenteral nutrition: The present invention relates to an amino acid solution for the parenteral nutrition of pediatric patients. The amino acid solution provides for an increased concentration of glutamine, tyrosine, cysteine and taurine, while the concentrations of phenylalanine and methionine is small. Glutamine and tyrosine are provided in the form of oligopeptides.... Agent: The Nath Law Group

20090203627 - Specific binding sites in collagen for integrins and use thereof: The present invention identified a high affinity binding sequence in collagen type III for the collagen-binding integrin I domains. Provided herein are the methods used to characterize the sequence, the peptides comprising this novel sequence and the use of the peptides in enabling cell adhesion. Also provided herein are methods... Agent: Benjamin Aaron Adler Adler & Associates

20090203628 - Composition, method and kit for treating skin disorders and improving skin condition: The present invention provides a composition, method and kit for treating skin disorders and improving skin condition. The composition, method and kit is particularly suited for treating acne vulgaris, seborrhea, rosacea, hirsutism, psoriasis, oily skin, dry skin, discoloration, post inflammatory hyper pigmentation, sun spots, and wrinkles.... Agent: Wilson Sonsini Goodrich & Rosati

20090203629 - Inhibitors of cathepsin b: The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway... Agent: Townsend And Townsend And Crew, LLP

20090203631 - Peptide deformylase inhibitors as novel antibiotics: A macrocyclic peptide deformylase (PDF) inhibitor comprising a peptide or peptide mimetic having three residues, P1′, P2′, and P3′, wherein P2′ connects P1′ and P3′, wherein P1′ and P3′ each have a side chain, and wherein the side chains on P1′ and P3′ are crosslinked to form the macrocyclic PDF... Agent: Calfee Halter & Griswold, LLP

20090203630 - Process for preparing atazanavir bisulfate and novel forms: m

20090203632 - Compositions and methods for treating contracture: A method for treating contracture is provided that includes administering to a patient in need thereof a composition that includes a therapeutic agent effective in treating contracture. Compositions, devices, and kits for use in treating contracture are also described.... Agent: Seed Intellectual Property Law Group PLLC

20090203633 - Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof: while the other represents an optionally substituted C1-6 alkyl group etc.; R2 represents H, a halogen atom, OH, an optionally substituted C1-6 alkyl group etc.; X represents a single bond, O or S; Y represents an optionally substituted C1-6 alkylene group etc.; Z represents —RB, —CORC etc. in which RB... Agent: Sughrue Mion, PLLC

20090203634 - Compositions and uses of amooranin compounds: Amooranin (AMR) has been found to cause tumor cell death through G2/M cell cycle arrest, caspase activation, and apoptosis. Furthermore, it has been demonstrated that AMR is a substrate for P-glycoprotein. Based on these activities, AMR compounds, including AMR analogs, can be used in the treatment of a number of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090203635 - Hxaaa01 polynucleotides: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20090203767 - Inhibition stat-1: The present invention relates to inhibitors of the transcription factor STAT-1, their use as therapeutic means as well as their use for the prevention or therapy of cardio-vascular complications like restenosis after percutaneous angioplasty or stenosis of venous bypasses, the graft versus host reaction, the ischemia/refusion-related damage in the context... Agent: Fulbright & Jaworski L.L.P.

20090203765 - Modulation of eif4e-bp2 expression: Compounds, compositions and methods are provided for modulating the expression of eIF4E-BP2. The compositions comprise oligonucleotides, targeted to nucleic acid encoding eIF4E-BP2. Methods of using these compounds for modulation of eIF4E-BP2 expression and for diagnosis and treatment of diseases and conditions associated with expression of eIF4E-BP2 are provided.... Agent: Mcdermott Will & Emery

20090203766 - Vwf aptamer formulations and methods for use: The invention relates to the formulation, dosing, administration and use of an aptamer antagonist therapeutic that binds to von Willebrand Factor.... Agent: Mintz, Levin, Cohn, Ferris, Glovskyand Popeo, P.C.

20090203769 - Modulation of the integrin-linked kinase signaling pathway provides beneficial human cardiac hypertrophy and post myocardial infarction remodeling: Modulation of the integrin-linked kinase (ILK) signaling pathway is used to enhance the remodeling process relevant to a wide range of cardiac diseases. More specifically, a process for mediating a broadly adaptive form of human cardiac hypertrophy and a protective process for post myocardial infarction (MI), both comprising illiciting an... Agent: Vedder Price, PC

20090203768 - Nucleic acid-containing complex: A nucleic acid-containing complex, containing a nucleic acid and a biodegradable polymer, especially a positively-charged water-insoluble biodegradable polymer, is disclosed. The complex has excellent properties of sustainedly releasing a desired nucleic acid, especially DNA, to a site in need of a treatment. Since the complex can be taken up to... Agent: Foley & Lardner LLP

20090203636 - Prevention and treatment of cancer and other diseases: Nucleoside chemical compounds, which interact with specific structures of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) are disclosed. The compounds interfere with the activities of telomerase and reverse transcriptase, and are useful as antivirals, antibacterials and anticancer agents. Methods of treating or preventing cancers in patients involving administration of a... Agent: Nanda P B A Kumar Reed Smith

20090203637 - Novel cytostatic 7-deazapurine nucleosides: c

20090203638 - Pharmaceutical compositions and methods for metabolic modulation: Pharmaceutical compositions include compounds with cytokinin activity to modulate glucose and/or lipid metabolism in a mammal. Especially preferred compounds include those comprising a purine scaffold, and it is further preferred that contemplated compositions are employed to prevent and/or treat various diseases, including pre-diabetes, insulin resistance, type-2 diabetes, Syndrome X, and... Agent: Fish & Associates, PC Robert D. Fish

20090203640 - Crystalline forms of gemcitabine amide prodrug, compositions and use thereof: The present invention relates to novel crystal forms of an amide prodrug of gemcitabine, compositions thereof and methods for using.... Agent: Eli Lilly & Company

20090203639 - Methylation markers for diagnoses and treatment of cancers: Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the... Agent: Banner & Witcoff, Ltd.

20090203641 - Antibiotic compositions and related screening methods: Moenomycin inhibits bacterial growth by clocking the transglycosylase activity of class A penicillin-binding proteins (PBPs), which are key enzymes in bacterial cell wall synthesis. The binding affinities of moenomycin A with various truncated PBPs were compared showing that the transmembrane domain is important for moenomycin binding. Full-length class-A PBPs from... Agent: Greenberg Traurig LLP (la)

20090203643 - Method and composition for avoiding or mitigating the formation of preservative residues on the surface of wood treated with micronized copper-containing compositions: Disclosed is a wood preservative composition comprising micronized copper and copper-amine complex, wherein the copper component of the copper amine complex is from about 5% to about 50% by weight, based upon the total weight of copper in the composition. The copper amine complex serves to avoid wood surface “chalking”... Agent: Wiggin And Dana LLP Attention: Patent Docketing

20090203642 - Spray-dried chitin nanofibrils, method for production and uses thereof: The invention relates to a novel method for production of nanofibrillar chitin, sustainable from an industrial manufacturing standpoint and suitable for producing chitin nanofibrils having improved properties and free from less crystalline components. The invention also relates to novel chitin nanofibrils obtained with said method and characterized by an increased... Agent: Nixon & Vanderhye, PC

20090203645 - Broad spectrum disinfecting and sterilizing composition: The present invention relates to antimicrobial compositions including an aromatic dialdehyde and a quaternary ammonium compound wherein the aromatic dialdehyde is orthophthalaldehyde, isophthalaldehyde, terephthalaldehyde, or combinations thereof, and the ratio of aromatic dialdehyde to quaternary ammonium compound is from about 10:1 to about 1:5. The invention also relates to methods... Agent: Hoffmann & Baron, LLP

20090203644 - Compositions for treating and/or preventing diseases characterized by the presence of metal ions: The present invention generally relates to the treatment and/or prevention of Alzheimer's disease, other neurodegenerative diseases, and/or diseases characterized by the presence of certain metal ions, by using certain compositions including silicon-amino compounds. In some cases, a silicon-amino compound of the invention may be bidentate, tridentate, or otherwise polydentate, and... Agent: Wolf Greenfield & Sacks, P.C.

20090203646 - Use of sodium narcistatin for reducing internal adhesions and fibrosis: The present invention concerns a method for reducing or preventing development of adhesions, fibrosis or scar tissue within serous body cavities by using sodium narcistatin.... Agent: Jennings, Strouss & Salmon, P.L.C

20090203647 - 5-fluoro pyrimidine derivatives: This present disclosure is related to the field of 5-fluoro pyrimidines and their derivatives and to the use of these compounds as fungicides.... Agent: Dow Agrosciences LLC

20090203648 - Modified phosphocalcic compound, injectable composition containing same: A phosphocalcic compound modified by a gem-bisphosphonic acid or one of its salts, a method for preparing same, as well as its use for preparing an injectable composition. The modified phosphocalcic compound is obtained by adding a gem-bisphosphonic acid or one of its alkali metal or alkaline earth salts to... Agent: Buchanan, Ingersoll & Rooney PC

20090203649 - Dermatological anti-wrinkle agent: p

20090203650 - Use of phytate as agent inhibiting dissolution of crystals of calcium salts for the prevention of osteoporosis: The present invention relates to the use of myo-inositol hexaphosphate or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention or treatment of a disease associated with the dissolution of crystals of calcium salts, in particular osteoporosis. These compounds may be utilized in the manufacture... Agent: Darby & Darby P.C.

20090203651 - Use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and metabolic syndrome: e

20090203652 - Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases: where Ar is an aromatic ring and Ra, Rb, are as defined in the description, are useful in therapy as drugs for the treatment of diseases mediated by infiltrations of neutrophils induced by IL-8, such as psoriasis, rheumatoid arthritis, ulcerative cholitis and for the treatment of damages caused by ischemia... Agent: Birch, Stewart, Kolasch & Birch, LLP

20090203653 - Compositions and methods using apocynin compounds and nitric oxide donors: The invention describes novel compositions comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The invention also provides novel kits comprising at least one apocynin compound or a pharmaceutically acceptable salt thereof, and... Agent: Wilmerhale/nitromed

20090203654 - Cosmetic and pharmaceutical compositions: e

20090203655 - Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation: This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical... Agent: Hunton & Williams LLP Intellectual Property Department

20090203656 - Method for the reduction of dangerous blood sugar levels: The present invention relates to a method and procedure for reducing immediate serum glucose levels without resort to drugs. Specifically, the invention discloses a regular regimen comprising modest exercise, daily nutritional supplements and a series of specific, time sensitive steps, which, when followed will optimize the effects of the invention.... Agent: Edward P. Black

20090203657 - Dual pharmacophores - pde4-muscarinic antagonistics: e

20090203659 - Method of enhancing hair growth: wherein the dashed bonds represent a single or double bond which can be in the cis or trans configuration, A, B, Z, X, R1 and R2 are as defined in the specification. Such compositions are used in treating the skin or scalp of a human or non-human animal. Bimatoprost is... Agent: Allergan, Inc.

20090203658 - Neuroactive steroid compositions and methods of use therefor: Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090203660 - Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in... Agent: Allergan, Inc.

20090203661 - Betulinic acid, derivatives and analogs thereof and uses therefor: Provided herein provided herein are novel analogs and derivatives of betulinic acid. Also provided is a method for inhibiting an activity of one or more specificity protein (Sp) transcription factors cells associated with a neoplastic disease using betulinic acid, betulinic acid analog(s) and/or derivative(s) effective to decrease expression of a... Agent: Benjamin Aaron Adler Adler & Associates

20090203662 - Novel derivatives of cholest-4-en-3-one oxime, pharmaceutical compositions containing them and preparation method: or one of its esters and/or of its addition salts with pharmaceutically acceptable acids, particularly as a cytoprotective drug, preferentially a cardioprotective and/or neuroprotective drug, the compounds of formula I wherein R is R2, R3, R4, R5 or R6 as novel compounds as well as their preparation method and use.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090203663 - Chemical compounds: The present invention relates to compounds that inhibit a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm blooded animals such as humans of diseases... Agent: Astrazeneca R&d Boston

20090203664 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6- diazabicyclo[3.2.0]heptane: The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.... Agent: Paul D. Yasger Abbott Laboratories

20090203665 - Heterocyclic-substituted phenyl methanones: e

20090203666 - Compounds and compositions as hedgehog pathway modulators: The invention provides a method for modulating the activity of the hedgehog signaling pathway. In particular, the invention provides a method for inhibiting aberrant growth states resulting from phenotypes such as Ptc loss-of-function, hedgehog gain-of-function, smoothened gain-of-function or Gli gain-of-function, comprising contacting a cell with a sufficient amount of a... Agent: Genomics Institute Of The Novartis Research Foundation

20090203667 - Pentadienamide derivatives: e

20090203668 - Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors:

20090203670 - Combination antidepressants wafer: A sheet-like pharmaceutical preparation (dosage form) that quickly disintegrates on contact with moisture, based on hydrophilic polymers for the release of at least one active agent. The dosage form contains an active agent combination for treating depression, and at least one active agent selected from the antidepressant group of drugs.... Agent: D. Peter Hochberg Co. L.p.a.

20090203669 - Compositions and methods for the treatment of addiction and other neuropsychiatric disorders: The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including addiction (e.g., to a substance or to an activity) as well as to alleviate some of the symptoms experienced... Agent: Fish & Richardson PC

20090203671 - Method of treating cancer: Methods of treating cancer in patients comprising administering thereto aurora kinase inhibitors and TRAIL (tumor necrosis factor (TNF)-related apoptosis inducing ligand) inhibitors is disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20090203672 - Substituted sulfonamide compounds: t

20090203673 - 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments: The present invention encompasses compounds of general Formula (I) wherein X and R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090203674 - Pyrimidine compound and pests controlling composition containing the same: wherein R1 represents a hydrogen atom, halogen atom or C1-C4 alkyl; R2 represents C3-C7 alkynyloxy; R3 represents a hydrogen atom, halogen atom or C1-C3 alkyl; X represents C4 polymethylene, in which a CH2—CH2 may be replaced with a CH═CH, optionally substituted with at least one substituent selected from the group... Agent: Sughrue Mion, PLLC

20090203675 - Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses: Compounds, methods and pharmaceutical compositions for treating viral infections, by administering certain novel semicarbazides, sulfonyl carbazides, ureas and related compounds in therapeutically effective amounts are disclosed. Methods for preparing the compounds and methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20090203677 - Dual pharmacophores - pde4-muscarinic antagonistics: m

20090203676 - G-protein coupled receptor agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20090203678 - Pharmaceutical compositions for the treatment of protozoan parasitic diseases: The present invention relates to the use of a Rho/ROCK/PI3K/Akt pathway modulator for the manufacture of a medicament intended for the prevention or the treatment of pathologies associated with an infection by a protozoan parasite.... Agent: Young & Thompson

20090203679 - Galenical formulations of organic compounds: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of HCTZ and a hydrophilic filler selected from the group a carbohydrate or combinations thereof, e.g. sugars, sugar alcohols and starches or combinations... Agent: Novartis Corporate Intellectual Property

20090203680 - In vivo studies of crystalline forms of meloxicam: The invention is directed to novel crystalline forms of meloxicam. These novel crystalline forms of meloxicam have improved bioavailability, an enhanced rate of dissolution and shorter time to Cmax in blood, as compared to pure meloxicam.... Agent: Rakoczy Molino Mazzochi Siwik LLP

20090203681 - Novel n-(2-amino-phenyl)-amide derivatives: and pharmaceutically acceptable salts thereof, processes for the manufacture of these novel compounds and medicaments containing such compounds. The compounds of the present invention show anti-proliferative and differentiation-inducing activity, which results in inhibition of tumor cell proliferation, induction of apoptosis and inhibition of invasion. The invention also covers the use... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090203682 - Rapamycin analogues and the uses thereof in the treatment of neurological disorders: Method of treatment of neurological disorders or complications due to stroke or head injury through the administration of a pharmaceutical composition including a pharmaceutically acceptable excipient or carrier and a compound of formula I are provided:... Agent: Wyeth Patent Law Group

20090203683 - Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them: wherein Ra, Rb, Rc, A, B, C, D, and X are as defined herein, or a tautomer, stereoisomer, or salt thereof, particularly a physiologically acceptable salt thereof. In addition, pharmaceutical compositions comprising an effective amount of a compound of formula (I), methods for the treatment or prophylaxis of benign or... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090203684 - Tyrosine kinase inhibitors: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine derivatives of formula (I) that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat... Agent: Merck And Co., Inc

20090203686 - Aminoalkyl-amidomethyl-substituted 2-(4-sulphonylamino)- 3-hydroxy-3,4-dihydro-2h-chroman-6-yl derivatives: e

20090203685 - Anti-proliferative compounds from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and uses thereof: The present invention is directed to molecules deriving from a 3-aryl-coumarine or 3-aryl-quinolin-2-one and having potent anti-proliferative and/or cytotoxic activity, especially against tumoral cells. The present invention also concerns the uses of these molecules in therapeutic application, for the treatment of different cancers. The invention also discloses the use of... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090203689 - Abca-1 elevating compounds and methods: useful for treating various disease states, in particular, insulin resistance, diabetes, dyslipidemia, coronary artery disease, and inflammation. The compounds of the present invention elevate cellular expression of the ABCA-1 gene as well as increasing the level of ABCA-1 protein, which may result in an increase in HDL levels in the... Agent: Cv Therapeutics, Inc.

20090203687 - Fused ring heterocycle kinase modulators: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.... Agent: Wilson Sonsini Goodrich & Rosati

20090203688 - Heterocyclic compounds: e

20090203690 - 5-substituted indazoles as kinase inhibitors: wherein A, R1, R2, R3 and m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4,... Agent: Paul D. Yasger Abbott Laboratories

20090203691 - Novel 1h-indazole compounds: Wherein R1 is a C6-C14 aromatic cyclic hydrocarbon group etc.; R2, R4 and R5 each independently represent a hydrogen atom, a halogen atom, a cyano group etc.; L is a single bond, or a C1-C6 alkylene group etc.; X is a single bond, or a group represented by —CO—NH— or... Agent: Birch Stewart Kolasch & Birch

20090203692 - Novel chemical compounds: This invention relates to newly identified compounds for inhibiting hYAK3 proteins and methods for treating diseases associated with hYAK3 activity.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090203693 - Therapeutic agent for liver fibrosis: The present invention provides a therapeutic agent for hepatic fibrosis and a method for treatment of hepatic fibrosis. 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analogue thereof can prevent the fibrillation in the liver, and therefore can be used as a therapeutic agent for hepatic fibrosis or in the method for treatment of hepatic... Agent: Darby & Darby P.C.

20090203694 - Inhibitors of undecaprenyl pyrophosphate synthase: The present invention relates to compounds that are selective and/or potent inhibitors of UPPS. In addition to compounds which inhibit UPPS, the invention also provides pharmaceutical compositions comprising these compounds and methods of using these compounds for treating bacterial disease, such as bacterial infection.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090203696 - Aryl- and heteroaryl-ethyl-acylguanidine derivatives, their preparation and their application in therapeutics: wherein A, Q, X, Y, Z, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10 and R11 are as defined herein. The disclosure also relates to pharmaceutical compositions containing a compound of formula (I), to processes for preparing the compounds of formula (I), and to methods of using the... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090203695 - Compounds iv: e

20090203697 - Heterocyclic type cinnamide derivative: (In the formula, Ar1 represents a triazolyl group or the like which may be substituted with a C1-6 alkyl group or the like; Ar2 represents a phenyl group or the like which may be substituted with a C1-6 alkoxy group or the like; X1 represents —CR3═CR4— (wherein R3 and R4... Agent: Birch Stewart Kolasch & Birch

20090203698 - Compounds for enzyme inhibition: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of... Agent: Ropes & Gray LLP

20090203699 - Aminomethylpyridine derivatives, method for preparing same and therapeutic use thereof: The present invention pertains to aminomethylpyridine derivatives, to their preparation and to their therapeutic application.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090203700 - Azolylmethyloxiranes, their use for controlling phytopathogenic fungi, and compositions comprising them: e

20090203701 - Prophylactic and/or therapeutic agent for rheumatoid arthritis:

20090203702 - Inhibitors of p38: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions... Agent: Ropes & Gray LLP

20090203704 - Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic device using quinoxaline derivative: An object is to provide a novel quinoxaline derivative. Another object is to provide a light-emitting element with low driving voltage. Still another object is to provide a light-emitting element with low power consumption. Yet another object is to provide a light-emitting device and an electronic device each having low... Agent: Cook Alex Ltd

20090203703 - Thienopyrimidine derivatives: or salts thereof, which exhibit an inhibitory effect on PDE9, and are therefore useful for prevention or treatment of overactive bladder syndrome, pollakiuria, urinary incontinence, dysuria associated with prostatic hyperplasia, urolithiasis, Alzheimer's disease, chronic obstructive pulmonary disease, myocardial infarction, thrombosis, diabetes and the like.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090203705 - Spiro compounds as npy y5 receptor antagonists:

20090203706 - Lysine-based polymeric linkers: The present invention provides polymeric linkers containing branching moieties. Methods of making the polymeric linkers and methods of making conjugates using the same are also disclosed.... Agent: Lucas & Mercanti, LLP

20090203707 - Methods for treating pain: This invention relates to methods for treating a patient suffering from neuropathic or nociceptive pain which may be mechanical, visceral, and/or inflammatory in nature, comprising administering a therapeutically effective amount of Ranolazine to a patient in need thereof.... Agent: Cv Therapeutics, Inc.

20090203708 - Novel substituted-1-h-quinazoline-2,4-dione derivatives, preparation method thereof and pharmaceutical composition containing the same: Disclosed herein are novel substituted-1H-quinazoline-2,4-dione derivatives, a preparation method thereof, and a pharmaceutical composition containing the same. The novel substituted-1H-quinazoline-2,4-dione derivatives are excellent in binding affinity and selectivity for 5-HT6 receptors over other receptors, inhibit serotonin(5-HT)-stimulated cAMP accumulation, and disrupt apomorphine(2 mg/kg, i.p.)-induced hyperactivity in rats. Thanks to these effects,... Agent: Lucas & Mercanti, LLP

20090203709 - Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor: A pharmaceutical dosage form comprises a solid dispersion product of at least one tyrosine kinase inhibitor, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer.... Agent: Paul D. Yasger Abbott Laboratories

20090203710 - Novel piperidine derivative: Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep... Agent: Merck And Co., Inc

20090203711 - Inhibitors of p38 map kinase: wherein R1 is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxylesterase enzymes to a carboxylic acid group; R4 is hydrogen; or optionally substituted C1-C6 alkyl, C3-C7cycloalkyl, aryl or heteroaryl or —(C═O)R3, —(C═O)OR3, or —(C═O)NR3 wherein R3 is hydrogen or optionally... Agent: Banner & Witcoff, Ltd.

20090203712 - Urea derivative: e

20090203713 - Hedgehog pathway antagonists to treat disease: Compounds, compositions, kits and methods for modulating hedgehog pathway activity, and treating conditions related to abnormal or aberrant hedgehog pathway activity, are disclosed.... Agent: Edwards Angell Palmer & Dodge LLP

20090203714 - Furo[3,2-b]pyrrol-3-one derivatives and their use as cysteinyl proteinase inhibitors: The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as... Agent: Edwards Angell Palmer & Dodge LLP

20090203715 - Novel 2-hetarylthiazole-4-carboxamide derivatives, their preparation and use as pharmaceuticals: The present invention relates to 2-hetarylthiazole-4-carboxamide derivatives of the formula (I), the use thereof as medicament for the treatment of various disorders, and processes for the preparation thereof... Agent: Millen, White, Zelano & Branigan, P.C.

20090203716 - Pyrimidine low molecular weight ligands for modulating hormone receptors: e

20090203717 - Fused heterocyclic compound: wherein W is C(R1) or N, each A is an optionally substituted aryl group or a heteroaryl group, X1 is —NR3—Y1—, —O—, —S—, —SO—, —SO2— or —CHR3— wherein R3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R3 is optionally bonded to A to form an... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090203718 - Cancer treatment method: The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and an IGF-1R inhibitor to a mammal suffering from a cancer.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090203719 - Enhancing treatment of mdr cancer with adenosine a3 antagonists: The present invention discloses the use of high affinity adenosine A3 receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A3 receptors and cancers expressing P-glycoprotein or MRP. In preferred embodiments, adenosine A3 receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or... Agent: King Pharmaceuticals, Inc.

20090203720 - Methods for inhibiting cell growth: Cell growth is inhibited and/or cell death is induced in a cell by administering an RXR agonist and an inhibitor of casein kinase 1α. A cell or a tissue can be screened for enhanced susceptibility to cell death or interference with cell growth. Conditions characterized by uncontrolled cell growth or... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090203721 - Use of siramesine in the treatment of cancer: The present invention relates to the treatment of cancer. In particular, the invention provides pharmaceutical compositions comprising siramesine for the treatment of cancer. The invention further provides a method of treatment comprising administering siramesine to a patient suffering from cancer.... Agent: Lundbeck Research Usa, Inc. Attention: Stephen G. Kalinchak, Legal

20090203723 - 6,7-unsaturated-7-carbamoyl substituted morphinan derivative: e

20090203722 - Novel compositions and methods for enhancing potency or reducing adverse side effects of opiold agonists: The invention generally relates to novel compositions and methods with an opioid agonist and an opioid antagonist to differentially dose a human subject so as to either enhance analgesic potency without attenuating an adverse side effect of the agonist, or alternatively maintain the analgesic potency of the agonist while attenuating... Agent: Bell, Boyd & Lloyd, LLP

20090203724 - Solid and crystalline dutasteride and processes for preparation thereof: The solid state chemistry of 17β-N-[2,5-bis(trifluoromethyl)phenyl]carbamoyl-4-aza-5-α-androst-1-en-3-one of which the international nonproprietary name is Dutasteride (the active ingredient in products marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) and its process for preparing. The synthetic process comprises formation of the mixed anhydride, its subsequent reaction with 2,5-bis(trifluoromethyl)phenylamine in the presence... Agent: Patent Central LLC Stephan A. Pendorf

20090203725 - Androgen receptor modulator compounds and methods: Provided herein are compounds that bind to androgen receptors and/or modulate activity of androgen receptors and/or modulate the amount of androgen receptors; and to methods for making and using such compounds. Also provided are compositions containing such compounds and methods for making and using such compositions.... Agent: K&l Gates LLP

20090203727 - Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion: The present invention relates to a pharmaceutical composition including loratadine or a pharmaceutically acceptable form thereof, and phenylephrine or a pharmaceutically acceptable form thereof, for treating upper respiratory/mucosal congestion, optionally by administering to a patient four times a day.... Agent: HallihanIPPartners, LLC

20090203726 - Substituted tetrahydroquinolines as antibacterial agents: e

20090203728 - Naphthalamide derivatives having antiproliferative activity: The invention relates to compounds for use in medicine. The compounds are of general formula (I) as disclosed herein and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, wherein X, X′ and X″ are independently O or S; Z is N or P; R3 is optional and... Agent: Wilmerhale/new York

20090203730 - Bicyclic ppat inhibitors as antibacterial agents: Disclosed are compounds of Formula I, pharmaceutical compositions comprising Formula I and methods of treating bacterial infections. The disclosed compounds are inhibitors of PPAT (phosphopantetheine adenyl transferase), and are useful in the treatment and prevention of diseases caused by bacteria, particularly bacteria dependent on PPAT, for example, species such Escherichia... Agent: Mccarter & English, LLP Boston

20090203729 - Process for producing high-purity prasugrel and acid addition salt thereof: The present invention is directed to providing prasugrel hydrochloride or the like with a reduced content of OXTP. A method for producing prasugrel hydrochloride with a reduced content of OXTP, comprising dissolving free prasugrel containing OXTP in an inert solvent and adding hydrochloric acid optionally dropwise to the solution for... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090203731 - Treatment of depression and other affective disorders: The present invention relates to use of gaboxadol for preparing a pharmaceutical composition for treating depression. Moreover, it relates to the use of gaboxadol for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor, or any other compound which causes an elevation in... Agent: Darby & Darby P.C.

20090203732 - Thiazolones for use as p13 kinase inhibitors: Invented is a method of inhibiting the activity/function of PI3 kinases using substituted thiazolones. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection,... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090203733 - Pharmaceutical composition: This invention relates to a pharmaceutical composition for mammals and, more particularly, to a pharmaceutical composition which enhances the action of an anaesthetic used in both human and veterinary applications, which, at least partly, reduces the risk of respiratory depression and enhances pulmonary perfusion. The pharmaceutical composition is characterised in... Agent: Darby & Darby P.C.

20090203734 - F1f0-atpase inhibitors and related methods: The present invention relates to inhibitors of mitochondrial F1F0-ATPase, methods for their discovery, and their therapeutic use. In particular, the present invention provides the compound PK11195 and structurally and functionally related compounds as F1F0-ATPase inhibitors, and methods of using such inhibitors as therapeutic agents to treat a number of conditions.... Agent: Casimir Jones, S.c.

20090203735 - Treatments for neuropathy: Small fiber neuropathy is treated or prevented by topically administering to a subject in need thereof topically active quinoline compounds or pharmaceutically acceptable salts thereof under conditions effective to treat or prevent neuropathy in the subject. Glial cell-derived neurotrophic factor (GDNF) receptors are modulated with the subject active quinoline compounds,... Agent: Richard Aron Osman

20090203736 - Piperidine sulphonamide derivatives: wherein Ar1, Ar2, R1, R2, m and n are as defined in the description and claims, or pharmaceutically suitable acid addition salts thereof. The compounds of formula I are orexin receptor antagonists and the related compounds can be useful in the treatment of sleep apnea, narcolepsy, insomnia, parasomnia, jet lag... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090203737 - Pyrrole derivatives as positive allosteric modulators of metabotropic receptors: The present invention relates to new compounds which are Pyrrole derivatives of formula (I) wherein A, B, P, Q5W, R1 and R2 are defined in the description. Invention compounds are useful in the prevention or treatment of central or peripheral nervous system disorders as well as other disorders modulated by... Agent: Edwards Angell Palmer & Dodge LLP

20090203738 - Pharmaceutical composition for treating bulimia and depression arising from bulimia: Provided is a pharmaceutical composition for the treatment of bulimia in which a cholinesterase inhibitor is combined with at least one member selected from the group consisting of sibutramine, a pharmacologically acceptable salt thereof, an active metabolite thereof, a prodrug thereof and a solvate thereof. The pharmaceutical composition is useful... Agent: Venable LLP

20090203739 - Anti-inflammatory agents: The invention provides compounds, pharmaceutical compositions and uses of compounds of general formula (I) or a pharmaceutically acceptable salt thereof, for the preparation of a medicament intended to treat an inflammatory disorder; wherein z X is 1, 2 or 4; X is —CO—Yk—(R1)n or SO2—Yk—(R1)n; k is 0 or 1;... Agent: Schwegman, Lundberg & Woessner, P.A.

20090203740 - 2-phenylpropionic acid derivatives and pharmaceutical compositions containing them: 4-(trifluoromethanesulfonyloxyphenyl)propionic acid derivatives and pharmaceutical composition containing such compounds are useful in inhibiting the chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2 membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. Notably, these... Agent: Birch Stewart Kolasch & Birch

20090203742 - Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors: wherein R1 is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from C1-6alkyl, hydroxy, amino, halogen, aminoC1-4alkyl and mono- or di(C1-4alkyl)amino; R2 is hydrogen or C1-6alkyl; L is a direct bond, —O—, C1-6alkanediyl-O— or —O—C1-6alkanediyl; R3 is phenylC1-4alkyl; R4 is C1-6alkyl; R5... Agent: Philip S. Johnson Johnson & Johnson

20090203741 - Crystals of benzoxadiazole derivative: Means for Resolution A solving means includes β-form crystal of 4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole, which shows an endothermic peak at 145 to 150° C. according to a differential scanning calorimeter analysis (DSC analysis) and shows X-ray powder diffraction peaks at 9.8, 11.1, 12.8, 13.3, 17.1, 20.2, 21.2 and 22.3 in 2θ(°), and the... Agent: Sughrue-265550

20090203743 - Small molecule entry inhibitors: N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(═O)—, —O—C(═O)—,... Agent: Philip S. Johnson Johnson & Johnson

20090203744 - Novel pyridine derivatives: The present invention relates to novel pyridine derivatives of the formula (I), their stereoisomers, and their pharmaceutically acceptable salts, and compositions. The present invention more particularly provides novel pyridine derivatives of the general formula (I).... Agent: Greenblum & Bernstein, P.L.C

20090203745 - Heterocyclic compounds for the inhibition of integrins and use thereof: The present invention relates to compounds of formula (I) wherein: A is a radical selected from the group comprising aromatic heterocyclic 5-membered ring systems; Ar is a radical selected from the group comprising optionally substituted 5- and 6-membered aromatic ring systems, whereby the ring system contains 0, 1, 2 or... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090203746 - Synergistic insecticidal composition containing chloronicotynyle and pyrethroids compounds: A synergistic insecticidal composition is formed containing a Chloronicotynyle compound and a Pyrethroids compound. The Chloronicotynyle compound is provided in an amount preferably ranging from 0.1 to 5.0% by weight of the synergistic insecticidal composition. The Pyrethroids compound is provided in an amount preferably ranging from 1 to 60% by... Agent: Jones, Tullar & Cooper, P.C.

20090203747 - Novel chemical compounds and the uses thereof as a medicine: s

20090203748 - Nicotinic acid compositions for treating hyperlipidemia and related methods therefor: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological... Agent: Paul D. Yasger Abbott Laboratories

20090203750 - 5-ht2c receptor agonists as anorectic agents: This invention relates to compounds which modulate receptors of the 5-HT2 family of receptors, and particularly to compounds which modulate 5-HT2C receptors. Compounds of the invention include agonists and selective agonists for the 5-HT2C receptor Compounds of the invention include selective agonists for the 5-HT2C receptor which exhibit significantly less... Agent: Greenlee Winner And Sullivan P C

20090203749 - Agent for control of degranulation reaction and cytokine production: To provide an agent capable of controlling the degranulation reaction and/or cytokine production of mast cell and the like. The present invention provides an agent for controlling a degranulation reaction and an agent for controlling a cytokine production, comprising a substance capable of controlling an intracellular zinc ion concentration, particularly,... Agent: Leydig Voit & Mayer, Ltd

20090203751 - Novel 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators: The present invention is directed to novel 1,2,4-thiadiazol-2-ium derivatives useful as agonists or antagonists of the melanocortin receptor. More particularly, the compounds of the present invention are useful for the treatment of metabolic, CNS and dermatological disorders such as obesity, impaired oral glucose tolerance, elevated blood glucose levels, type II... Agent: Philip S. Johnson Johnson & Johnson

20090203752 - Compounds for nonsense suppression, and methods for their use: The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a... Agent: Hoffmann & Baron, LLP

20090203753 - 7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3h)-one-derivatives as beta2 adrenoreceptor agonists: The present invention provides compounds of formula (I) wherein e, R1, R2, R3, R4, R5, R4′, R5′, R6, R7, A, D, m and n are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.... Agent: Fish & Richardson P.C.

20090203754 - Anti-bacterial drug targeting of genome maintenance interfaces: Methods for the design and identification of novel antimicrobial compounds are provided, as well as antimicrobial compounds identified using these methods. Pharmaceutical compositions that include these antimicrobial compounds are provided as well. The antimicrobial compounds inhibit the binding of a prokaryotic single-stranded DNA binding protein to a polypeptide. In some... Agent: Warf/bhgl

20090203755 - Use of crf1 receptor antagonists for preparing a drug for treating metabolic syndrome and/or obesity and/or dyslipoproteinemia: t

20090203756 - Biocidal compositions:

20090203757 - Ethylene glycol esters as photoactive agents:

20090203758 - Alpha crystalline form of the arginine salt of perindopril, a process for its preparation and pharmceutical compositions containing it.:

20090203760 - Cyclic agonists and antagonists of c5a receptors and g protein-coupled receptors: The present invention relates to novel cyclic or constrained acyclic compounds which modulate the activity of G protein-coupled receptors and are useful in the treatment of conditions mediated by G protein-coupled receptors, for example, inflammatory conditions.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090203759 - Pharmaceutical formulation of nitrooxyderivatives of nsaids: e

20090203761 - Process for preparing (3-oxo-2,3-dihydro-1h-isoindol-1-yl) acetylguanidine derivatives:

20090203762 - Methods for the production of biliverdin: The present invention relates to compositions and methods for the production of biliverdin. In particular, the invention concerns methods for producing biliverdin in yeast, especially Candida albicans, and other microorganisms.... Agent: Berenato, White & Stavish, LLC

20090203763 - Substituted benzhydrylethers: Disclosed herein are substituted benzhydrylethers of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of their use thereof.... Agent: Global Patent Group - Apx

20090203764 - Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases: Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several... Agent: Morrison & Foerster LLP

20090203770 - Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins: The present invention provides agents and compositions for modulating the apoptotic state of a cell. The agents comprise derivatives of antimycins which bind to an anti-apoptotic Bcl-2 family member protein. Further, the agents preferentially induce apoptosis in cells that over-express anti-apoptotic Bcl-2 family member proteins and typically exhibit reduced binding... Agent: Townsend And Townsend And Crew, LLP

20090203771 - Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate: The present invention provides a novel method for producing a compound represented by formula (III) shown below, which comprises treating a compound represented by formula (I) shown below with a trivalent chromium compound and at least one kind of metal selected from the group consisting of manganese and zinc in... Agent: Clark & Elbing LLP / Eisai

20090203772 - Vaginal health products: The invention provides compositions and methods for increasing cell growth, stimulating cell turnover and promoting the secretion of mucus within the reproductive tract of a female mammal.... Agent: Dority & Manning, P.A.

20090203773 - Compounds for the treatment of non-autoimmune type 2 diabetes mellitus and/or syndrome x: The present invention relates to compounds of the formula (I); wherein R1 is H, CH3 or OCH3; R3=H, OH, CH3, OCH3, O-glucose or benzoyloxy; R4=H; R5=H or OH; R6=H or OCH3; R7=H, CH3, OCH3, cinnamoyloxy or (3,4,5-trimethoxy)-benzoyloxy; R8=H, OH, CH3 or OCH3; or R7 and R8 form together a group... Agent: Nixon & Vanderhye, PC

20090203774 - Substituted benzyl ester derivative and use thereof: e

20090203775 - Novel compound and a novel microorganism for producing the novel compound: The present invention relates to a novel compound represented as by formula (I). The present invention also provides a novel strain named as Alternaria alternata var. monosporus, which can produce the compound of formula (I). The inventive strain is cultured in the medium to produce and mass the inventive compound... Agent: Birch Stewart Kolasch & Birch

20090203776 - Methods of using menthol propyleneglycol-carbonate and analogs thereof for producing anti-inflammatory and anti-angiogenic effects: Menthol propyleneglycal-carbonate, analogs thereof and compositions containing such compounds are administered to mammals, preferably humans, to produce anti-inflammatory or anti-angiogenic effects.... Agent: Brooks Kushman P.C.

20090203777 - Organic compounds: The invention describes novel pharmaceutically acceptable salt forms of camostat, processes for lyophilisation, taste-masked formulations, nebulised formulations and the use of each of the fore-going in the treatment of respiratory diseases, particularly cystic fibrosis and chronic obstructive pulmonary disease (COPD).... Agent: Novartis Institutes For Biomedical Research, Inc.

20090203779 - Esters of long-chain alcohols and preparation thereof: Disclosed is a composition and methods of treating a skin condition. The ester includes an ester and a dermatologically acceptable carrier. The ester is represented by the general formula 1:... Agent: Brett L. Nelson Eastman Chemical Company

20090203778 - Fatty acid analogues, i.e. including dha derivatives for uses as a medicament: A compound of formula (I) wherein R1 and R2 are different and each is chosen from a methyl group and a hydrogen atom; wherein X is chosen from a carboxylic acid group, a carboxylate group, a carboxamide group; or any pharmaceutically acceptable salt, solvate, complex, or pro-drug of said compound.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090203780 - Use of a polyunsaturated fatty acid compound: A polyunsaturated fatty acid having 20 carbon atoms and four double bonds, or a derivative thereof, in an orally administrable form, can be used to treat or prevent obesity and/or for weight management. The polyunsaturated fatty acid may, for example, be used in the form of a food supplement, a... Agent: Morgan Lewis & Bockius LLP

20090203781 - N-n-acyloxypropyl lysine methyl ester-and n,n-bis(n-acyloxypropyl) lysine methyl ester-type compounds and use thereof as surface-active agents with an antimicrobial activity: The invention relates to novel compounds having an amphiphilic character (cationic, anionic, amphoteric and non-ionic), derivatives of n acyloxypropyl-type lysine amino acid according to general formula (I), which are intended to be used in the food, pharmaceutical and cosmetic industries as surface-active agents having a self-aggregating capacity and antimicrobial properties.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090203782 - Alpha 2 delta ligands for fibromyalgia and other disorders: R2 is straight or branched alkyl of from 4 to 8 carbon atoms, straight or branched alkenyl of from 2 to 8 carbon atoms, cycloalkyl of from 3 to 7 carbon atoms, alkoxy of from 1 to 6 carbon atoms, -alkylcycloalkyl, -alkylalkoxy, -alkyl OH, -alkylphenyl, -alkylphenoxy, or -substituted phenyl. The... Agent: Pfizer Inc. Patent Department

20090203783 - Therapeutic agent for acute cerebral infarct: An agent for treating acute cerebral infarction, comprising (2R)-2-propyloctanoic acid or a salt thereof, which is used for administration after a lapse of time of from about 5 hours to about 72 hours from the onset of the disease is useful for treating acute cerebral infarction, since it safely improves... Agent: Sughrue-265550

20090203785 - Method and process for producing youthful-appearing, small-pored, and smooth skin: A method and process for producing youthful appearing, small-pored, and smooth skin by pre-treating the skin topically with retinoic acid, applying carbon particles on the skin, removing the carbon particles by exploding them with laser light, and post-treating the skin topically with retinoic acid. When treating the face, removing the... Agent: Bush Intellectual Property Law Group, LLC

20090203784 - Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors: The present invention relates to methods and compositions for treating diseases. More specifically, the present invention relates to the administration of multiple drugs as part of a treatment of disease. Specific embodiments of the invention relate to a treatment regimen for neuroblastomas and other N-MYC, c-MYC, and L-MYC amplified and... Agent: Davis Wright Tremaine LLP - San Francisco

20090203788 - Method of enhancing reproductive function of mammals by feeding of conjugated linoleic acids: This invention provides methods for improving reproductive performance of lactating dairy cows and other mammals. The method in the case of cows comprises feeding to the cows, a composition comprising conjugated linoleic acids (CLAs), cis-9, trans-11 and trans-10, cis-12. When these CLAs are fed daily to dairy cows starting at... Agent: Hodgson Russ LLP The Guaranty Building

20090203786 - Methods and composition for improving cognitive function: Compositions and methods for enhancing cognitive function in animals are disclosed. The compositions and methods utilize long chain polyunsaturated fatty acids.... Agent: Wendell Ray Guffey Nestle Purina Petcare Global Resources

20090203787 - Very long chain polyunsaturated fatty acids, methods of production, and uses: The present invention relates to processes for production of Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs). The present invention also relates to compositions (e.g., nutritional supplements and food products) containing such VLC-PUFAs. In one embodiment, the present invention is directed to methods for biosynthesis and production of the VLC-PUFAs described... Agent: Dunlap Codding, P.C.

20090203789 - Fast dissolution amino acid composition: The present invention relates to oral dosage formulations for the rapid release of amino acids. A rapid release is achieved through the process of milling whereby the milled amino acids are more readily bioavailable.... Agent: Torys LLP

20090203790 - Gamma-l-pga producing microorganism, method of producing gamma-l-pga using the microorganism, crosslinked substance produced using the microorganism, and external dermal agent produced using the microorganism: There are provided a microorganism characterized by producing poly-γ-L-glutamate with a molecular weight of 1,300,000 or greater and uniform optical purity under liquid culture conditions, a method of screening for the microorganism, a method of producing poly-γ-L-glutamate having large molecular weight by using the microorganism, and poly-γ-L-glutamate having an average... Agent: Leydig Voit & Mayer, Ltd

20090203792 - Methods of treating non-painful bladder disorders using alpha2delta subunit calcium channel modulators: A method is provided for treatment of non-painful bladder disorders, particularly non-painful overactive bladder without loss of urine. The method comprises administration of an α2δ subunit calcium channel modulator, including gabapentin, pregabalin, GABA analogs, fused bicyclic or tricyclic amino acid analogs of gabapentin, amino acid compounds, and other compounds that... Agent: Alston & Bird LLP

20090203791 - Nateglinide-containing preparation: The present invention discloses, as a immediate-release preparation useful as an antidiabetic, a nateglinide-containing preparation comprising nateglinide as an active ingredient wherein the nateglinide is amorphous.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090203793 - Compounds for the treatment of metabolic disorders: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, hyper-lipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed as Formula (I).... Agent: Wellstat Management Company. LLC

20090203794 - Aqueous anaesthetic composition comprising propofol: The invention discloses an aqueous anaesthetic Propofol composition that is stable, autoclave sterilized, suitable for parental administration, having reduced incidence of pain upon injection. The composition comprises propofol, 2-hydroxypropyl-β-cyclodextrin and a local anaesthetic, Lignocaine.... Agent: Thorpe North & Western, LLP.

20090203795 - Polyquaternium-1 synthesis methods and associated formulations: A multipurpose solution for contact lens care, comprising: an aqueous liquid medium; a quaternary ammonium polymer having an average molecular weight as determined by the proton NMR method of at least 22 k, and methods for making.... Agent: Abbott Medical Optics, Inc.

20090203796 - Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen: The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk... Agent: Foley And Lardner LLP Suite 500

20090203797 - Antimycotic patch: e

20090203798 - Solid pharmaceutical compositions comprising a sip receptor agonist and a sugar alcohol: A solid pharmaceutical composition suitable for oral administration, comprising: (a) S 1 P receptor agonist; and (b) a sugar alcohol.... Agent: Novartis Corporate Intellectual Property

20090203799 - Novel compositions comprising carotenoids: A novel composition for delivering carotenoids (e.g. α- and β-carotene, lycopene) and/or other physiologically active ingredients to the colon of humans after ingestion and for producing liquid food compositions insusceptible to polyphenol-protein reactions can be obtained by encapsulating said active ingredients with pectin, in particular with low-methoxylated pectin.... Agent: Nixon & Vanderhye, PC

20090203800 - Cytostatic composition: A cytostatic composition comprising an effective amount of an aldehyde in a pharmacological salt solution is shown to be effective at inhibiting growth of a number of cancerous cell lines.... Agent: Donn K. Harms Patent & Trademark Law Center

20090203801 - Methods of inhibiting ethylene responses in plants using dicyclopropene compounds: Methods of applying dicyclopropene compounds and compositions thereof to block ethylene receptors in plants are disclosed. Methods include applying to the plant an effective ethylene response-inhibiting amount of a dicyclopropene compound or composition thereof. Dicyclopropene compounds, enantiomers, stereoisomers or salts thereof are also provided.... Agent: Myers Bigel Sibley & Sajovec

20090203802 - Powder composition, a dispersion of powder in oil, and a cosmetic comprising the same: and a powder and/or a coloring agent, a dispersion of powder in an oil in which the powder composition is dispersed, and cosmetics comprising the same, wherein each R1 is, independently, an organic group selected from the group consisting of C1-30 alkyl groups, aryl groups, aralkyl groups, fluorinated alkyl groups,... Agent: Birch Stewart Kolasch & Birch

20090203803 - N-acylated chitinous polymers and methods of use thereof: The invention pertains to N-acetylated, N, O-carboxyalkylchitosans and methods for using the chitosans to treat disorders, such as cancer, nervous system disorders, urinary tract disorders, and reproductive tract disorders.... Agent: Edwards Angell Palmer & Dodge LLP

  
08/06/2009 > patent applications in patent subcategories. inventions list

20090197794 - Methods of diagnosing and treating an inflammatory response: The present invention relates to the discovery that VEGF, PlGF, and sFlt-1 levels are increased in inflammatory response such as in sepsis, severe sepsis, or septic shock. Additionally, the invention provides methods of identifying treatments as well as providing treatments for such an inflammatory response, which include decreasing VEGF or... Agent: Clark & Elbing LLP

20090197795 - Preparation and use of aryl alkyl acid derivatives for the treatment of obesity: This invention relates to certain aryl alkyl acid compounds, compositions, and methods for treating or preventing obesity and related diseases.... Agent: Edwards Angell Palmer & Dodge LLP

20090197796 - Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors: Methods are provided for treating HPG axis-positive cancers, preventing or slowing proliferation of cells of HPG axis-positive cancer origin, preventing HPG axis-positive cancers in a patient at risk of contracting such cancers, preventing or inhibiting an upregulation of the cell cycle in HPG axis-positive cancer-derived cells in a patient, and... Agent: Covington & Burling, LLP Attn: Patent Docketing

20090197797 - Use of hyaluronic acid as a carrier molecule for different classes of therapeutic active agents: The present invention refers to a drug delivery system consisting of hyaluronic acid and a therapeutic active agent.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090197798 - Composition for treating cancer and use thereof: The present invention provides a cyclic peptide containing RRXR motif. The present invention also provides a composition comprising the said cyclic peptide and a pharmaceutical acceptable carrier. The present invention further provides a method for treating cancer.... Agent: Wpat, PC Intellectual Property Attorneys

20090197799 - Methods for preparing purified lipotides: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against... Agent: Lando & Anastasi, LLP

20090197806 - Adiponectin for treatment of various disorders: Methods for treating various disorders by orally administering adiponectin or a biologically active fragment thereof are described.... Agent: Occhiuti Rohlicek & Tsao, LLP

20090197802 - Analogues of glp-1: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.... Agent: Biomeasure, Incorporated

20090197809 - Antifungal methods: A system for reducing the incidence or severity of fungal infection of a plant, comprising a chemical fungicide component, which may be provided by foliar or root (soil or liquid nutrient) application, together with an antifungal plant defensin not in nature expressed in the plant being protected or expressed in... Agent: Greenlee Winner And Sullivan P C

20090197805 - Insulin receptor antagonists and related compositions, uses and methods: Provided are new peptidic insulin receptor antagonists (PIRAs) and related compounds and compositions. Also provided are new uses of PIRAs and methods of obtaining PIRAs.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090197800 - Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof: Methods for binding insulin receptors (and typically activating one or more function of an insulin receptor) by contacting insulin receptor-presenting cells, such as cells in a subject, with an effective amount of one or more insulin receptor binding peptides, where upregulation of one or more components of the insulin receptor-associated... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090197803 - Methods and compositions for modulating t helper (th) cell development and function: Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.... Agent: Fitzpatrick Cella Harper & Scinto

20090197804 - Methods and compositions for the prevention and treatment of kidney disease: Compositions for preventing or treating kidney disease comprising one or more food ingredients containing relatively low amounts of protein, sodium, and potassium, typically protein in amounts of from about 5% to about 40%, sodium in amounts of from about 0.01% to about 1%, and potassium in amounts of from about... Agent: Colgate-palmolive Company

20090197808 - Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease: The present invention relates generally to the use of recombinant human CC10 (rhCC10), also known as recombinant human uteroglobin, for use as a therapeutic in the treatment of Respiratory Distress Syndrome (RDS), Bronchopulmonary dysplasia (BPD), chronic lung disease and/or pulmonary fibrosis, Asthma and Chronic Obstructive Pulmonary Disease (COPD). More particularly,... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20090197801 - Neuritogenic peptides: The present invention relates to peptide compounds that are capable of stimulating neuronal differentiation, neurite outgrowth and survival of neural cells, and enhancing synaptic plasticity, learning and memory, methods of treating diseases and conditions of nervous system by administration of compositions comprising said compounds. The compounds and compositions of the... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090197807 - Sulphated hyaluronic acid for treating degenerative osteoarthritis: This invention relates to oral and intra-articular formulations based on sulphated hyaluronic acid which are effective in the treatment of degenerative osteoarthritis.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090197810 - Alpha conotoxin peptides with analgesic properties: in which Xaa1 is Gly or Asp; Xaa3 is Pro, Hyp or Glu; each of Xaa2 to Xaa8 and Xaa11 is independently any amino acid; Xaa9 is Pro, Hyp or Glu; Xaa10 is Asp, Glu or γ-carboxyGlu; Xaa11 is optionally absent; and the C-terminus is optionally amidated, with the proviso... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090197811 - Orally administered peptides to improve or prevent hepatic fibrosis: The present invention generally relates to liver disease. More specifically the invention provides compositions and methods, including D-4F, that are useful in treating or preventing hepatic fibrosis.... Agent: Hogan & Hartson L.L.P.

20090197813 - Methods for treating fsh related conditions with gnrh antagonists: Methods for treating FSH related conditions, such as prostatic intraepithelial neoplasia, pedophilia, infertility, or vaginal bleeding, with GnRH antagonists are disclosed. The methods of the invention generally feature administering to a subject a GnRH antagonist suitable for in vivo administration and able to reduce both plasma FSH and LH levels... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090197812 - Peptides for inhibiting transglutaminase: Disclosed herein are transglutaminase peptide inhibitors which have inhibitory activity against transglutaminase, and a pharmaceutical composition comprising one of them as an active ingredient. The inhibitors or the composition is useful in the prevention and treatment of various diseases caused by aberrant transglutaminase activation, including inflammatory diseases and cancers. Also,... Agent: Casimir Jones, S.c.

20090197815 - Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist: The present invention concerns a product containing Sandostatin® LAR® at 40 mg/28 days or pasireotide and either a dopamine-agonist, preferably cabergoline, or a growth hormone receptor antagonist, preferably pegvisomant, as a combined preparation for simultaneous, separate or sequential use in acromegalic therapy. In particular, this therapy is useful for treating... Agent: Novartis Corporate Intellectual Property

20090197814 - Method of inhibiting the emigration of cells from the intravascular compartment into tissues: A method of inhibiting the emigration of cells from the intravascular compartment into tissues (or through any membrane limiting any body compartment from another) by confronting the cells with an agonist specific for receptors involved with migration of said cells via a receptor thereby making the cell unresponsive to further... Agent: Jacobson Holman PLLC

20090197816 - Stabilizing alkylglycoside compositions and methods thereof: The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example amylin, a monoclonal antibody, insulin, Peptide T or analog thereof, gastrin, gastrir releasing... Agent: Dla Piper LLP (us)

20090197817 - Tetrahdrofuro[3,2-b] pyrrol-3- one as cathepsin k inhibitors: The invention further relates to pharmaceutical compositions comprising compounds of formula (I), and the use of such compounds in the treatment of a disease selected from osteoporosis, Paget's disease, Chagas's disease, malaria, gingival diseases, hypercalaemia, metabolic bone disease, diseases involving matrix or cartilage degradation, and bone cancer disorders such as... Agent: Edwards Angell Palmer & Dodge LLP

20090197820 - Compositions and methods for improving cardiovascular health: Compositions and methods for improving cardiovascular health in the elderly by delivering a selection of essential amino acids, phytosterols, stanols, and isoflavones, which may be supplemented with a low glycemic carbohydrate and/or a medium chain fatty acid.... Agent: Lewis, Rice & Fingersh, Lc Attn: BoxIPDept.

20090197819 - Compositions for improving and repairing skin: Compositions for improving the condition of the skin or for repairing damaged skin are disclosed. The compositions contain D-ribose as the active ingredient plus a penetrant to deliver D-ribose to the basal cells and dermis of the skin. Compositions further containing emollients and emulsifiers are disclosed.... Agent: Kathleen R. Terry

20090197818 - Use of ribose for recovery from anaesthesia: D-Ribose is administered before and after general anaesthesia to reduce the time to recover from the effects of general anaesthesia. Preferably, pyrogen-free D-Ribose is administered intravenously during general anaesthesia and the interval post-anaesthesia before oral administration can be resumed. D-Glucose may be co-administered to reduce the effect of hypoglycemia that... Agent: Kathleen R. Terry Bioenergy, Inc.

20090197821 - Compositions and methods for the delivery of poorly water soluble drugs and methods of treatment: The present embodiment of the invention is generally directed to compositions comprising suspensions of poorly water-soluble compounds recrystallized in nanoparticulate sizes ranging from 0.1 to 5 μm. In addition, the embodiment of the invention is directed to methods for preparation and administration of these compositions to a patient for prevention... Agent: Innovar, LLC

20090197822 - Compositions and methods for the treatment of chronic infections: The present disclosure provides compositions and methods for the treatment and elimination of chronic intracellular infections in cells or organisms. The compositions may include one or more acidic substances and one or more antimicrobial substances, administered in combination or separately. The methods may include administering an amount of one or... Agent: Luedeka, Neely & Graham, P.C.

20090197823 - Aliskiren modulation of neurogenesis: The disclosure provides compositions and methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis by use of a renin inhibitor in combination with one or more neurogenic agents. The disclosure also includes compositions and methods for stimulating or activating the formation... Agent: Dla Piper LLP (us)

20090197824 - Extended release pharmaceutical formulations of s-adenosylmethionine: Extended release formulations of S-methyladenosylmethionine (SAMe) are provided, as are methods of treating various disorders using extended release SAMe formulations. The extended release formulations may be used to treat a variety of disorders, including liver disorders, psychiatric disorders and joint disorders. Thus, extended release SAMe formulations may be used to... Agent: Wilson Sonsini Goodrich & Rosati

20090197825 - Novel compounds and compositions and methods of use: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.... Agent: Wilson Sonsini Goodrich & Rosati

20090197826 - P-toluene sulfonic acid salt of 5-amino-3-(2'-o-acetyl-3'-deoxy-beta-d-ribofuranosyl)-3h-thiazole[4,5-d]pyrimidine-2-one and methods for preparation: s

20090197827 - Combination therapy for treatment of fiv infection: The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090197828 - System, method and package for providing a sucrose solution: A solution of sucrose and water is packaged and placed in an aseptic state in a cup-shaped container with a removable cover for single patient use. A plurality of containers is shipped from a preparation site to a site of usage such as a hospital. A single container of the... Agent: Philips Intellectual Property & Standards

20090197829 - Crosslinked polysaccharides and methods of production thereof: A substantially boron-free method for making a cationic guar comprises reacting particles of polysaccharide with a derivatizing agent to produce derivatized polysaccharide particles, washing the derivatized polysaccharide particles, and contacting, prior to or after the washing step, the particles with a glyoxal compound in order to crosslink the derivatized polysaccharide... Agent: Rhodia, Inc.

20090197830 - Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia: Combinations of therapeutic compounds for prophylaxis or treatment of hyperlipidemia and hyperlipidemia related disorders, such as hypercholesterolemia and the resultant atherosclerosis in a mammal. The combinations are useful for reducing serum cholesterol, and/or cholesteryl ester, triglycerides, phospholipids and fatty acids in a mammal. The methods of the preferred embodiments comprise... Agent: Choate, Hall & Stewart LLP

20090197831 - Composition for the treatment of obesity and hyperlipidemia: Current invention is related to the pharmaceutical industry in general and to the industry of the manufacture of pharmaceutical products for weight reduction and hyperlipidemia treatment. The advantages of the current invention respect of the similar of the state of the art are that in the present invention side effects... Agent: Harness, Dickey, & Pierce, P.l.c

20090197832 - Polymer mixtures of anionic and cationic polysaccharides and use thereof: Described in the present application are compositions comprising mixtures of polyanionic polysaccharides and polycationic polysaccharides consisting of oligosaccharide derivatives of chitosan. In the compositions of the invention said mixtures have proven to be soluble in aqueous environments, despite ionic complexes forming between the acid polysaccharides and chitosan derivatives. Said compositions... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090197833 - Silicon containing compounds having selective cox-2 inhibitory activity and methods of making and using the same: Silicon-containing compounds having selective COX-2 inhibitory activity, as well as compositions thereof are provided. The subject compounds find use in a variety of applications, including therapeutic applications. Also provided are kits containing the subject compounds and pharmaceutical preparations thereof.... Agent: Bozicevic, Field & Francis LLP

20090197834 - Quinolone derivative or pharmaceutically acceptable salt thereof: [Means for Resolution] It was found that quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; —N(R0)C(O)-lower alkylene-CO2R0, lower alkylene-CO2R0, lower alkenylene-CO2R0, —O-lower alkylene-CO2R0, —O-(lower alkylene which may be substituted with —CO2R0)-aryl or —O-lower alkenylene-CO2R0 (wherein R0 is H or lower alkyl) at... Agent: Sughrue-265550

20090197835 - Vinyl phosphonate lysophosphatidic acid receptor antagonists: The present invention provides LPA analogs that are antagonists at the LPA receptors.... Agent: Iplm Group, P.A.

20090197836 - Combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes: A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090197837 - Alendronate formulations, method of making and method of use thereof: Disclosed is a liquid, oral dosage form comprising alendronic acid or pharmaceutically acceptable salts thereof, a process for the preparation of such liquid dosage forms, and use thereof.... Agent: Cantor Colburn, LLP

20090197838 - Antimicrobial n-halogenated amino acid salts: The present invention relates to a formulation comprising a N-halogenated amino acid and a phase transfer agent. The present invention also describes a method for disinfecting and/or cleaning a contact lens comprising contacting a contact lens with a formulation comprising a N-halogenated amino acid salt for a time sufficient to... Agent: Alcon

20090197839 - Method of obtaining total fixed lipids from seeds of the sapodilla family, for the preparation of cosmetics and dermatological pharmaceutical compositions: Procedure for the obtaining a concentrate of the total fixed lipids of the kernels of the family Sapotaceae, genus Calocarpum, Chrysophyllum and Lucuma. The kernels (seeds removed of the endocarp), are squeezed by means of mechanical techniques that use pressure and heat, without using extractive liquids, getting a concentrate of... Agent: Hoffman Wasson & Gitler, P.c Crystal Center 2, Suite 522

20090197840 - Composition and method for enhancing skin cell growth, proliferation and repair: A skin treatment composition is provided which contains calcium glycerophosphate and a fatty acid source derived from an animal or a vegetable. The composition enhances skin cell proliferation and growth and repair of damage to skin cells. Methods for enhancing skin cell repair, proliferation, and growth and for enhancing ceramide... Agent: Panitch Schwarze Belisario & Nadel LLP

20090197841 - Inhalant propellant-free aerosol formulation: The invention relates to inhalant propellant-free aerosol formulations containing at least one inert, non-volatile auxiliary substance for adjusting defined droplet sizes.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090197842 - Therapeutic agent for neuropathic pain: The present invention provides a therapeutic agent for neuropathic pain having an excellent treating effect on neuropathic pain, which is an intractable disorder. More specifically, the present invention provides a therapeutic agent for neuropathic pain and a pharmaceutical composition for treating neuropathic pain, comprising (1) a compound having an anti-progesterone... Agent: Foley And Lardner LLP Suite 500

20090197844 - Demethylpenclomedine analogs and their use as anti-cancer agents: This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders. In one embodiment the analogs are represented by the formula... Agent: Klarquist Sparkman, LLP

20090197845 - Method for treating olfactory disorder: Disclosed is a method for treating olfactory disorders, which comprises administering to a patient a therapeutically effective amount of 3-β-hydroxymethylglutarate CoA (HMG-CoA) reductase, which has excellent effects of protecting and regenerating olfactory nerve.... Agent: Edwards Angell Palmer & Dodge LLP

20090197843 - Treatment of prevention of unscheduled bleeding in women on progestogen containing medication: The present invention relates to a method of treating or preventing unscheduled bleeding in women, the unscheduled bleeding being the result of repeated administration of a hormonal composition that contains a progestogen, wherein the method includes the administration of an effective amount of Renin Angiotensin System (RAS) suppressor selected from... Agent: The Webb Law Firm, P.C.

20090197846 - Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in... Agent: Allergan, Inc.

20090197847 - Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods: Pharmaceutical compositions suitable for administration into the interior of an eye of a person or animal are described. The present compositions include one or more components which are effective in providing a reduced toxicity relative to existing intraocular ophthalmic compositions. The present compositions include one or more therapeutic agents in... Agent: Allergan, Inc.

20090197848 - Synthetic mimics of mammalian cell surface receptors: method and compositions: The present invention relates to new synthetic receptors. More particularly, the present invention relates to the use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pennsylvania State University

20090197850 - Coatings comprising self-assembled molecular structures: A coating for an implantable medical device is disclosed, the coating including a self-assembled molecular structure. The coating can be used for altering the release rate of a therapeutic substance from the implantable device.... Agent: Squire, Sanders & Dempsey LLP

20090197849 - Transdermal and topical administration of drugs using basic permeation enhancers: Methods are provided for enhancing the permeability of skin or mucosal tissue to topical or transdermal application of pharmacologically or cosmeceutically active agents. The methods entail the use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of... Agent: Intellectual Property Group Fredrikson & Byron, P.A.

20090197851 - Therapy and use of compounds in therapy: A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids... Agent: Norris, Mclaughlin & Marcus, P.A.

20090197852 - Method of treating breast cancer using 17-aag or 17-ag or a prodrug of either in combination with a her2 inhibitor: A method for treating a breast cancer in a subject by administering 17-allylamino-17-demethoxy-geldanamycin (17-AAG) or 17-amino-17-demethoxygeldanamycin (17-AG), or a prodrug of either 17-AAG or 17-AG, in combination with a HER2 inhibitor.... Agent: Fox Rothschild LLP Bristol-myers Squibb

20090197853 - Methods and compositions of treating cancer: The present disclosure involves the use of metal-containing texaphyrins and zinc (II) reagents for the treatment of tumors, atheromas and other neoplastic tissue. The present application demonstrates increased oxidative stress, alterations in zinc homeostasis, cell cycle arrest, and apoptosis of cancer cells in the presence of texaphyrins and/or zinc. One... Agent: Wilson Sonsini Goodrich & Rosati

20090197854 - Use of picoplatin to treat colorectal cancer: The invention provides a method of treatment of colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with 5-FU and leucovorin in a variety of treatment regimens. Dosages, dosing schedules, and ancillary treatments are described.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090197855 - Pharmaceutical compositions of cefdinir: A chewable tablet dosage form comprising Cefdinir or pharmaceutically acceptable salts thereof for the oral administration of Cefdinir in a manner that is more palatable and less objectionable to population group's especially young children and older patients. A method of preparing the chewable tablets comprising Cefdinir and method of treatment... Agent: Merchant & Gould PC

20090197856 - Antiviral compounds: Provided are compounds of Formula (I) or a pharmaceutically acceptable salt or solvate thereof. The compounds and compositions are useful for treating viral infections caused by the Flaviviridae family of viruses.... Agent: Glaxosmithkline C/o Foley & Lardner LLP

20090197857 - Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes: The present invention provides novel substituted amino-azetidines that are useful as cannabinoid receptor antagonists/inverse agonists and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, hepatic disorders, and a combination thereof.... Agent: Vance Intellectual Property, PC

20090197858 - Hypercholestrolemia and tendinous injuries: This invention provides compositions and methods of inhibiting, suppressing, or treating a tendinous or musculoskeletal soft tissue injury. The invention further provides a method of ameliorating symptoms associated with a tendinous or musculoskeletal soft tissue injury. Additionally, the invention provides methods for evaluating the risk of developing a tendinous or... Agent: Pearl Cohen Zedek Latzer, LLP

20090197860 - Biaryl substituted diazabicycloalkane derivatives: The invention relates biaryl substituted diazabicycloalkanes, and more particularly bicycloheteroaryl substituted fused diazabicycloalkane derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20090197861 - Inhibitors of integrin alpha2beta1 with modified urea moiety: Novel compounds inhibiting the integrin α2β1/GPIa-IIa receptor are disclosed. Also disclosed are pharmaceutical compositions containing the compounds, as well as methods of their therapeutic use. The compounds disclosed are useful, inter alia, as inhibitors of integrin α2β1/GPIa-IIa-mediated activity.... Agent: Woodcock Washburn LLP

20090197862 - 2-aminopyridine kinase inhibitors: 2-Aminopyridine compounds having the structure of Formula I, and pharmaceutically acceptable salts of these compounds. Compounds of Formula I inhibit the activity of tyrosine kinase enzymes in animals, including humans, and are useful in the treatment and/or prevention of various diseases and conditions. In particular, compounds disclosed herein are inhibitors... Agent: Osi Pharmaceuticals, Inc.

20090197859 - Pyridinyl amides for the treatment of cns and metabolic disorders: wherein Y, Z, L, R1 through R11, n, m, p, q, t are as defined herein, that are 5-HT receptor ligands, particularly the 5-HT6 subtype, and as such are useful for treating diseases wherein modulation of 5-HT activity is desired. The present invention relates to novel pyridinyl derivatives including their... Agent: Pfizer Inc Mary J Hosley

20090197863 - Benzoxazole carboxamide inhibitors of poly(adp-ribose)polymerase (parp): wherein the variables Y, R1, R2, R3, and R4 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and... Agent: Wilson Sonsini Goodrich & Rosati

20090197864 - Furo- and thieno [3,2-c] pyridines: Furo[3,2-c]Pyridine and Thieno[3,2-c]pyridine compounds of Formula I, and pharmaceutically acceptable salts thereof, preparation, intermediates, pharmaceutical compositions, and use, such as in disease treatment, including cancers, including conditions in which EMT is involved, including conditions mediated by protein kinase activity such as RON and/or MET.... Agent: Osi Pharmaceuticals, Inc.

20090197865 - Therapeutic methods, compositions and compounds: In one embodiment the invention provides a method of combating cyanide poisoning, which comprises administering to a subject a compound capable of releasing 3-mercapto-pyruvate in vivo. In other embodiments the invention also provides pharmaceutical compositions comprising a compound capable of releasing 3-mercaptopyruvate in vivo, as well as novel compounds that... Agent: Viksnins Harris & Padys Pllp

20090197866 - Pyrazolylbenzimidazole derivatives, compositions containing them and use thereof:

20090197867 - Enantiomerically enriched imidazoazepinone compounds:

20090197868 - 5ht2c receptor modulator compositions and methods of use: The present invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist. In addition, the invention relates to a composition comprising phentermine and a selective 5HT-2C receptor agonist having Formula (I): or a pharmaceutically acceptable salt, solvate or hydrate thereof. These compositions are useful in pharmaceutical compositions... Agent: Bozicevic, Field & Francis LLP

20090197869 - Azepine inhibitors of janus kinases: The present invention provides compounds that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.... Agent: Fish & Richardson PC

20090197870 - Pharmaceutical compositions: Compounds for use in compositions and methods for modulating the activity of nuclear receptors are provided. In particular, compounds for use in compositions and methods for modulating the estrogen related receptors are provided. In one embodiment, the compounds provided herein are ERR modulators. In another embodiment, the compounds provided herein... Agent: Mcdonnell Boehnen Hulbert @ Berghoff LLP

20090197871 - Dual pharmacophores - pde4-muscarinic antagonistics: The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090197873 - Compositions comprising alprazolam for treating primary insomnia and insomnia associate with anxiety states and process for preparing them: Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of alprazolam sublingual tablets having a disintegration time lower than 30 seconds and having the alprazolam preferably in non-crystalline or partially crystalline form according to... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090197872 - Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use: Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases... Agent: Birch Stewart Kolasch & Birch

20090197874 - Solid forms containing meloxicam with improved buccal taste and process for their preparation: A solid dosage form of meloxicam containing an acid and sugars or polyalcohols or a mixture thereof.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090197875 - Aryl-isoxazolo-4-yl-oxadiazole derivatives: s

20090197876 - Indolinone derivatives substituted in the 6 position, their preparation and their use as medicaments: R1 to R6 and X are as defined in Claim 1, to their tautomers, enantiomers, diastereomers, to their mixtures and to their salts, in particular their physiologically acceptable salts, which have useful pharmacological properties, in particular in inhibiting action on various receptor tyrosine kinases and on the proliferation of endothelial... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090197877 - Antibacterial compositions: Compounds of formula (I) have antibacterial activity: wherein: m is 0 or 1; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (—O—), thioether (—S—) or amino (—NR)— link, wherein R is hydrogen, —CN or C1-C3 alkyl;... Agent: Banner & Witcoff, Ltd.

20090197878 - Substituted benzo[d][1,3]oxazin-2(4h)-ones and related derivatives and their uses for modulating the progesterone receptor: Compounds of formula (I), or pharmaceutically acceptable salts thereof, are provided, wherein R1-R6 and X are defined herein. Also provided are methods of preparing the compounds of formula (I), pharmaceutical compositions and kits containing a compound of formula (I), as are methods of treating endometriosis, hormone-dependent carcinomas, leiomyoma, fibroids, dysfunctional... Agent: Howson & Howson LLP / Wyeth

20090197879 - Vanilloid receptor ligands and their use in treatments: and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic... Agent: Amgen Inc.

20090197880 - Anti-viral compounds, compositions, and methods of use: Disclosed are compounds of Formula (I), pharmaceutically acceptable salts and solvates thereof, compositions thereof, and methods for their preparation and uses for treating viral infections mediated at least in part by a virus in the Flaviviridae family of viruses.... Agent: Glaxosmithkline C/o Foley & Lardner LLP

20090197881 - Azaindole derivative having pgd2 receptor antagonistic activity: wherein the ring A is an aromatic carbocyclic ring etc.; the ring B is a 3- to 8-membered nitrogen-containing non-aromatic heterocyclic ring etc.; the formula of -X1=X2-X3=X4- is a formula of —C(R1)═C(R2)—C(R3)═N— etc.; R1, R2, R3, R4 and R5 are independently a hydrogen atom or a halogen atom etc.; R6... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090197882 - Indazole derivatives for the treatment of hsp90-induced diseases: Novel indazole derivatives of the formula (I), in which R1-R3 have the meanings indicated in Claim (1), are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.... Agent: Millen, White, Zelano & Branigan, P.C.

20090197883 - Diphenyl substituted cycloalkanes, compositions containing such compounds and methods of use: The instant invention provides compounds of Formula (I) which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula (I) are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.... Agent: Merck And Co., Inc

20090197884 - Compounds useful as antagonists of ccr2: The present invention provides compounds of general formula I: or a pharmaceutically acceptable salt thereof, wherein X, n, Y, and R1 are defined generally and in subsets herein. Compounds of the invention are inhibitors of CCR2 and accordingly are useful for the treatment of a variety of inflammatory, allergic, and... Agent: Millennium Pharmaceuticals, Inc.

20090197885 - Compositions and treatments using pyridazine compounds and cholinesterase inhibitors: The invention relates to compositions, conjugates and methods comprising pyridazine compounds and cholinesterase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications.... Agent: Millen, White, Zelano & Branigan, P.C.

20090197886 - Hexahydro-cycloheptapyrazole cannabinoid modulators: e

20090197887 - Piperazinylpiperidine derivatives as chemokine receptor antagonists: wherein variable substituents are defined herein, that modulate the activity of or bind to chemokine receptors such as CCR5. In some embodiments, the compounds of the invention are selective for CCR5. The compounds can be used, for example, to treat diseases associated with chemokine receptor expression or activity such as... Agent: Fish & Richardson PC

20090197888 - Fluorinated tripeptide hcv serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090197889 - Synthesis and anti-proliferative effect of benzimidazole derivatives: This invention provides for compounds, compositions, and methods that involve anti-proliferative and anti-neoplastic activity in cancer cells. In particular, a series of benzimidazole, purine, imidazopyridine, and imidazopyrizine compounds having selected substitution patterns are disclosed, and the activity of various subject compounds is demonstrated.... Agent: Sutherland Asbill & Brennan LLP

20090197890 - Pyridazine derivatives and their use as therapeutic agents: where x, y, W, V, R2, R3, R4, R5, R6, R6a, R7, R7a, R8, R8a, R9 and R9a are defined herein. The SCD-mediated disease or condition may be selected from the group consisting of Type II diabetes, impaired glucose tolerance, insulin resistance, obesity, fatty liver, non-alcoholic steatohepatitis, dyslipidemia, metabolic syndrome,... Agent: Osha Liang L.L.P.

20090197891 - Use of (4-alkylpiperazinyl)(phenyl) methanones in the treatment of alzheimer's disease: The invention provides a therapeutic method for treating at least one symptom of Alzheimer's disease in a mammal, such as a human, wherein the toxicity of a pathogen of β amyloid peptide mammalian cells is implicated and inhibition of the subsequently-induced pathological pathways is desired comprising administering to a mammal... Agent: Schwegman, Lundberg & Woessner, P.A.

20090197892 - Anhydrous compositions useful for attaining enhanced sexual wellness: The invention relates to an anhydrous composition comprising a vasodilator and an acceptable carrier wherein the vasodilator is present in an amount effective to increase the blood flow when the composition is applied to human tissue. The compositions according to the invention are non-flushing.... Agent: Philip S. Johnson Johnson & Johnson

20090197893 - Methods of identifying and treating individuals exhibiting complex karyotypes: The invention described herein relates to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that harbor complex karyotypes. The present invention also related to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of... Agent: Louis J. Wille Bristol-myers Squibb Company

20090197894 - Nicotinamide derivatives and their use as therapeutic agents: e

20090197895 - Oxazole-pyrrole-piperazine alpha-helix mimetic: Amphiphilic α-helix mimetics are provided. These compounds are constructed using an oxazole-pyrrole-piperazine (OPP) scaffold. The amphiphilic α-helix mimetics are also employable for making libraries and for treating diseases or conditions effected by the inhibition or disruption of interactions with the alpha helix of a protein.... Agent: Darby & Darby P.C.

20090197896 - Methods and compositions for increasing solubility of azole drug compounds that are poorly soluble in water: The combination of any two of a polyol, a polyol ether, and a low carbon organic alcohol provides a synergistic effect on the solubility of azole compounds, such as metronidazole, in aqueous fluid.... Agent: Howard Eisenberg, Esq.

20090197897 - Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors: The present invention relates to new compounds which are Oxadiazole derivatives of formula (I) wherein B, P, Q, W, R1 and R2 are defined in the description. Invention compounds are useful in the prevention or treatment of central or peripheral nervous system disorders as well as other disorders modulated by... Agent: Edwards Angell Palmer & Dodge LLP

20090197898 - Selective subtype alpha 2 adrenergic agents and methods for use thereof: The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.... Agent: Allergan, Inc.

20090197899 - 3-(dihydro-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide derivatives and methods of use: This invention relates to novel 3-(dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-propoxybenzenesulfonamide compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering inhibitors of cyclic guanosine... Agent: Edwards Angell Palmer & Dodge LLP

20090197900 - Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist: Provided herein are methods of improving, maintaining and restoring renal function, treating heart failure, treating subjects with acute fluid overload, and slowing or reversing an existing or developing renal impairment in subjects with BNP levels of at least 400 pg/mL and/or NT-proBNP levels of at least about 1500 pg/mL by... Agent: Merck And Co., Inc

20090197901 - Variolin derivatives and their use as antitumor agents: Variolin derivatives of formula (5) are provided, wherein the substituent groups defined by X2, R1, R2, R3, R6, R7, and R12 are each independently selected from the group consisting of H, OH, OR′, SH, SR′, SOR′, SO2R′, NO2, NH2, NHR′, N(R′)2, NHCOR′, NHSO2R′, CN, halogen, ═O, C(═O)H, C(═O)R′, CO2H, CO2R′,... Agent: Fish & Richardson PC

20090197902 - Use of pyrimidine compounds in the preparation of parasiticides: The invention relates to the use of compounds of the general formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, X1 and X2 have the significances given in claim 1, and optionally the enantiomers and geometrical isomers thereof, for controlling parasites on warm-blooded... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090197903 - Process for preparing spray dried formulation of tmc125: This invention relates to a process for producing a spray-dried powder comprising microcrystalline cellulose in a solid dispersion of the anti-HIV compound etravirine (TMC125) in a water-soluble polymer.... Agent: Philip S. Johnson Johnson & Johnson

20090197904 - Sulphamides for treatment of cancer: Bridged bicyclic sulphamides of formula (I) are disclosed for treatment of cancer.... Agent: Merck And Co., Inc

20090197905 - Quaternary opioid carboxamides: i

20090197906 - Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives: The invention relates to the use of 9-hydroxy ellipticine derivatives for the treatment of cancer. 9-hydroxy ellipticine derivatives may prove particularly useful for the treatment of metastatic cancers or cancers escaping conventional cytotoxic chemotherapies.... Agent: Stites & Harbison PLLC

20090197908 - Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met: The present invention relates to 5H-benzo[4,5]cyclohepta[1,2-b]pyridine compounds, that are useful for treating cellular proliferative diseases, for treating disorders associated with MET activity, and for inhibiting the receptor tyrosine kinase MET. The invention also related to compositions which comprise these compounds, and methods of using them to treat cancer in mammals.... Agent: Merck And Co., Inc

20090197907 - Novel crystalline form of rupatadine free base: The present invention relates to a novel crystalline form of rupatadine free base, process for its preparation and to a pharmaceutical composition containing it. In accordance with the present invention rupatadine is suspended in n-hexane, n-heptane, cyclohexane, diethyl ether or diisopropyl ether, stirred for at least 1 hour, filtered the... Agent: Caesar, Rivise, Bernstein, Cohen & Pokotilow, Ltd.

20090197909 - Bis-heterocyclic imidazolyl compounds: The patent application relates to new heterocyclic compounds of the general formula (I) in which R, R1, R2, R3, R4 and n have the definitions elucidated in more detail in the description, to a process for preparing them and to the use of these C compounds as medicaments, particularly as... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090197911 - Lonidamine analogues and treatment of polycystic kidney disease: Lonidamine derivatives can be useful in methods of treating, inhibiting, and/or preventing polycystic kidney disease (PKD). Accordingly, lonidamine derivatives can be administered in a therapeutically effective amount for inhibiting, and/or preventing polycystic kidney disease (PKD) in the subject. This can include administering a therapeutically effective amount of the lonidamine derivatives... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090197910 - Novel viral replication inhibitors: The present invention relates to a pharmaceutical composition for the treatment or prevention of viral infections comprising as an active principle at least one benzimidazole conjugates derivative having the general formula (I). The invention also relates to processes for the preparation of compounds according to the invention having above mentioned... Agent: Clark & Elbing LLP

20090197912 - Sulfonamide derivatives for the treatment of diseases: e

20090197913 - Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor:

20090197914 - Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them: The present invention provides a compound of a formula (I) wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) mediated disease state.... Agent: Fish & Richardson P.C.

20090197915 - Sigma receptor compounds: The present invention relates to compounds of formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.... Agent: Heslin Rothenberg Farley & Mesiti PC

20090197916 - Soluble epoxide hydrolase inhibitors for treatment of metabolic syndrome and related disorders: Compounds, compositions, and methods for inhibiting the onset of metabolic syndrome and treating related disorders in a subject in need of such therapy are disclosed.... Agent: Foley & Lardner LLP

20090197917 - Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes: The invention relates to the use of rimonabant, either alone or combined with another active ingredient, for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes or non-insulin-dependent diabetes and/or its complications.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20090197918 - Pesticide benzyloxy- and phenetyl-substituted phenyl-amidine derivatives: The present invention relates to benzyloxy- and phenethyl-substituted phenyl-amidine derivatives of formula (I) wherein the substituents are as in the description, their process of preparation, their use as fungicide or insecticide active agents, particularly in the form of fungicide or insecticide compositions, and methods for the control of phytopathogenic fungi... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090197920 - Methods and compositions for modulating calcium channels: The present invention relates to methods and compositions for modulating calcium channels. In particular, the present invention provides methods and compositions for modulating (e.g., disrupting) Cav1.3a calcium channels for research and therapeutic methods (e.g., treating dopaminergic diseases and conditions).... Agent: Casimir Jones, S.c.

20090197919 - Novel method for preparation of ammonium salts of esomeprazole: The present invention relates to a process for the preparation of quartenary ammoniumsalts of esomeprazole. Further, the present invention also relates to the use quartenary ammoniumsalts of esomeprazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing them as well as the quartenary ammoniumsalts of esomeprazole, as such.... Agent: White & Case LLP Patent Department

20090197921 - Use of nicotine, analogues, thereof, precursors thereof or derivatives therof in the treatment of various pathological processes capable of improvement with a-msh administered in prophylactic or therapeutic form: This invention protects the use of nicotine, analogues thereof precursors thereof or its derivates for treatment of inflammatory, infectious, candidal or degenerative (of the joints and/or of the central nervous system, of kidneys, the lungs, liver), depression, obesity, bone disease and the like, which can be improved by means of... Agent: Panitch Schwarze Belisario & Nadel LLP

20090197922 - Compositions and methods for treating pulmonary hypertension: Compositions and methods of the invention are related to treating pulmonary hypertension using a Raf kinase inhibitor, such as sorafenib. IQ a particular aspect, pulmonary hypertension is pulmonary arterial hypertension.... Agent: Fulbright & Jaworski L.L.P.

20090197923 - Method of providing pirfenidone therapy to a patient: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used... Agent: Marshall, Gerstein & Borun LLP

20090197924 - 2-amino-2-phenyl-alkanol derivatives, their preparation and pharmaceutical compositions containing them: 2-amino-2-phenyl-alkanol ester derivatives of general formula (I) in which: R1 is H, straight or branched 1 to 4C alkyl, straight or branched 2 to 4C alkyl substituted by OH, alkoxy, alkylthio, acyloxy, NH2, alkylamino, dialkylamino, alkylcarbamoyloxy, alkoxycarbonylamino, ureido or alkylureido, R2 is a —CO—R radical in which R is H,... Agent: Harness, Dickey & Pierce, P.L.C

20090197925 - O-cyclopropyl-carboxanilides and their use: Het is a 5- or 6-membered heterocyclic ring containing one to three heteroatoms, each independently selected from oxygen, nitrogen and sulphur, the ring being substituted by groups R4, R5 and R6; R1 is hydrogen or halo; R2 is hydrogen or halo; R3 is optionally substituted C2-12 alkyl, optionally substituted C2-12... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20090197926 - Benzimidazoles and their use for the treatment of diabetes: wherein: R1 is selected from optionally substituted phenyl, cyclopentyl, cyclohexyl and 5- or 6-membered heteroaryl; L1 is a direct bond or a linker selected from, for example, —O—, —OCH2— and —CH2O—; R2 is selected from, for example, (3-6C)cycloalkyl, (5-12C)bicycloalkyl, phenyl and a 4, 5- or 6-membered saturated, partially or fully... Agent: Morgan Lewis & Bockius LLP

20090197927 - Jasmonate derivatives, pharmaceutical compositions and methods of use thereof: The present invention relates to novel jasmonate derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for prevention and treatment of cancers.... Agent: Fennemore Craig

20090197928 - Novel receptor antagonists and their methods of use: e

20090197929 - Azolylmethyloxiranes, their use for controlling phytopathogenic fungi and agents containing said compounds:

20090197930 - Eyedrops: It is intended to provide eyedrops which have an ocular tension-lowering effect and a hypotensive effect based on novel function mechanisms. The above-described eyedrops contain a muscle relaxant as the active ingredient and dantrolene sodium is preferably usable as the muscle relaxant employed as the active ingredient. The eyedrops lower... Agent: Birch Stewart Kolasch & Birch

20090197931 - Imidazolinylmethy aryl sulfonamide:

20090197932 - Imidazolinylmethyl aryl sulfonamide:

20090197933 - Imidazolinylmethyl aryl sulfonamide:

20090197934 - Imidazolinylmethyl aryl sulfonamide:

20090197935 - Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto: The present invention pertains to certain compounds of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial... Agent: Fish & Richardson P.C.

20090197936 - Salts of n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide: Salts of N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)ethyl]amino]methyl]phenyl]-2E-2-propenamide are prepared and characterized.... Agent: Novartis Corporate Intellectual Property

20090197937 - Marine actinomycete taxon for drug and fermentation product discovery: The invention is the discovery of an actinomycete genus, given the name Salinospora gen. nov., that displays an obligate requirement of seawater (Na+) for growth and unique 16S rRNA signature nucleotides. The invention is also the use of the genus for the production and discovery of active biomolecules such as... Agent: Dla Piper LLP (us)

20090197940 - Chondropsin-class antitumor v-atpase inhibitor compounds, compositions and methods of use thereof: e

20090197939 - Methods of treating skin with aromatic skin-active ingredients: A method for treating skin, reducing oxidative damage to a skin cell, reducing lipoxygenase (LO) activity in a skin cell, reducing cyclooxygenase (COX) activity in a skin cell, reducing tumor necrosis factor alpha (TNF-α) in a skin cell, or reduction matrix metalloproteinase enzyme activity in a skin cell comprising contacting... Agent: Fulbright & Jaworski L.L.P.

20090197938 - Polyphenol type compounds, compositions containing same and use thereof for preventing or treating diseases involving abnormal cell proliferation: The invention concerns compounds of formula (I), wherein —XmR1 and YnR2, identical or different are present, or one of the XmR1 or YnR2 is absent and YaR2, identical or different, is present, and in that case the bond between C1 and C2 is a double bond, XmR1 and YnR2 together... Agent: Harness, Dickey & Pierce, P.L.C

20090197941 - Pharmaceutical compositons for the treatment of chronic obstructive pulmonary disease: The invention relates to the use of a combination of cannabinoids for the treatment of Chronic Obstructive Pulmonary Disease (COPD). Preferably the combination of cannabinoids are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). More preferably the cannabinoids are in a predefined ratio by weight of approximately 1:1 of CBD to THC.... Agent: Wolf Greenfield & Sacks, P.C.

20090197944 - Agent for improving muscle force: Provision of an agent for improving muscle force and for improving exercise effect. An agent for improving muscle force containing a catechin as an effective ingredient.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090197943 - Flavonoid dimers and methods of making and using such: Multidrug resistance (MDR) is a major problem in cancer chemotherapy. The best characterized resistance mechanism is the one mediated by the over-expression of drug efflux transporters, permeability-glycoprotein (P-gp), which pump a variety of anticancer drugs out of the cells, resulting in lowered intracellular drug accumulation. A series of flavonoid dimers... Agent: Buchanan, Ingersoll & Rooney PC

20090197942 - Method for producing polyphenol-rich composition: An object of the present invention is to provide a method for producing polyphenol-containing compositions and purifying polyphenols safely and simply. By contacting a polyphenol-containing solution to a specific polysaccharide to support polyphenols with the polysaccharide, a polyphenol-containing composition usable as an additive for foods and drinks can be obtained.... Agent: Rankin, Hill & Clark LLP

20090197945 - Method for generating reference controls for pharmacogenomic testing: Reference controls for use with pharmacogenomic testing, and methods for their identification, preparation, and use, are disclosed. The reference controls can confirm that pharmacogenomic testing correctly identifies individuals that do or do not have the mutation of interest, in both clinical trial and patient treatment settings. The reference controls can... Agent: Intellectual Property / Technology Law

20090197946 - Composition and method for treatment of inflamation and infections of the genitalia, contraceptive and the prophylaxis of sexually transmitted diseases: A composition, employed topically for its microbicidal, spermatocidal activity upon application to the human genitalia and/or anorectal area, and the prophylaxis of sexually transmitted diseases, contraception, and the relief from symptoms of local inflamation and infection. The embodiment incorporates L-Ascorbic acid in a concentration of about 2% to about 25%... Agent: Felix L. Fischer, Attorney At Law

20090197947 - Medicaments and methods for lowering plasma lipid levels and screening drugs: The invention relates to compositions, medicaments, methods for treating individuals with high plasma lipid levels, and methods for screening drug candidates useful in, for example, the treatment of hypercholesterolemia. Specifically, the invention relates to the discovery that MTP inhibition leads to increased accumulation in cellular free-cholesterol and is useful in... Agent: Hoffmann & Baron, LLP

20090197948 - Skin external preparation: (In the formula, Y is the residue given by removing hydroxyl groups from a polyhydric alcohol having 3 to 6 hydroxyl groups, and k is the number of hydroxyl groups of the polyhydric alcohol. EO is an oxyethylene group; AO is an oxyalkylene group having 3 to 4 carbon atoms,... Agent: Rankin, Hill & Clark LLP

20090197949 - Antitumor methods and compositions comprising sesquiterpene derivatives: The present invention relates to novel antitumor compositions, the use of sesquiterpene derivatives as antitumor agents and to methods of treatment thereof. More precisely, The present invention relates to an antitumor composition comprising a therapeutically effective quantity of at least one sesquiterpene derivative in association with a pharmaceutically acceptable carrier.... Agent: Birch Stewart Kolasch & Birch

20090197951 - Substituted fullerene formulations and their use in ameliorating oxidative stress diseases or inhibiting cell death: This patent discloses a composition comprising a substituted fullerene, wherein the substituted fullerene comprises a fullerene core (Cn), wherein n is an even integer greater than or equal to 60, and at least one substituent group bonded to at least one carbon atom of the fullerene core, and at least... Agent: Williams, Morgan & Amerson

20090197950 - Substituted fullerenes and their use as inhibitors of cell death: This patent discloses the use of water-soluble substituted fullerenes as inhibitors of cell death. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX1X2) groups bonded to the fullerene core; (ii) from 1 to 18 —X3 groups bonded to the fullerene... Agent: Williams, Morgan & Amerson

20090197952 - Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose: Provided are alternative sources of ketone bodies for reducing or eliminating symptoms of Parkinson's disease, amyotrophic lateral sclerosis (ALS, also called Lou Gehrig's disease), Alzheimer's disease, Huntington's disease, epilepsy and other diseases or disorders characterized by impaired glucose metabolism. The alternative sources of ketone bodies include mono-, di- and triglyceride... Agent: Patent Docket Clerk Cowan, Liebowitz & Latman, P.C.

20090197953 - Pharmaceutical composition for the specific treatment of acute myeloid leukemia: The present invention provides the use of all-trans retinoic acid for the production of a pharmaceutical composition for the treatment of acute myeloid leukemia, which use is characterized in that the patients are selected from the group of non-M3 acute myeloid leukemia patients according to a physiologic concentration, e.g. a... Agent: Greer, Burns & Crain

20090197954 - Linoleic acid preparations for the topical treatment of male and female pattern androgenetic alopecia, age-related alopecia, and keratosis pilaris: A preparation for the topical application of linoleic acid to treat male and female androgenetic alopecia, age-related alopecia, and keratosis pilaris contains between about 0.1% and about 10%, preferably between about 1% and about 5%, and specifically about 2% linoleic acid by volume in its carrier vehicle. This acts to... Agent: William R. Mcdaniel

20090197955 - Methods of improving dha deposition and related function and/or development: The present invention provides for improved deposition of DHA in human or animal tissues by incorporating healthy lipids containing stearidonic acid into humans or animal through prolonged food or feed, as well as through supplements, and therapeutics. Improved deposition of DHA through consumptions of edible compositions comprising stearidonic acid can... Agent: Armstrong Teasdale LLP (29135) Christopher M. Goff

20090197956 - Treatment of acute otitis media with xylitol and n-acetylcysteine: The present invention relates to the discovery that the treatment of Acute Otis Media (AOM) can be accomplished by a synergistic combination of xylitol and N-acetylcysteine. The treatment with this combination shows that symptoms of AOM can be decreased and or treated to a greater degree than know with xylitol... Agent: Passe' Intellectual Property, LLC

20090197957 - Methods and compositions for the treatment of pain: The present invention relates generally to the area of pain management and more particularly, to a method of analgesia and agents useful for same. More particularly, the present invention relates to a method of analgesia utilising a compound of formula (I). The method of the present invention is useful, inter... Agent: Wilson Sonsini Goodrich & Rosati

20090197959 - N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions that include the compounds described herein, and methods of using such antagonists of PGD2 receptors, alone or in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.... Agent: Wilson Sonsini Goodrich & Rosati

20090197958 - Sustained release particulate oral dosage forms of (r) baclofen and methods of treatment: Sustained release particulate oral dosage forms of (R)-baclofen prodrugs and methods of treating a disease comprising orally administering such dosage forms are disclosed.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20090197961 - Diclofenac formulations and methods of use: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090197960 - Method of inhibiting polyneuropathic pain with 3-(2-dimethylaminomethylcyclohexyl) phenol: A method of using 3-(2-dimethylaminomethylcyclohexyl)phenol or a pharmaceutically acceptable salt thereof as an active pharmaceutical ingredient for treating or inhibiting polyneuropathic pain, in particular in diabetic polyneuropathy.... Agent: Crowell & Moring LLP Intellectual Property Group

20090197962 - Substituted cyclopentanes having prostaglandin activity: Therapeutic compounds, compositions, methods, and medicaments related thereto are disclosed herein.... Agent: Allergan, Inc.

20090197963 - Method and compositions for suppressing appetite or treating obesity: The present invention provides a method for reducing the appetite in a mammal by contacting the mammal with an amount of a noxious smelling agent effective in reducing appetite or by contacting the mammal with an agent effective in inhibiting the effect of another agent in stimulating appetite. Also, the... Agent: Klauber & Jackson

20090197964 - Methods and compositions for treatment for coronary and arterial aneurysmal subarachnoid hemorrhage: Methods and compositions for treating a complication associated with aneurysmal subarachnoid hemorrhage (SAH), the method comprising administering an effective amount of a nitric oxide precursor to a subject in need thereof. Methods and compositions for treating vasospasm, the method comprising administering an effective amount of a nitric oxide precursor to... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20090197965 - Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease: Bis- and tris-dihydroxyaryl compounds and their methylenedioxy analogs and pharmaceutically acceptable esters, their synthesis, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, especially Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed... Agent: Jones Day

20090197966 - Use of hypothermia inducing drugs: The present invention relates to the induction of hypothermia in humans in a predictable and dose responsive fashion by use of a pharmaceutical composition comprising a vanilloid receptor agonists, capsaicinoid or capsaicinoid-like agonist capable of inducing hypothermia, thereby benefiting patients suffering from illnesses characterized by tissue anoxia.... Agent: Nixon & Vanderhye, PC

20090197967 - Compositions and methods for treatment of ophthalmic diseases and disorders: Provided herein are compositions and methods for treating ophthalmic diseases and disorders. Compositions comprising retinylamine derivative compounds provided herein are useful for treating and preventing ophthalmic diseases and disorders, including diabetic retinopathy diabetic maculopathy, diabetic macular edema, retinal ischemia, ischemia-reperfusion related retinal injury, and metabolic optic neuropathy.... Agent: Wilson Sonsini Goodrich & Rosati

20090197968 - Extended-release capsules comprising venlafaxine hydrochloride: A capsule comprising venlafaxine hydrochloride wherein part of the drug content is in the form of delayed-release coated spheroids and a second part of the drug content is in a prompt-release form.... Agent: Nixon & Vanderhye, PC

20090197969 - Method of reducing brain cell damage or death: A method of reducing the occurrence of brain cell damage or death caused by transient cerebral hypoxia/ischemia condition or a traumatic brain injury (TBI) event. The method typically comprises identifying a subject with a transient cerebral hypoxic and/or ischemic condition, or a TBI, and within 24 hours of onset of... Agent: Fennemore Craig

20090197970 - Crystalline form of cinacalcet: The present invention relates to the polymorph form II of Cinacalcet hydrochloride, methods for the preparation of pure form II of Cinacalcet hydrochloride, and pharmaceutical compositions comprising the new polymorphic form in an pharmaceutically effective amount The present invention also provides novel solvates of Cinacalcet hydrochloride, methods for the preparation... Agent: Manelli Denison & Selter

20090197971 - Method for improving flavor of astaxanthin-containing extract: A method for improving the flavor of an astaxanthin-containing extract of the present invention includes the steps of: mixing 0.5 to 1000 parts by weight of ethanol and 1 part by weight of the astaxanthin-containing extract so as to obtain an ethanol mixture; collecting a solid precipitated from the ethanol... Agent: Mcleland Patent Law Office, P.l.l.c.

20090197972 - Bone replacement material comprising crystalline phases: The present invention relates to an X-ray amorphous-crystalline material with high solubility which can be used as a bioactive bone replacement material and as a substrate material in biotechnology. The new material comprising crystalline and X-ray amorphous phases is characterized in that according to 31P-NMR measurements, it contains Q0-groups of... Agent: Gregory A. Nelson Novak Druce & Quigg LLP

20090197973 - Method for preparing emulsion or dispersion, and foodstuff, skin externals and medicaments containing emulsion or dispersion obtained by the method: The present invention provides that a method for preparing an emulsion or a dispersion composed of an oily phase and an aqueous phase by contacting the oily phase with the aqueous phase, the method comprising: injecting the oily phase, which contains a water-soluble organic solvent and at least one hydrophobic... Agent: Moss & Burke, PLLC

20090197974 - Natural dietary supplement tablet: An all-natural or substantially all-natural dietary supplement in a tablet form that comprises at least 95 percent Certified Organic ingredients by weight and exhibits desirable hardness, friability and release of the active dietary supplement is formulated with naturally occurring saccharides that exhibit tablet binder, tablet disintegrant, or both tablet binder... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20090197975 - Compositions formulated for solvent-regulated drug release: This application relates to a composition comprising a mixture of different organic solvents formulated for controlled drug release. The release profile of the drug can be regulated by adjusting the compositional ratios of the solvents. In one embodiment of the invention a first solvent is water-soluble and a second solvent... Agent: Rissman Hendricks & Oliverio, LLP

20090197976 - Treatment and composition for achieving skin anti-aging benefits by corneum protease activation: Novel methods and compositions for treating aged and environmentally damaged skin are disclosed which provide improvements in the skin's visual appearance, function and clinical/biophysical properties by activating at least one proteolytic enzyme in the skin's stratum corneum. The disclosed treatment methods involve topical application of a novel cosmetic composition containing... Agent: Fulbright & Jaworski L.L.P.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140710: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 5.16822 seconds

PATENT INFO